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Historical relations between physics and medicine accelerated with the discovery of X-ray 
radiation and shortly thereafter with the discovery of radioactivity in the 19th century. At present, 
the term medical physics refers to physicists whose work is mainly concerned with medical 
applications of radiation. One of the most prominent applications of physics and chemistry in the 
medical field is nuclear medicine. Nuclear medicine can be defined as the medical specialization 
that uses radionuclides to investigate organ metabolism and to provide diagnosis and therapeutic 
interventions. The origin of nuclear medicine and radiopharmaceutical chemistry was started 
with the fundamental research started by George De Hevesy, and the first cyclotron was built by 
Ernest Orlando Lawrence in 1930. About 95% of the radiopharmaceuticals are employed in 
nuclear medicine for diagnosis, while the rest are used for therapy. A radiopharmaceutical 
consists of two components: a radionuclide and a pharmaceutical compound. First, a 
pharmaceutical compound is chosen that preferentially targets a given receptor or other cellular 
targets, then an appropriate radionuclide is attached to it for diagnosis or therapy. According to 
the available data at the International Atomic Energy Agency (IAEA), 134 countries use nuclear 
medicine facilities and equipment. Due to the rising prevalence of NCDs (Non-Communicable 
Diseases), the availability of new tracers, and the high demand for early and accurate diagnoses, 
NCD are expected to be the fastest-growing segment in nuclear medicine. There is an increasing 
demand for a personalized medicine approach in this era with scientific and technological 
developments. Several factors have resulted in the growth of personalized medicine, such as 
advances in molecular biology, a better understanding of processes, and more excellent 
knowledge of individual diseases' mechanisms.  
Theranostics, which is a combination of therapy and diagnosis, has introduced a new chapter in 
the field of nuclear medicine for providing personalized treatment to the patient. Among the 
different radioisotopes, Cu offers several radioisotopes potentially appropriate for use in nuclear 
medicine. One of the most promising pairs is 61Cu/67Cu that could be applied in theranostic 
applications. However, its optimized production and its availability in large quantity have been 
among the main challenges in nuclear medicine and constitute our inspiration to start this Ph.D. 





This thesis was performed in the framework of the Sinergia project “PHOtonuclear Reactions 
(PHOR): Breakthrough Research in Radionuclides for Theranostics” funded by Swiss National 
Science Foundation (SNSF). This enterprise is based on a collaboration among the Department 
of Chemistry, Biochemistry, and Pharmacy (DCBP) and the Laboratory of High Energy Physics 
(LHEP) of the University of Bern, and the Federal Institute of Metrology (METAS). 
This thesis is structured in 5 chapters: 
The first chapter introduces and deals with the basics of radiopharmaceutical chemistry and 
different production methods. In addition, the first chapter presents an introduction of nuclear 
medicine and its applications in diagnosis and therapy, along with introducing different 
radionuclide production facilities such as cyclotron, reactor, and electron accelerators. Chapter 
two focuses on the investigation of 61Cu and 67Cu production through different nuclear reactions 
and finally production of 61Cu by irradiation of 64Zn using a proton cyclotron at SWAN Isotopen 
AG at Inselspital Bern and production of 67Cu via irradiations of 68Zn with Bremsstrahlung 
generated by a 22 MeV Microtron at METAS. Chapter three introduces a novel method based on 
an evaporation technique for the efficient separation of Cu from the irradiated Zn targets, 
followed by a liquid chemical separation using extraction chromatography. To achieve this, an 
automated system (using a Modular-Lab PharmTracer system) was developed and installed in 
the framework of this thesis. With this automated system, Cu was completely separated and 
purified from the irradiated Zn targets. Moreover, in chapter three, radiolabeling of Cu with DOTA 
peptide was investigated. In chapter four, as a part of this study, the production of further 
potentially suitable radionuclides for medical applications such as 167Tm, 165Er, and 135La were 
investigated. Chapter five gives a summary of all processes that were considered and employed 
































1.1 Cancer and cancer therapy 
Cancer occurs when cells start dividing in an abnormal and uncontrolled way. This behavior may 
cause growth, which is called a tumor. Cancerous tumors are malignant and are able to spread 
into or invade nearby tissues, and, afterward move to other places in the body through the 
bloodstream or the lymph system. Cancer cells differ from normal cells. One crucial difference is 
that cancer cells are less specialized than normal cells, whereas normal cells differentiate into 
very distinct cell types with specific functions. Cancer cells are able to influence the normal cells 
and blood vessels that surround a tumor—an area known as the microenvironment [1]. There 
are more than 200 types of cancers known such as lung cancer, brain cancer, blood cancer etc. 
[2, 3]. Solid tumors can occur in several places, such as bones, muscles and organs. However, 
blood cancers are completely different from solid cancers. Blood cancers affect the white blood cells 
whose function is fighting against infections. There are three major types of blood cancer named 
leukemia, lymphoma, and myeloma. Myeloma cancer is located in the bone marrow and affects 
plasma cells, which produce antibodies that can attack diseases and infections and thus damage 
or weaken bone. Myeloma can be treated with radiation therapy or targeted radionuclide 
therapy.  Leukemia, a cancer of the blood cells starts in the bone marrow and spreads through 
the bloodstream. The bone marrow produces mutated cells, which can spread into the blood, 
where they crowd out healthy blood cells. This type of blood cancer may need aggressive 
treatment. Finally, lymphomas affect the cells in the lymphatic system, and then immune cells 
grow out of control [2]. 
Different types of cancer treatment such as surgery, external radiation therapy, internal radiation 
therapy, targeted radionuclide therapy, and chemotherapy depend mainly on the type of cancer 
and how advanced it is.  
Surgery is an invasive procedure in which the tissue will be removed from the body by a surgeon. 
Radiation therapy has been used for cancer treatment for more than 100 years (after the 
discovery of X-rays by Wilhelm Röntgen in 1895). It was found that exposure to them caused 
living tissue to have an adverse effect upon the duration of exposure. The observation of a burn 





a variety of tumors. Afterward, in 1934, Irene and Pierre Joliot-Curie discovered that they could 
produce radioactive elements that were not initially radioactive and just can be produced by 
exposing stable elements to alpha particles or neutrons [4, 5, 6]. 
Radiation therapy can be categorized into internal and external therapy. Currently, radiation 
therapy is considered as one of the most widely used treatment modalities, with approximately 
50% of patients with localized tumors in developed countries. Ionizing radiations (i.e., X-rays and 
γ-radiations) are used in radiation therapy to damage cancer cells. Using radiation therapy, many 
different cellular components such as lipids, proteins, and nucleic acids are damaged [7, 8, 9]. In 
external radiation therapy, the source of radiation (such as 60Co) is placed outside the body and 
therefore exposes the entire body to radiation, including both cancerous and normal tissue. The 
influence of ionizing radiation in external radiation therapy is not only limited to cancer cells but 
also damages surrounding non-cancerous healthy cells. The side effects rely on the dose and 
treated area of the body. In external radiation therapy, a high dose of X-rays and γ-radiation is 
required. The X-rays are generated outside the patient’s body via an electron accelerator such as 
Linear Electron Accelerator called LINAC. External radiation therapy is mainly used for the cancer 
treatment of the head, neck, lung, and breast [8, 9]. 
Internal radiation therapy is a treatment in which the radiation source is put in or near the tumor 
that is able to allow delivering a radiation dose to cancerous cells and, therefore, reduces the 
damage to surrounding non-cancerous cells. For this purpose, the radiation source is enclosed 
into a container such as a rod, tube, or needle. Internal radiation therapy is called brachytherapy 
when implants are put for an extended period of time. Some of the used radionuclides in 
brachytherapy are 192Ir and 103Pd, which are employed for breast and prostate cancer treatment. 
It is worth pointing out that internal radiation therapy is used for cancer treatment of the 
prostate, vagina, uterus, etc. [10, 11, 12, 13].     
The method of targeted radionuclide therapy stands for the selective accumulation of 
radionuclide-containing pharmaceuticals in cancer cells only, to prevent undesirable influencing 
of normal cells.  On this basis, the use of high-affinity molecules as carriers to the cancer cells for 





method, pharmaceuticals are often injected intracavitary or intravenously. After the injection, 
these drugs enter the bloodstream where they can finally reach the target (which is a target 
molecule placed on the surface of the tumor cell). The attached radionuclide to the 
pharmaceutical can directly interact and influence the tumor cell. An advantage of targeted 
radionuclide therapy is not only the precision of selectively destroying tumor cells but also the 
patients well-fare. This is due to the relatively fast clearance (however, some 
radiopharmaceuticals such as antibody-based ones have slow clearance and long half-life, so they 
are in the bloodstream for extended periods of time [14]) and subsequently affecting the tumor 
without any additional interventions (within this period of time) [15, 16]. The radionuclide 
selection in targeted radionuclide therapy is of great importance and requires complying with 
several requirements, including the radiative decay mode, radionuclide half-life, binding to a 
wide variety of carrier molecules, large-scale production, ability to be used as theranostic pair 
application, etc. In targeted radionuclide therapy, β-emitters, α-emitters, and Auger electron 
emitters are considered to provide the highest therapeutic efficiency due to providing more 
substantial destruction of biological systems at a given dose called biological effectiveness 
compared to X-rays and γ-radiation (see Fig. 1.1). Importantly, β-particles, α-particles, and Auger 
electrons have different ranges in tissue. Alpha and beta particles have a range of, 40–100 µm 
and 50–12,000 µm, respectively, while Auger/conversion electrons possess a very short range of 
only 0.002–0.5 µm. The importance of the range stems from the fact that delivery of the 
radiolabeled compounds carrying a radionuclide with a short-range requires it to be extremely 
close to or directly in/near the cell nucleus to lead to DNA damage [17, 18, 19]. Accordingly, Auger 








Fig. 1.1 Schematic view of ionization events due to interaction of (A) β-particles, (B) α-particles, 
and (C) Auger electrons. LET stands for the Linear Energy Transfer and is defined as the average 
amount of deposited energy per unit path length of an ionizing particle/radiation along its 
track. The LET of particles is higher than the LET of X-rays and γ. The LET of X-rays and g-
radiation increases with increasing atomic number of the absorber. Moreover, the LET 
decreases by increasing the incident particle/radiation energy. Increasing the LET results in 
increased biological effectiveness [17, 20]. 
 
 
In targeted radionuclide therapy, the half-life of the radionuclide should be longer (although not 
much longer) than the time required for the pharmaceutical preparation, to be delivered to the 
clinic, including injection into the patient, and the time required to localize a tumor. However, it 
should not be too long due to increased absorbed doses in the cancerous tissue and the 
undesirable irradiation of surrounding areas. The long half-life of radionuclides and/or a long 
biological half-life make patients themselves a source of radioactivity and they contaminate 
clinical facilities such as liquid waste disposal systems. Considering all of these factors, an optimal 
half-life from six hours to seven days is usually assumed appropriate for isotopes used for 





radionuclide therapy are 177Lu, 90Y, and 131I, so that in almost 90% of clinical practice, beta-
emitting radionuclides are employed. This is due to their appropriate emission characteristics 
and cost-effectiveness in production. 131I can be employed in both visualization and therapy and 
exhibits successful applications for different malignant tumors, including thyroid cancer. One 
disadvantage of 131I-tyrosine is the release of free 131I to the blood stream of patients. Moreover, 
γ-radiation emitted by 131I can pose radiation hazards for the healthcare personnel and patient 
family members.  90Y is an alternative to 131I because it is a pure beta-minus emitter and its 
ionizing radiation is mostly limited to the patient’s organism and, therefore, has a lower radiation 
hazard compared to 131I. 90Y has a shorter half-life, higher energy of β-particles, and higher 
retention in cancerous cells compared to 131I. Over the last decade, the use of 177Lu for targeted 
radionuclide therapy has attracted considerable attention due to its advantage in lower beta-
minus energy and an equally or even better complex formation constant with the DOTA chelator 
[15, 10, 22, 23, 24]. 67Cu is an ideal radionuclide for targeted radionuclide therapy, considering 
the ability to pair with 61Cu and 64Cu as a theranostic application. However, 67Cu has not entered 
into clinical use yet due to large-scale production difficulties [25, 26, 27, 28, 29]. 
The application of α-emitting radionuclides in targeted radionuclide therapy has been 
investigated and attracted great attention due to their high relative biological effectiveness and 
higher Linear Energy Transfer (LET) compared to β-emitting radionuclides. 211At, 225Ac, 223Ra, and 
227Th are among the best candidates for α-emitters. Some of the associated problems with the 
application of α-emitting radionuclides in targeted radionuclide therapy are presence of 
daughter products with a long half-life that causing patient isolation (e.g., β-emitter 207Bi as the 
daughter product 211At) and the potential tendency of them to self-radiolysis and partial drug 
destruction because of their radioactivity [15, 23, 30, 26, 31]. 
Chemotherapy was introduced for the chemical treatment of diseases by Paul Ehrlich, who 
received the Nobel Prize for Medicine in 1908. Up to now, more than a hundred different 
chemical drugs have been approved for cancer treatment. These drugs affect cells at different 
phases of the cell cycle. Most chemotherapeutic drugs are cell cycle-specific, and act on cells 
undergoing division, and are most effective in the case of high growth fraction malignancies (e.g., 





related plateau and therefore is not increasing with further increased dosage [9, 32, 33]. This is 
due to the fact that at a certain time point, only a subset of cells is fully drug-sensitive [9, 32, 33]. 
However, cell cycle non-specific drugs exhibit a linear dose-response curve and are shown to be 
effective for both cases of low and high growth fraction tumors [9, 32, 33, 34, 35]. 
1.2 Nuclear medicine 
Nuclear medicine is an area of medicine in which small amounts of radioactive materials or 
radiopharmaceuticals are used in the diagnosis and treatment of disease. Nuclear medicine 
comprises two applications; clinical diagnostics and radionuclide therapy. In diagnostic nuclear 
medicine, radiographers use equipment such as Single Photon Emission Computed Tomography 
(SPECT) or Positron Emission Tomography (PET) to produce images to makes cancerous tissues 
visible. However, in radionuclide therapy, the specialist person uses radiation to treat cancer and 
tissue defects [10, 21].  
in 1899, in Stockholm, Thor Stenbeck started the treatment of a 49-year-old woman's basal-cell 
carcinoma of the skin of the nose and delivered more than 100 treatments in 9 months. Also, at 
the same time, Tage Sjörgen started curing a squamous cell epithelioma with fifty treatments for 
30 months. Then after, in 1907, Louis Wickham and Paul Desgrais, treated a child with erectile 
angioma using beta therapy delivered by applying an external source of 226Ra (see Fig. 1.2) [36].  
 
 





As reviewing the nuclear medicine history, in 1943, George de Hevesy received the Nobel prize 
for the invention of the radiotracer technology. In radiotracer technology, a radiotracer is a 
chemical compound in which one or more atoms have been replaced by an appropriate 
radionuclide (e.g., 14C, 32P) and is used to explore the mechanism of chemical reactions by tracing 
the radionuclide [37]. In studying the metabolic processes of plants and animals, radiotracer 
technology is an important process in the industry [38]. It is usually used to diagnose specific 
causes of inefficiency in a process operation and investigate processes related transport of 
sediments where a cost-benefit ratio can be obtained from process optimization [38].  
In 1948, Seidlin reported success in treating a patient with thyroid cancer with 131I, a beta-minus 
emitter. In this study, doses from 500 to 2000 mCi of 131I were administered orally to patients on 
non-restricted diets and thereafter, urine was collected and studied for radioactive iodine 
content. Forty-eight hours after the dose was administrated, invivo readings were performed 
with a Geiger-Mueller counter to measure the degree of localization of 131I in the thyroid gland 
and the metastases. However, the cases that listed as negative results are those in which it was 
not possible to demonstrate such a concentration of 131I [39, 40].  
By the 1950s, the clinical use of nuclear medicine spread as researchers globally increased their 
knowledge of detecting radioactivity and using radionuclides to monitor the processes. Later, the 
Society of Nuclear Medicine was officially formed in 1954 in Spokane, Washington, USA, and in 
1960 they launched the Journal of Nuclear Medicine for the first time, which became the most 
well-known journal associated with this field [41, 42]. 
1.2.1 Imaging modalities 
1.2.1.1 SPECT 
Single Photon Emission Computed Tomography (SPECT) is a tomographic medical imaging 
technique using gamma rays and is able to provide 3D information. The SPECT technique needs 
delivery of gamma-emitting radionuclides (such as 99mTc and 123I) into the bloodstream. The 
radionuclide is attached to a specific ligand to create a radioligand (that is described in the 





to a place of interest in the body. A nuclear de-excitation event occurs, and the excited nucleus 
decays into a more stable form and releases a γ-ray photon. These photons traverse the patient's 
tissues and interact with the electrons of atoms in the tissue through Compton scattering or 
photoelectric absorption*. Once the gamma-ray photon exits the patient's body, it interacts with 
a collimator (which consists of a high density and high atomic number element like tungsten or 
lead that leads photons to enter the detector under a defined angle). Photons that can succeed 
in passing the collimator are those that have the appropriate angle of incidence for optimum 
image resolution. The detector consists of a scintillation crystal (such as NaI (Tl) crystal) coupled 
with photomultiplier tubes (PMT) (see Fig. 1.3). Once a scintillation crystal absorbs photons, it 
emits visible light. This visible light then interacts with a PMT, which generates an amplified 
electronic signal through the photoelectric effect. Multiple-detector-based SPECT systems 
surrounding the patient are to provide higher detection efficiency [43, 44].  
 
Fig. 1.3 Schematic view of SPECT [45] 
 
                                                          
* Compton scattering refers to the inelastic scattering of photons from a free (or a loosely bound) electron. 
Photoelectric absorption refers to a process when a photon interacts with a tightly bound orbital electron (inner 






1.2.1.2 PET  
Positron Emission Tomography (PET) imaging is a functional imaging technique that uses 
radioactive substances to reveal the metabolic function of tissues and organs. In PET imaging, a 
positron emitting radioactive tracer is injected into the body, and the two annihilation photons 
that are produced back-to-back after positron annihilation are detected by a large number of 
detectors (see fig. 1.4) operated in coincidence mode. Measured pulses are reconstructed into 
either 2D slice images or 3D representations. Since PET can detect tissue metabolism (similar to 
SPECT, in the case of gamma emitting radionuclides), it can provide molecular-level information 
much earlier than any anatomic changes are visible.  Dynamic Whole-Body (DWB) PET can 
demonstrate organ function. DWB PET is performed within reasonable clinical imaging times and 
enables a generation of multiple PET images [46]. In comparison between PET and SPECT, image 
quality is the most common comparison point. Based on previous studies, SPECT resolution is at 
about 10 mm, and SPECT cannot provide a quantifiable estimate of the blood flow while PET 
provides high resolution (about 2.5 mm) and dynamic PET provide quantitative estimates of 
blood flow and how tissue is actually behaving [47, 48]. 
 







1.2.1.3 Magnetic resonance imaging (MRI) 
MRI is a medical imaging method that uses strong magnetic fields and radio waves to form 
pictures of the anatomy of the body (see Fig. 1.5). Hydrogen nuclei that are in tissues consist of 
a proton which is very sensitive to magnetic fields. The MRI scanner produces a radiofrequency 
current that creates a magnetic field. Then, the protons (in the tissue) absorb the energy from 
the magnetic field, are deflected, and jump to a higher energy state. When the magnetic field of 
the MRI scanner is turned off, the protons return to their normal spin, and the return process 
produces a radio signal that is measured by receivers in the scanner [49]. Protons in different 
types of tissues return to their normal spins at different rates, so regarding that, the scanner can 












1.2.1.4 SPECT/CT, SPECT/MRI 
SPECT can be combined with other modalities (CT and MRI) to provide precise information. This 
technology allows the combination of the exquisite anatomic details provided by CT with the 
functional and physiologic information provided by SPECT. Hybrid imaging technology (refers to 
the fusion of two or more imaging modalities to form a new technique) has the potential of 
providing an image with increased specificity and localization, thus providing more accurate 
diagnosis [51]. The original motivation to produce a combined SPECT/CT system was raised to 
provide improved anatomical localization of the SPECT radiopharmaceutical and to improve the 
capability of the SPECT system to provide images with correction for the photon scattering and 
attenuation that lead to degradation of the image. In other words, the CT data are used to correct 
tissue attenuation in the SPECT imaging [52, 53]. In the SPECT/CT system, the CT and SPECT 
scanners are positioned (see Fig. 1.6 a) so that the patient is enabled to be moved directly from 
the CT scanner to the SPECT scanner by an extension of the CT table. 
 
Fig. 1.6 (a) Schematic of a SPECT/CT system. Position of the SPECT scanner adjacent to the 
multi–detector row CT scanner (MDCT), (b) Schematic of a SPECT/MRI system.  [54, 55] 
SPECT can also be combined with MRI to provide precise information (see Fig. 1.6 b). However, 
the implementation of a combined SPECT/MRI system has not yet happened in clinical practice 
due to the incompatibility between SPECT components (like PMT tube) and magnetic field in MRI. 
Recent developments include using silicon photomultipliers (SiPM) and new detector 
technologies like semiconductors (which have immunity to intense magnetic fields) to solve the 





1.2.1.5 PET/CT, PET/MRI 
PET can be combined with other modalities (CT and MRI) to acquire sequential images from both 
devices in the same session, which then are combined into a single image (see Fig. 1.7). In the 
case of PET/CT, the functional imaging obtained by PET is more precisely aligned or correlated 
with anatomic imaging obtained by CT. PET/CT system has revolutionized medical imaging by 




Fig.1.7 (a) Schematic of PET/CT system. CT is positioned in front of a PET scanner, and centers 
of imaging fields are separated by 80 cm (b) Schematic of PET/MRI system [58, 55]. 
 
In the case of a PET/MRI system, combined PET and MRI is an emerging technology that aims to 
capitalize the advantages of MRI, including increased soft tissue contrast and lack of ionizing 
radiation exposure. However, PET-MRI systems are more costly than PET/CT systems due to the 
inherent costs of MRI compared to CT technology [59]. Both PET/CT and PET/MRI have some 
strengths and limitations. As an example, PET/CT are more available compared with PET/MRI; 






1.2.2 Suitable radionuclides for SPECT 
Radionuclides used for SPECT emit low energy γ-rays. Gamma emission occurs when a nuclide, 
which is in an excited state, decays to the ground state with the emission of a quantum of high-
energy electromagnetic radiation (gamma-ray). In this case, there is no change in the mass 
number or atomic number during the emission of a gamma-ray (see Eq. 1.1).  
  𝑃𝐸𝑥𝑐𝑖𝑡𝑒𝑑 𝑠𝑡𝑎𝑡𝑒∗𝑍
𝐴 →  𝐺𝑟𝑜𝑢𝑛𝑑 𝑠𝑡𝑎𝑡𝑒 + ϒ0
0
𝑍
𝐴 . Eq. 1.1 
In the SPECT process, first, a tracer is injected into the bloodstream, and then the tracer emits 
gamma rays (see more details in SPECT section) [61].  
Examples of commonly used radionuclides for imaging are 99mTc and 123I. After injection or 
administered orally, the concentration of radionuclides in tumors and organs can be made visible 
with a SPECT system by detection of the emitted gamma (as discussed above).  
99mTc with a half-life of about 6 hours is the most widely used radionuclide in diagnosis, which 
decays to 99Tc through a gamma emission of 141 keV [62, 63]. There are two common ways for 
the production of 99mTc via nuclear reactor and a cyclotron. A large majority of 99mTc is produced 
in nuclear reactors. More precisely, 99Mo is produced in a nuclear reactor with thermal neutron 
bombardment of enriched uranium targets or through neutron activation of 98Mo [64]. Then 
99Mo (with a half-life of 67 hours) decays by emitting a beta particle to 99mTc. The 99Mo/99mT 
generator system is based on the principle that the shorter-lived radioactive daughter nuclide 
(99mTc) can be easily and repeatedly isolated from 99Mo [64]. However, a Coordinated Research 
Project (CRP) on Accelerator-based production of 99Mo/99mTc as an alternative to Non-HEU 
Production was initiated. There are different potential methods for the production of 99mTc from 
accelerators. The direct production of 99mTc through 100Mo(p,2n)99mTc reaction using accelerators 
is one of the proposed alternatives. Usable quantities of 99mTc are produced through the 
100Mo(p,2n)99mTc reaction, which has a peak in the cross-section at 15–16 MeV. Using this 
reaction, 350 GBq (>9 Ci) of 99mTc, is produced (using 18 MeV protons, 250μA, 6 h irradiation), 





123I with a half-life of 13.2 hours decays 100% by electron capture to 123Te and emits gamma 
radiation with predominant energy of 159 keV. 123I can be produced through different reactions 
(such as 124Te(p, 2n)123I, 123Te(p, n)123I, 122Te(d, n)123I and 124Xe(p, pn)123Xe: 123I) [66]; however, 
the most common reaction for the production of 123I is 124Te(p, 2n)123I reaction on highly enriched 
124Te with the useful proton energy range of 26-20 MeV. The reason for a highly enriched 124Te 
target is due to the production of 124I contamination through 125Te(p, 2n)124I reaction [66].  In the 
production of radiopharmaceuticals, the specific radioactivity (As, which is defined as the 
radioactivity per mass of a labeled compound) must be assessed. However, conventionally 
radioactivity per mol is termed as specific radioactivity. The maximum specific activity of 123I of 
biological interest is 237 Ci/µmol [67].  
1.2.3 Suitable radionuclides for PET 
β+ emitting radionuclides refer to those nuclides which are located on the neutron deficient side 
of the line of beta stability (see Fig. 1.8), and the energy difference between the initial state and 
final state must be more than 1.022 MeV [68]. A beta-plus particle is named a positron, which is 
the antimatter of an electron. The difference in atomic and mass number of parent and its 
daughter results in a neutron, a positron, and a neutrino production (See Eq. 1.2 & Fig. 1.9). The 
positron then scatters off other electrons before its kinetic energy is low enough to annihilate 
with an electron and send off two 511 keV photons under 180 degrees (See Fig. 1.10). The 
location of the annihilation reaction is not the same as where the beta-plus emitting nuclide 
decayed. The higher the positron energy, the further away the positron travels before 




𝐴 →  𝐷𝑎𝑢𝑔ℎ𝑡𝑒𝑟 + 𝑒+ + 𝜈 + 𝐸𝑛𝑒𝑟𝑔𝑦𝑍−1


















Fig. 1.10 Electron-positron annihilation scheme [70]  
 
Radionuclides used in PET imaging are mostly nuclides with short half-lives (see Table 1.1). These 
radionuclides are incorporated into compounds or into molecules that bind to receptors of the 
cancer cells (for more details, see radiopharmaceutical section). The most common radionuclides 
for PET imaging are 18F, 11C, 15O, 13N, 124I, and 68Ga. 18F (with a half-life of 109 min) is the most 
commonly used radiotracer in clinical PET imaging for labeling an FDG molecule. This 18F-FDG 
radiotracer is used mostly in scans for oncology and neurology and makes up the large majority 
of the radiotracers (>95%) used in PET imaging [71]. This is mainly due to the short half-life of 18F, 
which is preferred for imaging, and lack of additional gamma emission (which causes better 
resolution). 18F is produced through proton irradiation of water enriched in the 18O isotope by a 
cyclotron. Two important factors that have an effect on the production yield of 18F are the proton 
beam energy and the beam current being used. One can expect approximately 167 GBq of 18F 
during one hour of irradiation with a 14–19 MeV proton beam at a beam current of 50 µA [72].  
11C with a half-life of 20 min is a suitable radionuclide for PET imaging. While there are several 
routes for producing 11C, the 14N(p,α)11C reaction using nitrogen gas can be considered as an 
important reaction in the context of routine production and use in biomedical research. 
Regarding the experimental data, the expected activity for one hour of irradiation with a 4–17 





15O with a half-life of 2 min is another radionuclide that can be used for PET imaging. There are 
several routes for the production of 15O via a PET cyclotron such as 15N(p,n)15O (with a proton 
energy range of 4-10) and 12C(α,n)15O (with an alpha energy range of 12-30). Regarding the 
previously published studies, the production yield via the 15N(p,n)15O reaction was 2976MBq with 
a beam intensity of 40 μA [74]. 
68Ga with a half-life of 68 min is an interesting radionuclide for PET imaging. 68Ga mostly is 
obtained via a 68Ge/68Ga generator or through the 68Zn(p,n)68Ga reaction. In a 68Ge/68Ga 
generator, the long-lived parent 68Ge (with a half-life of 271 d) is usually obtained by a proton 
cyclotron through the 69Ga(p,2n)68Ge reaction or though the 66Zn(α, 2n) 68Ge reaction. Regarding 
the previous experimental data, 68Zn(p,n)68Ga nuclear reaction resulted in the highest 



















Table 1.1 Decay characteristics for some PET radionuclides [77] 
Radionuclides Half-Life 𝑬𝜷𝒂𝒗
+  [keV] 
Branching 
ratio* (Iβ+) 
15O 2 min 735 100 
13N 10 min 491 100 
11C 20 min 385 100 
18F 110 min 242 100 
68Ga 1.1 h 740 88 
61Cu 3.3 h 309 51 
43Sc 3.8 h 419 70 
44Sc 4 h 596 94.3 
64Cu 12.7 h 124 17.4 
86Y 14.7 h 217 11 
152Tb 17.5 h 210 6 
124I 4.1 d 192 11 
*Branching Ratio (BR) is the ratio of the number of particles that decay via a specific decay 
mode with respect to the total number of particles that decay via all decay modes [78]. 
1.3 Radiopharmaceuticals 
Radiolabeled molecules, called “radiopharmaceuticals,” are considered an essential element in 
nuclear medicine [79, 80]. A radiopharmaceutical comprises two components, including a 
radionuclide and a pharmaceutical. The characteristics of these two components determine the 
usefulness of a radiopharmaceutical. For diagnostic purposes the radionuclide of choice needs to 
be easily detected by radiation detectors and result in minimal radiation dose to the patient. 





In detail, the metallic-based radiopharmaceutical is a metallic radionuclide that has been 
combined with a chelator which is a small molecule that can form very stable complexes with 
radionuclides. However, non-metallic radionuclides (e.g., 15O, 18F, and 11C) allow radiolabeling 
without the help of chelators [82]. There are two main requirements for the chelator choice. 
First, the chelator must form stable complexes with the radionuclide that are stable in human 
serum. Second, it must be possible to react the chelator with biomolecules (that deliver the 
radionuclide to the organ of interest) without affecting its chelating properties [83]. 
Most chelators (e.g., dodecane tetraacetic acid; DOTA) are simple molecules that are easily 
manufactured. These chelators can be chemically linked to a variety of tumor seeking peptides 
such as the Prostate-Specific Membrane Antigen (PSMA). Bifunctional Chelating Agents (BFCAs) 
are employed to stabilize the link between the radionuclide complex and the carrier moiety of 
the radiopharmaceutical [84]. There are several BFCAs that are used as a cross-linker between 
the carrier and the radionuclide. [85]. In Fig. 1.11, a schematic view of a standard four-component 
radiopharmaceutical consisting of a radionuclide complexed by a bifunctional chelator that 
connects this entity via a linker to a bioconjugate is shown in details. 
 
Fig. 1.11 Schematic view of a four-component radiopharmaceutical compound [86] 
Receptors are macromolecular structures composed of proteins on the cell surface that can 





a receptor and eventually lead to some form of cellular or tissue response. It is worth pointing 
out that the retention of the receptor radiopharmaceutical is because of their binding to receptor 
sites. As can be seen in Fig.1.12, the radiopharmaceutical is fixed to the cancer cells through 
interaction with specific receptors, which are found on the cell surface. The binding affinity 
between the ligand and receptor is of great importance in determining the extent of 
accumulation of radioactivity to tumor cells. High binding affinity to non-receptors or other 
receptors can cause a high background radioactivity in imaging [87].  
 
Fig. 1.12 Schematic representation of accumulation of radionuclides to cancer cells through 
binding with specific receptors [88]  
1.3.1 Labeled peptides and antibodies 
A peptide is a short string of amino acids (mostly comprising two to some tens of amino acids) 
that is employed to target specific receptors expressed by the tumor cell [89]. The peptide can 
be labeled with an appropriate radionuclide to localize the radionuclide in the cancer cells. As 
can be seen in Fig. 1.13, the radionuclide attaches to the chelator and then the compound will 
be connected to a peptide using a linker.  The first radiolabeled peptide (111In-pentetreotide, 
111In-DTPA-octreotide, OctreoScan) was used in the diagnosis of neuroendocrine tumors and 
approved by the US Food and Drug Administration (FDA) [90]. Radiolabeled peptides are various 





are used in oncology, where they can be used in diagnostic imaging and therapy by changing the 
radionuclide. Radiolabeled peptides are also being used in cardiac imaging and neurology [90]. 
Peptides are easier absorbed in the body compared to proteins. This is due to the fact that 
peptides are smaller and more broken down compared to proteins. Peptides can be categorized 
based on their application and localization in the body such as Edotreotide (C65H92N14O18S2) or 
DOTATOC which mimics natural somatostatin pharmacologically, or the prostate-specific 
membrane antigen (PSMA), a transmembrane protein expressed in all types of prostatic tissue. 
Fig. 1.14 shows a schematic structure of DOTATOC and PSMA [91, 92]. A pharmacokinetic 
modifying (PKM) linker (Fig. 1.13) is used to modify the radiotracer's pharmacokinetics and 
improve the excretion kinetics of radiolabeled biomolecules [ 93, 94].  
An antibody is a large Y-shaped protein employed by the immune system, which its function is to 
neutralize foreign objects, such as viruses and bacteria. Human antibodies are categorized into 
five isotypes (IgM, IgD, IgG, IgA, and IgE) that provide each isotype with distinct characteristics 
and functions. IgG, which constitutes 70-75% of human antibodies, is the most abundant 
antibody isotype in the blood (plasma). IgM mostly circulates in the blood and comprises about 
10% of human antibodies. IgA (accounting for 10-15% of human antibodies) is abundant in saliva, 
breast milk, serum, and intestinal fluid. IgE (with no more than 0.001% of human antibodies) and 
IgD (with less than 1% of human antibodies) have functions in protecting against parasites and 
involvement in the induction process of antibody production in white blood cells of the 
lymphocyte.  
Antibodies have mainly three functions; 1) Antibodies are inside the bloodstream and mucosa 
and bind to foreign substances such as pathogens and toxins and inactivate them. 2) Antibodies 
have functions in destroying bacterial cells by punching holes in the cell wall. 3) Antibodies 
facilitate phagocytosis of foreign substances by using phagocytic cells. Phagocytosis is a process 
in which a cell takes in bacteria, dead host cells, parasites, or cellular and foreign debris. 
Phagocytosis occurs after the foreign body (for example, a bacterial cell), has bound to receptors 





Radiolabeled antibodies were studied for the first time in the case of tumor detection by single-
photon imaging. It was shown that radiolabeled antibodies could be effective in the treatment of 
lymphoma. Many monoclonal antibodies could be used to treat cancer. Monoclonal antibodies 
(mAb) are made by cloning (a process of generating a genetically identical copy of a cell or an 
organism) of 1 cell (white blood cell) [96, 97]. Monoclonal antibodies are an identical population 
of antibodies that bind to a single epitope of the antigen [96]. Some monoclonal antibodies are 
also used in immunotherapy because they can help turn the immune system against cancer. For 
example, some monoclonal antibodies help the immune system to better recognize and destroy 
cancer cells by marking them. Other monoclonal antibodies helping the immune cells kill the 
cancer cells by bringing T cells close to cancer cells. T cells are one of the most important type of 
white blood cells of the immune system and have a crucial role in the adaptive immune response. 
Radiolabeled antibodies used in minimal (or even small-size) metastatic disease have presented 
promising clinical efficacy while in solid tumors that are less accessible to large molecules (such 
as antibodies), clinical efficacy is limited [98]. As shown in Fig. 1.15, the concept of radiolabeling 
of antibodies and peptides is similar and consists of chelator, linker and radionuclide.       
 






Fig. 1.14 Schematic view of PSMA* (formula depends on PSMA type) and DOTATOC 




Fig. 1.15 Schematic representation of radiolabeling process with antibody [102] 
 
1.3.2 Analogs 
All cells in the body use glucose to get energy. But cancer cells use almost 200 times more glucose 
than normal cells. Tumors that start in the thin, flat cells in the lungs require even more glucose. 
Through this process, cancer cells grow quickly and divide faster. 18F-fluorodeoxyglucose (FDG) is 
a radiotracer used in positron emission tomography (PET) and can be actively transported across 





metabolism and is high in high-grade tumors [103]. Through 18F-FDG PET/CT, malignant lesions 
are detected by identifying regions with increased glycolytic metabolism. However, it is shown 
that increased 18FDG uptake is not only in malignant lesions but also in inflammatory or infectious 
lesions.  So, 18FDG uptake can be observed also in other lesions in the neck, head, pelvis, bones, 
or vasculature.  
FDG uptake patterns are classified as focal or diffuse FDG uptake in the thyroid. In focal uptake, 
lesions were defined as areas of increased tracer uptake compared to the surrounding structures 
by the thyroid, and this focal pattern is associated with a 25–50% risk of malignancy (Fig. 1.16). 
However, diffuse FDG uptake by the thyroid gland is defined as FDG uptake in the whole thyroid 
gland (Fig. 1.17) [104]. 
18FDG also can be used for Cardiac imaging. Positron Emission Tomography (PET) utilizing 18FDG 
is considered the most sensitive modality for detecting myocardial viability in coronary artery 
disease. Based on the reports, 18FDG PET imaging has a benefit over 99mTc- SPECT in 
understanding functional recovery in patients with impaired left ventricular function. The 
diagnostic accuracy of 18F-FDG PET shows sensitivity being superior to other techniques (SPECT, 
echocardiography, and cardiac MRI); however, cardiac PET is not as widely available as other 
techniques [105].  
 
 
Fig. 1.16 Focal 18FDG uptake in thyroid tissue where axial fused PET/CT shows focal uptake in 







Fig. 1.17 Diffuse 18FDG uptake in thyroid gland. As is shown, FDG uptake is in the whole thyroid 
gland [107] 
1.3.3 Therapeutic radionuclides 
Targeted radionuclide therapy or radiotherapy is a cancer treatment that uses high doses of 
radiation to shrink and kill the cancer cells. In radionuclide therapy, mostly radionuclides which 
emit β- or α-particles are used [68].  
 
1.3.3.1 Alpha (α) decay 
Alpha decay occurs in heavy nuclides with many nucleons. In this process, the parent nuclide 
emits a helium nucleus (α-particle) (see Eq. 1.3).  
 𝑃𝑎𝑟𝑒𝑛𝑡 ∗𝑍
𝐴 →  𝐷𝑎𝑢𝑔ℎ𝑡𝑒𝑟 + 𝐻𝑒 + 𝐸𝑛𝑒𝑟𝑔𝑦2 
4 
𝑍−2
𝐴−4  Eq. 1.3 
Targeted alpha therapy is a therapeutic option in patients with multiple micro-metastases. In this 





capabilities, the activity as a high radiation dose is delivered to cancerous cells [68]. An alpha 
particle is an energetic positively charged helium nucleus with an energy range of 4-9 MeV. 
Because alpha particles have a short path length, known as a high linear energy transfer (LET), it 
deposits about 1500 times more energy per unit path length than a β− particle [68].   
Some of the α-emitting radionuclides, which have been investigated and used in animals or 
humans, are listed in Table. 1.2. Among them, 225Ac is particularly attractive due to its relatively 
long half-life (T1/2=10 days), making it appropriate for vector molecules with longer biological 
half-life and internalizing peptides [108]. Moreover, 225Ac decays by four alpha particles 
successively (all half-lives are under 1 hour), which can improve the treatment. 
Table 1.2 Characteristics of selected alpha emitting radionuclides [77] 
Radionuclides Half-Life Decay mode (%) Eα[MeV] (Iα[%]) 

















































1.3.3.2 Beta radiation therapy 
Beta decay occurs in the nuclides that are neutron-rich. The neutral neutron decays into a proton 
(p), an electron (e-), and one electron antineutrino (See Fig. 1.18 & Eq. 1.4).  
 
 𝑃𝑎𝑟𝑒𝑛𝑡𝑍
𝐴 →  𝐷𝑎𝑢𝑔ℎ𝑡𝑒𝑟 + 𝑒 + 𝜈𝑒
− + 𝐸𝑛𝑒𝑟𝑔𝑦𝑍+1
𝐴  Eq. 1.4 
 
Fig. 1.18 Beta decay scheme 
 
Beta particles are electrons with energies of 18 keV up to several MeV that penetrate tissue up 
to 10 mm. In comparison with alpha particles, beta particles ionize differently (lower LET) and 
have a larger range in tissue. In this case, more particles are required to cause lethal damage to 
cancer cells. 177Lu, 131I and 90Y are the widest radionuclides used in clinics because of their suitable 
emission characteristics and affordable production [46]. 131I is used in both visualization and 
therapy in order to implement many malignant tumors successfully [109]. However, 90Y has been 
replaced mostly by 177Lu in cancer therapy due to kidney damage. Some other clinically used beta 








Table 1.3 Characteristics of selected beta-emitting radionuclides [77] 
Radionuclides Half-Life Decay mode (%) 𝑬𝜷𝒂𝒗
−  [keV] 
67Cu 61.83 h β- (100) 156 
90Y 2.7 d β- (100) 933 
177Lu 6.7 d β- (100) 148 
161Tb 6.9 d β- (100) 201 
131I 8.0 d β- (100) 192 
32P 14.3 d β- (100) 695 
 
1.3.4 Theranostic radionuclides 
Theranostic radionuclide is the term used for nuclides that can be applied for diagnosis and 
radiation therapy. This can be achieved by radionuclides that emit both therapeutic (e.g., α or β−) 
and diagnostic (e.g., γ or β+) radiation [110] or by two radionuclides of the same element 
(isotopes) that are separately employed for imaging and therapy (see Fig. 1.19) [111]. Using 
theranostic radiopharmaceuticals is relatively new. The most significant advantage of 
theranostics is that it can be applied to monitor the therapy course during treatment [111]. The 
first and famous theranostic radiopharmaceutical used in nuclear medicine was 131I. Another 
widely used radionuclides in theranostic applications is 177Lu. 131I and 177Lu are beta emitters and 





simultaneously. It is necessary that the production of these radionuclides occurs in non-carrier* 
added form. The currently available radionuclide pairs are illustrated in Fig. 1.20 with some other 
used therapeutic and diagnostic radionuclides. 
To reach the main goal of theranostics, new radionuclides which have optimum decay 
characteristics and chemical properties are needed [112]. Currently, one of the interesting 
pseudo-theranostic pairs is 68Ga/ 177Lu in which 177Lu-labelled counterpart for radionuclide 
therapy are combined with 68Ga-labelled compounds for PET diagnostics (a standard dose of 177Lu 
and 68Ga are between 5.55–7.4 GBq, and 200.0 MBq, respectively). Also, [68Ga] Ga-PSMA-11 for 
diagnosis of metastasized prostate cancer was successfully used for subsequent treatment with 
225Ac (a standard dose of 225Ac is about 6 MBq) in the form of [225Ac] Ac-PSMA-617 (see Fig. 1.21) 
[112, 113, 114]. 
Another very interesting pair for theranostics is 61Cu/67Cu labeled with DOTATOC that can be 
used for neuroendocrine tumors (NETs). NETs are neoplasms, which arise from the nervous 
systems and cells of the endocrine system. They commonly occur in the intestine; however, they 
also have been found in the lung, pancreas and the rest of the body. The 61Cu/67Cu pair can be 
considered as a promising theranostic pair due to having appropriate half-lives for diagnosis and 
therapy, respectively (61Cu with a half-life of 3.3 h and 67Cu with a half-life of 61.8 h). Moreover, 
61Cu, which emits β+ particles with an energy of 1.22 MeV and high Branching Ratio (BR=60%), is 
much better than 64Cu with BR of 17.7% (note that the higher BR results in smaller patient doses). 
67Cu as a therapeutic radionuclide has a dual application for therapy and imaging, it emits β- 
particles with an average energy of 141 keV and gamma-rays of 93 and 185 keV make it ideal for 
both radionuclide therapy and SPECT [115]. 
                                                          
* A preparation of a radioactive isotope which is essentially free from stable isotopes of the corresponding 
element. Minimizing contamination and high specific activity of the radioisotopes can be achieved when they are 














Fig. 1.20 Periodic table of the elements for diagnostic radionuclides suitable for therapeutic and 
PET radionuclides [112] 
 
 
Fig. 1.21 68Ga-PSMA-11 PET/CT scans of a patient. Pretherapeutic tumor spread (A), restaging 2 
mo after third cycle of 225Ac-PSMA-617 (B), and restaging 2 mo after one additional 





1.4 Radionuclide production methods 
1.4.1 Cyclotron production 
A cyclotron consists of different parts, which include: an ion source, a magnet, two D-shaped 
electrodes, and an acceleration chamber [116]. The function of each part is described as follows: 
The ion source produces an ion which can be a proton, deuteron, helium nucleus (3He, 4He), or a 
heavy ion. Then the particle is accelerated from the center (see Fig. 1.22), and a high-frequency 
voltage is applied between two “D”-shaped metal electrodes [117]. Two D-shaped electrodes are 
located between the poles of an electromagnet with a static magnetic field B. Using this magnetic 
field, the particle path will be bent in a circle due to the Lorentz force, which is perpendicular to 
their direction of motion while the particle is inside the “D”-shaped metal electrode the voltage 
is switched to achieve further acceleration across the gap (see Fig. 1.22). So, the particle energy 




, Eq. 1.5 
where q is particle charge, B is the magnetic field, R is the acceleration radius, and m is the 
charged particle’s mass. 
The first cyclotron devoted to medical applications was installed at Washington University in St. 
Louis in 1941 for 32P, 77As, and the production of other radionuclides [119]. Depending on the 
function for which they are intended, cyclotrons come in different sizes, but the basic 
characteristics of all cyclotrons are the same. 
Medical cyclotrons (level I to level III with energy lower than 20 MeV) [120] mostly accelerate 
negative ions, and after acceleration by removing electrons using a striper foil, the accelerated 
negative charges convert to positive charged ion. However, higher energy cyclotrons (level IV to 
level VI) [120] accelerate positive ions. Extraction of the beam in positive ion cyclotrons is 
different compared to negative charge ion cyclotrons. In a positive ion cyclotron, the beam is 
extracted using a deflector at negative extraction voltage, which bends the accelerated positive 





ions, the extraction of the beam is by using stripper foils (such as carbon foils) which remove the 
two electrons attached to the accelerated ion, let the magnetic field reverse the curvature of the 
positively charged particles' path and extract the particles out of the cyclotron (see Fig. 1.24).  
 
 











Fig. 1.24 Extraction mechanism in a negative ion cyclotron using a stripper foil [123] 
 
1.4.2 Nuclear reactor production 
Nuclear research reactors can be used for radionuclide production. Radionuclides are produced 
in a nuclear reactor by exposing target materials to the neutron flux for an appropriate time. 
Before the irradiation, target materials are sealed in a primary irradiation capsule and then 
loaded in special places assigned for irradiation in nuclear research reactors (see Fig. 1.25). In this 
production method, the neutron’s energy, neutron flux, activation cross-section for the desired 
reaction, and characteristics of the target material determine the rate of production [124]. The 
amount of neutron flux for radionuclide production in research reactors should be 1013 to 1014 
n/cm2.s which depends on the power of the nuclear reactor. Nuclear research reactors are used 
mostly for therapeutic radionuclide production such as 131I, 177Lu and 32P [125]. 
In general, there are two different types of nuclear reactors, the first one are nuclear power 
plants and the second one are nuclear research reactors. The former is used for heat generation 
and subsequent electricity production; however, the latter one is for different scientific research 
fields; in particular, for radionuclide production. Nuclear power plants work at high temperature 
and pressure and, therefore, the reactor core is within a pressure vessel which prevents any 
accessibility; in particular, near the fuels where the neutron flux is high. Moreover, they usually 
are working at power that means they usually work continuously since the startup time until the 
time of refueling (usually once per year for water-cooled reactors) or the time which is related to 





considerations). Accordingly, it can reasonably be argued that most nuclear power plants are not 
suitable for radionuclide production purposes. In contrast to nuclear power plants, nuclear 
research reactors are working at a suitable temperature and pressure (usually atmospheric 
condition), and the core is easily accessible for target irradiation.  
The problem associated with nuclear reactor production is that many research reactors are 





Fig. 1.25 Nuclear reactor used for radionuclide production [127] 
 
1.4.3 Electron accelerators 
Electron accelerators are one of the other alternatives for radionuclide production using 
photonuclear reactions. Electron accelerators come as different types, such as linear accelerator, 
Rhodotron, and Microtron, which operate based on different electron acceleration methods and 





1.4.3.1 Linear accelerators 
Linear accelerators are based on microwave technology to accelerate electrons. In a linear 
accelerator, electrons acquire energy while moving on a linear path. A linear accelerator will 
receive the electron beam from an electron source, bunch it at a given RF frequency and then 
accelerate it [128]. Electrons are accelerated through electric fields and are bent and focused 
through magnetic fields (see Fig 1.26). In a linear accelerator, the bunch of electrons will collide 
with a target located at the end of the accelerating electrodes and produce photons through the 
Bremsstrahlung process. Photon energies larger than 8 MeV are required to induce photonuclear 
reactions on the production target [129] (see more details in section 1.5.2). Electron Linacs are 
capable of producing photons with sufficiently high energies and intensities for radionuclide 
production [128, 130]. Through photonuclear reactions, the electron Linac is useful for 
radionuclide production. Regarding this issue, Argonne National Laboratory installed an 
upgraded 55 MeV electron Linac, which can produce a number of various medical isotopes 
through photonuclear reactions [130]. 
Commercially available Linacs are from the company MEVEX in Canada with an optimum energy 
of 33 MeV for 99Mo production. The electron energy of this type of Linac is up to 35 MeV and the 
beam power is up to 120 kW [131].  
Actually, using Linac has a disadvantage associated with radionuclide production. Since beam 
pulses are very short in Linacs (because of the high applied RF), and due to the high intensity of 
the beam (about 300 mA during a beam pulse), a considerable amount of energy is deposited on 






Fig. 1.26 Scheme of the electron Linac acceleration method [132] 
1.4.3.2 Microtron accelerator 
In a Microtron, the electrons which revolve in a uniform magnetic field are accelerated each time 
by passing through an electric field. In a Microtron, the electrons' momentum increases, and 
particle paths are different for each pass (see Fig. 1.27). 
In a Microtron, the particle paths are different for each pass due to the electrons' increasing 
momentum. In this case, the slow electrons need an electric field oscillation and the faster 
electrons need an integer multiple of this oscillation. There are some advantages associated with 
Microtron over a linear accelerator which are its simplicity, ease of energy selection, compact 
size, low energy dispersion and more efficient acceleration (due to circular rotation compared to 
the longitudinal direction in the linear accelerators for the same output electron energy, see Figs. 
1.26 & 1.27) [133].  
A Microtron exists at METAS (Federal Institute of Metrology) in Switzerland, which has a 
maximum energy of 22 MeV and beam currents up to 20 μA.  This system is equipped with a 
target that converts the primary electron beam into a high flux photon spectrum of up to about 
20 MeV photon energy. This Microtron is a suitable photon source for the production of 67Cu, 






Fig. 1.27 Microtron basis for electron acceleration [133] 
 
 
1.4.3.3 Rhodotron accelerator 
A Rhodotron is a high-power electron beam accelerator, which can accelerate electrons to high 
energies (up to 40 MeV) and allows for efficient radionuclide production through photonuclear 
interaction (see Fig. 1.28a). A Rhodotron works based on “re-circulating” a beam through 
successive diameters of a single coaxial cavity resonating in metric waves (see Fig. 1.28b) [134]). 
As can be seen in Fig. 1.28, a Rhodotron also is able to provide different beams with different 
electron beam energies depending on the number of passages through the cavity and 
acceleration voltage.  
Rhodotrons have been invented and patented by the IBA company. Commercially available 
Rhodotrons are available from the company IBA (40 MeV and 125 kW beam power). In this 
commercial Rhodotron, the maximum number of passes of an electron is 12, and the energy gain 
with each pass is 3.3 MeV.  
For efficient radionuclide production, the high-energy and high-power (or high-current) 





accelerator is the considerable amount of heat that is deposited in the converter target, which 
causes a sharp temperature rise and, therefore, mechanical instability.  
 
 
Fig. 1.28 a) Schematic representation of a Rhodotron accelerator, b) Rhodotron mechanism 
scheme, where Ei is the electron beam with different energy [134, 135] 
 
1.5 61Cu/67Cu theranostic pair 
The selection of suitable radionuclides for theranostic applications is of great importance and 
requires some properties: 1) appropriate half-life, which is close to the biological half-life of the 
radionuclide in the desired tissue); 2) existence of two different isotopes that are suitable for 
both imaging and therapy; 3) lack of high-energy gamma-ray emission, 4) availability and cost-
effective production of the radionuclide and 5) suitable chemical properties, i.e. suitable 
chelators. As such, copper isotopes are an excellent option for theranostic applications due to 
their appropriate half-lives and their decay properties (β+, β−, or EC), which are suitable for both 
imaging and therapy [136]. 
61Cu, with a half-life of 3.3 h, is a positron emitting radioisotope that can be used for PET imaging. 
61Cu (Eβ+= 1.22 MeV, BR (%)=60) has a much higher abundance of positron emission than 64Cu 





67Cu is a great candidate to be is used as a therapeutic isotope due to its appropriate half-life, 
and its dual application for therapy and imaging and it is a non-essential element for the body. 
The nuclide 67Cu (T1/2 = 62.83 h) emits β− particles with an average energy of 141 keV, and γ-rays 
(93 keV, BR (%)=16.1, and 185 keV, BR (%)= 48.7) make it ideal both for radionuclide therapy and 
SPECT imaging [139]. 
It is ideal if therapeutic radiopharmaceuticals localize in the tumor in sufficient concentration, 
which is called a target-specific radiopharmaceutical. Copper radioisotopes (61Cu/67Cu) are able 
to bind with a chelator and a targeting biomolecule and are very suitable for preparing chelates 
for the use as a theranostic application. However, 67Cu is also able to be used as a theranostic 
radionuclide by itself due to simultaneous use in radionuclide therapy coupled with SPECT 
technology [139]. In the following, 61Cu and 67Cu production through different reaction channels 
were investigated.  
1.5.1 61Cu production routes 
Radionuclide production for use in biomedical procedures is obtained through nuclear reactions 
in charged particle bombardments in accelerators or from nuclear reactors. Regardless of the 
production method, the beams (in accelerators)/ neutron flux (in nuclear reactors) must have 
enough energy required in the region of interest of the excitation function for the production of 
desired radionuclides and sufficient beam-current/flux to give practical yields. Another factor 
playing a significant role in the selection of the production method is that the reaction method 
must be chosen so that the product is produced in a non- carrier added form. In addition, the 
nuclear absorption cross-section, which represents the total probability of a nuclear reaction, 
should be as high as possible to allow for a high yield production of the desired radionuclide [140, 
141]. For 61Cu production, the most suitable nuclear reactions are 61Ni(p,n)61Cu, natNi(α,x)61Cu, 
and 64Zn(p,α)61Cu (see Fig. 1.29). In the following, these reaction routes are considered in detail. 
It is worth pointing out that the feasibility of 61Cu production in high radionuclide purity and 
amount to allow radiolabeling is the main objective for the selection of the best reaction route 







Fig. 1.29 61Cu different production routes 
natNi(p,x)61Cu reaction route 
61Cu can be produced from 61Ni and 62Ni via (p,n) and (p,2n) reaction channels, respectively. The 
production of 61Cu via these reaction channels results in a high yield due to high cross-sections (> 
300 mb). Regarding the experimental published data, the beneficial energy ranges to produce 
61Cu from a 61Ni target are proton energies from 5–20 MeV, and the maximum cross-section is 
418 mb at 10 MeV [145]. Due to low impurities' production, this reaction can be considered one 
of the desirable production routes. Regarding the experimental published data, 61Cu was 
produced with a maximum yield of 144 mCi using enriched 61Ni target ($37 per mg). Ni targets 
were prepared using an electroplating technique and then irradiated with approximately 14.7 









natNi(α,x)61Cu reaction route 
61Cu can be produced via alpha-particle irradiation on natural or enriched Ni targets. The natural 
Ni target is composed of two stable isotopes 58Ni (68.0%) and 60Ni (26.2%). Using these reaction 
channels, 61Cu can be produced with alpha-particle energies in the range between 8-24 MeV. It 
should be noted that the 58Ni(α,p)61Cu reaction is the only contributing channel in the energy 
range of 3–24 MeV (with a maximum cross-section of 501 mb at the energy of 15 MeV), while 
the threshold energy of the 60Ni (α,p2n)61Cu reaction channel is at 18 MeV (with a maximum 
cross-section of 278 mb at the energy of 40 MeV). So, due to the higher abundance of 58Ni target, 
lower threshold energy of the 58Ni(α,p)61Cu reaction, and higher cross-sections, one can conclude 
that production of 61Cu via the 58Ni(α,p)61Cu reaction is economical and practical [146, 147]. 
64Zn(p,α)61Cu reaction route 
The production of 61Cu from 64Zn target via proton-induced nuclear reactions is regarded as an 
attractive option due to low impurity production and high obtainable yield. According to 
published data [145], the best energy range for 61Cu production is 6–25 MeV, and the maximum-
cross section is 25 mb at an energy of 13 MeV. Moreover, regarding the high natural abundance 
of 64Zn target (48.6%), the target would be cost-effective (about 1.2 $ per mg). However, the low 
cross-section in comparison with the 61Ni(p,n)61Cu reaction, can be satisfied by irradiation of a 
tick target of 64Zn.  
Regarding the previously published study [148], 61Cu was produced from 64Zn with 99.30% 
isotopic enrichment (about 1.2 $ per mg). The irradiations were performed at two different 
cyclotrons. One cyclotron was a CC 18/9 (Efremov Institute, Russia) in Turku, and the second one 
was a Cyclone 18/9 (IBA, Louvain la Neuve, Belgium) in Rossendorf. The targets were irradiated 
with both cyclotrons for 0.5–3 h with various beam currents. Regarding the results, an activity of 
61Cu obtained was 290 MBq and 339 MBq at the Cyclone 18/9 (with a beam current of 12 µA) 







Nuclear model calculation for cyclotron production of 61Cu as a PET imaging 
Authors: Mahdi Sadeghi, Nadia Zandi, Mahdi Bakhtiari 
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Highlights: 61Cu with a half-life of 3.3 h, offers some advantages over 64Cu when using it for PET 
imaging [138]. In the paper presented in the following, cyclotron production of 61Cu via different 
reactions has been investigated. The ALICE/ASH and TALYS-1.2 codes were used to calculate 
excitation functions for proton, alpha and deuteron induced reactions on different targets that 
lead to the production of 61
the data obtained from this study was compared with the reported experimental data. Regarding 
the results presented in the paper, the theoretically obtained results were in good agreement 
with the reported experimental data. Moreover, optimal thicknesses of the targets and physical 
yield were obtained by calculating the stopping and range of ions in matter for each reaction. 
Finally, considering the possibilities to produce 61Cu and the existing facilities and materials, we 
used the natNi(p,x)61Cu reaction to test the target preparation. Accordingly, natural nickel (99.99% 
purity, purchased from Aldrich) was electroplated on a gold-coated copper backing with 48 μm 
thickness and 11.69 cm2 area (for more details, refer to the attached paper). 
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calculations, investigating the results and writing the manuscript. 
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Abstract 61Cu is positron emitter and can be used as the
PET and molecular imaging. In this study cyclotron produc-
tion of 61Cu via 61Ni(p,n)61Cu, natNi(p,x)61Cu, natNi(d,x)61Cu,
natNi(a,x)61Cu, natZn(p,x)61Cu and 59Co(a,2n)61Cu reactions
was investigated. The ALICE/ASH (hybrid and GDH mod-
els) and TALYS-1.2 codes were used to calculate excitation
functions for proton, alpha and deuteron induced on natNi,
proton on 61Ni and natZn and also alpha-particle on 59Co
targets that lead to the production of 61Cu radioisotopes using
intermediate energy accelerators. In addition, we compared
the data obtained from in this study with the reported mea-
surement by experimental data. Moreover, optimal thickness
of the targets and physical yield were obtained by stopping
and range of ions in matter code for each reaction. Eventually
61Ni(p,n)61Cu and 59Co(a,2n)61Cu reaction to produce 61Cu
in no-carrier added state with high production yield was
suggested. Finally the natNi(p,x)61Cu reaction was employed
to test the target preparation using electroplating technique.
Keywords Excitation function  61Cu  Physical yield 
TALYS-1.2  ALICE/ASH  Ni electroplating
Introduction
Copper has many radio-nuclides (60Cu, 61Cu, 62Cu, 64Cu,
and 67Cu) that can be used in nuclear medicine and
molecular imaging [1, 2]. 61Cu offers several advantages
over other Cu radioisotopes for labeling radiopharmaceu-
ticals for positron emission tomography (PET). Interest-
ingly, it has been shown that the tomographic images
obtained using 61Cu are superior to those using 64Cu, based
on the larger abundance of positrons emitted by 61Cu
compared with 64Cu [3]. 61Cu is a positron emitter
(T1/2 = 3.33 h, b
?: 62%, EC: 38%), with excellent
potentials for application in the PET method and molecular
imaging [4]. Molecular imaging is a new biomedical
research discipline enabling the visualization, character-
ization, and quantification of biologic processes taking
place at the cellular and sub-cellular levels within intact
living subjects including patients [5].
In our previous articles, we evaluated cyclotron pro-
duction parameters of 172Lu, 93mMo, 122Sb, and 109Cd via
various codes and compared with existing data [6–9]. In
this work, several methods for 61Cu production using
TALYS-1.2 and ALICE/ASH (hybrid and GDH models)
codes have been studied. There are different methods to
produce 61Cu via proton, deuteron and alpha particles on
various targets such as natNi, 61Ni, natZn, natCu and 59Co
[10–34]. The aim of the presented study is to compare the
calculated cross sections for the production of 61Cu via
different reactions with incident particle energy up to
50 MeV as a part of systematic studies on particle-induced
activations on metal targets, theoretical calculation of
physical yield, calculation of target thickness requirement
and suggestion for optimum reaction to produce 61Cu.
Theoretical calculation of physical yield and target thick-
ness was done using Stopping and Range of Ions in Matter
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(SRIM) code [35]. To find the aberration amount of the
acquired data from in this study and experimental data, and
TENDL-2010 [36], they were compared with each other.




Excitation functions of 61Ni(p,n)61Cu, natNi(p,x)61Cu,
natNi(d,x)61Cu, natNi(a,x)61Cu, natZn(p,x)61Cu and
59Co(a,2n)91Cu reactions were calculated using TALYS-
1.2 and ALICE/ASH (hybrid and GDH models) codes
[37, 38]. According to results an optimum energy range
was determined and employed to avoid the formation
of radionuclide impurities and decrease the excitation
functions of inactive impurities as far as possible.
The TALYS 1.2 code
The TALYS program simulates nuclear reactions that
involve gammas, neutrons, protons, deuterons, tritons, 3He
and a-particles in the incident energy range from 1 keV to
200 MeV for target nuclides of mass 12 and heavier. The
TALYS code was designed to calculate total and partial
cross sections, residual and isomer production cross sec-
tions, discrete and continuum c-ray production cross sec-
tions, energy spectra, angular distributions, double
differential spectra, as well as recoil cross sections. The
TALYS code takes into account three types of reaction
mechanisms: DIR [coupled channel analysis, distorted
wave born approximation, etc.], PEQ (one- and two-com-
ponent exciton models), and EQ (Hauser–Feshbach model)
[37].
ALICE/ASH code
The ALICE/ASH code is an advanced version of the ori-
ginal Blann code [38]. The code calculates energy and
angular distributions of particles emitted in nuclear reac-
tions, residual nuclear yields, and total non-elastic cross-
sections for nuclear reactions induced by particles and
nuclei with energies up to 300 MeV [38]. Concerning the
implementation in the code, the models are describing the
pre-compound composite particle emission and fast c-
emission, different approaches for the nuclear level density
calculation [39] and the model for the fission fragment
yield calculation. The geometry dependent hybrid (GDH)
model is used for the description of the pre-equilibrium
particle emission. Intra-nuclear transition rates are calcu-
lated using the effective cross section of nucleon–nucleon
interactions in nuclear matter. The equilibrium emission of
particles is described by the Weisskopf–Ewing model
without detail consideration of angular momentum.
Calculation of the physical yield and the target
thickness
Enhance of the projectile energy, beam current, and time
of bombardment increase the production yield. Theoreti-










r Eð Þ dE ð1Þ
where Y is the activity of the product (in Bq), NL is the
Avogadro number, H is the isotope abundance of the target
nuclide (%), M is the mass number of the target element
(g), r(E) is the cross-section at energy E (mb), I is the
projectile current (lA), dE/d(qx) is the stopping power
(MeV/mg/cm2), k is the decay constant of the product and
t is the time of irradiation (h). The physical yields were
deduced using the measured cross-sections by using the
Simpson numerical integral method from Eq. 1. To predict
theoretical physical yields calculated by means of the
acquired cross-section data and stopping powers of pro-
jectiles in target material, a nuclear code named SRIM [35]
was used. According to the SRIM code, the required
thickness of the target was calculated for each reaction.
The physical thickness of the target layer that was calcu-
lated by SRIM code is for 90 geometry beam toward the
target. To better heat transfer on the surface of the target
and the beam cover all surface of the target (11.69 cm2), 6
geometry beam toward the target during the bombardment
was performed [40]. So required layer thickness will be
less with coefficient 0.1.
Results and discussion
Excitation function of 61Ni(p,n)61Cu reaction
According to TALYS-1.2 code, beneficial energy range of
the projectile particle (proton) to produce 61Cu from 61Ni
target is 5–20 MeV that maximum cross section is 418 mb
at 10 MeV (Fig. 1). To limit the production of impurities
60Cu (23.7 m) and 58Co (70.86 days) and to attain its
benefit energy range, the 5–9 MeV energy range was
considered. In this reaction, data obtained from TALYS-
1.2, ALICE/ASH and TENDL-2010 are in good agreement
with the previous published results (Fig. 2). Accordingly
this reaction is suggested as one of the best method to
production of 61Cu in no carrier state. The calculated
778 M. Sadeghi et al.
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physical yield is 1379.7 MBq/lA h. The recommended
target thickness was calculated using the SRIM code
(Table 1).
Excitation function of natNi(p,x)61Cu reaction
In this study excitation functions of the proton-induced
reaction on natural nickel were measured by TALYS-1.2
and ALICE/ASH (hybrid and GDH models) codes and
compared to existing data (Fig. 3). Regarding to TALYS-
1.2 code data for this reaction, 61Cu has a maximum cross-
section of about 13 mb at 21 MeV; its beneficial excitation
functions occur between 17 and 24 MeV. Because of very
low cross section to produce 61Cu, this reaction basically is
not suggested as the one of the best reaction to produce
61Cu especially as the medically application. As the natural
nickel is composed of five stable isotopes (Table 2), the
natNi(p,x)61Cu reaction leading to the formation of the 60Cu
(23.7 m), 59Cu (81.5 s) and 58Cu (3.2 s) impurities in this
energy range. Figure 4 shows the comparison between
cross section values reported by Saleh [10], Michel [11, 12]
and Barrandon [13] and the results of nuclear model cal-
culations employing the different theoretical calculations.
Almost in all energy regions, calculated data from TALYS-
1.2 and ALICE/ASH codes are in good agreement with the
cross section value reported by experimental data.
According to SRIM-2006 code the required target thick-
ness to achieve this energy range should be 47.0 lm for 6
geometry beam toward the target (Table 1). The physical
yield of 61Cu was obtained 68.0 MBq/lA h.
Excitation function of natNi(d,x)61Cu reaction
Excitation functions based on TALYS-1.2 code calculation
are shown in Fig. 5 at different decay channels after deu-
teron bombardment of natural nickel. According to Fig. 5
the natNi(d,x)61Cu reaction leading to the formation of the
60/58/57Co and 60Cu impurities in 3–14 MeV. To restrict
production of impurities as far as possible, 3–8 MeV is
Fig. 1 Excitation function of 61Ni(p, x)61Cu reaction calculated by
TALYS-1.2 code
Fig. 2 Excitation function of 61Ni(p, x)61Cu reaction calculated by
ALICE/ASH (hybrid and GDH models) and TALYS-1.2 codes and
experimental data










61Ni(p,x)61Cu 20 ? 5 77.2 1379.7
natNi(p,x)61Cu 24 ? 17 47.0 68.0
natNi(d,x)61Cu 14 ? 3 23.8 52.8
natNi(a,x)61Cu 21 ? 8 6.2 167.2
natZn(p,x)61Cu 25 ? 6 56.5 110.7
59Co(a,2n)61Cu 35 ? 16 153.2 249
Fig. 3 Excitation function of natNi(p, x)61Cu reaction calculated by
TALYS-1.2 code
Cyclotron production of 61Cu as a PET imaging 779
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presented as the beneficial range of energy. Figure 6 shows
the comparison between cross section values reported
by Takacs et al. [16, 17], Hermanne et al. [18], Zweit [27]
and the results of nuclear model calculations employ-
ing the different theoretical calculations. It should be
noted that TALYS-1.2 code predicted cross sections for
natNi(d,x)61Cu reaction are lower than ALICE/ASH,
TENDL-2010 and experimental data. In the maximum
value point to production of 61Cu at 6 MeV, the ALICE/ASH
(hybrid and GDH models), TENDL-2010 and experimental
data are in good agreement with each others. According to
the SRIM code the required thickness of target is 23.8 lm for
6 geometry of the beam toward the target (Table 1). The
physical yield of 61Cu was obtained 52.8 MBq/lA h.
Excitation function of natNi(a,x)61Cu reaction
Using the natNi(a,x)61Cu reaction to produce 61Cu, the best
range of incident energy was assumed 8–21 MeV whose
maximum cross section by TALYS-1.2 code is 345 mb at
15 MeV (Fig. 7). In this energy range, 63/62/60Cu, 63/61Zn
are simultaneously produced. 63Cu is a stable isotope and
could not be separated by chemical methods; therefore this
reaction does not lead to produce 61Cu in no-carrier added
state [41, 42]. Figure 8 shows the comparison between
previous published results and the results of nuclear model
calculations employing the different theoretical calcula-
tions. As can be seen on Fig. 8, the predicted data by
TALYS-1.2, ALICE/ASH codes and data obtained from
TENDL-2010 are in acceptable agreement with Takacs
et al. [14], Singh et al. [15] and Michel et al. [26]. The
calculated physical yield is 167.2 MBq/lA h. The recom-
mended target thickness was calculated using the SRIM
code (Table 1).
Excitation function of natZn(p,x) 61Cu reaction
Although natural zinc are composed of five stable isotopes
(64Zn 48.6%, 66Zn 27.9%, 67Zn 4.1%, 68Zn 18.8% and 70Zn








Fig. 4 Excitation function of natNi(p, x)61Cu reaction calculated by
ALICE/ASH (hybrid and GDH models) and TALYS-1.2 codes and
experimental data
Fig. 5 Excitation function of natNi(d, x)61Cu reaction calculated by
TALYS-1.2 code
Fig. 6 Excitation function of natNi(d, x)61Cu reaction calculated by
ALICE/ASH (hybrid and GDH models) and TALYS-1.2 codes and
experimental data
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0.6%) but 61Cu can be produced from only channel of 64Zn.
Figure 9 presents the excitation function for 61Cu produc-
tion via natZn(p,x) 61Cu reaction. According to the figure,
the best energy range for 61Cu production is 6–25 MeV and
the maximum cross section (25.5 mb) appears at 13 MeV.
In this energy range there are some impurities such as
60/63/65Cu and 67Ga. Since 63Cu and 65Cu are stable iso-
topes and could not be separated by chemical methods, this
reaction does not lead to production of 61Cu in no-carrier
added form. The results obtained from in this study and the
previous published experimental data are compared in
Fig. 10. Recommended thickness of the target is 56.5 lm
for 6 geometry beam toward the target (Table 1). Theo-
retical physical yield in view of the chosen energy range is
110.7 MBq/lA h.
Excitation function of 59Co(a,2n) 61Cu reaction
Through this reaction to produce 61Cu the best range of
incident energy was assumed 16–35 MeV that maximum
cross-section is 292 mb at 25 MeV. In this energy range
57Co (271.7 days), 58Co (70.8 days), and 62Cu (10 min)
impurities are simultaneously produced (Fig. 11). To avoid
57Co production, its beneficial excitation functions occur
between 16 and 27 MeV. As the natural cobalt is composed
of 1 stable isotope (59Co 100%), this reaction is considered
the best reaction to no-carrier added production of 61Cu at
cyclotron. Figure 12 shows the comparison of calculated
data obtained from in this study and previous experimental
data. Physical yield and target thickness were calculated by
Fig. 7 Excitation function of natNi(a, x)61Cu reaction calculated by
TALYS-1.2 code
Fig. 8 Excitation function of natNi(a, x)61Cu reaction calculated by
ALICE/ASH (hybrid and GDH models) and TALYS-1.2 codes and
experimental data
Fig. 9 Excitation function of natZn(p, x)61Cu reaction calculated by
TALYS-1.2 code
Fig. 10 Excitation function of natZn(p, x)61Cu reaction calculated by
ALICE/ASH (hybrid and GDH models) and TALYS-1.2 codes and
experimental data
Cyclotron production of 61Cu as a PET imaging 781
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considering TALYS-1.2 code and SRIM data (Table 1).
Recommended thickness of the target is 153.2 lm for 60
geometry beam toward the target (Table 1). The calculated
physical yield is 249 MBq/lA h.
Target preparation
Among the possibilities to produce 61Cu, with respect to
existing facilities, we employed natNi(p,x)61Cu reaction to
test the target preparation. The medical application require
highly enriched 61Ni target. The natural nickel target was
prepared by stack foil technique reported by Saleh et al.
[10]. High purity Ni foils (99.9%) from Goodfellow Metals
Ltd UK, of thickness (12.6 and 25.2 mm) were used as
targets (circular foils of 10 mm diameter) [10]. In this
study we employed electroplating technique to prepare
natNi target. Natural nickel (99.99% purity, Aldrich) was
electroplated on a gold-coated copper backing (48 lm
thickness, 11.69 cm2). Appropriate quantities of nickel
metal were dissolved in hot 6 M nitric acid and evaporated
to dryness. The residue was treated with concentrated
sulfuric acid followed by dilution with de-ionized water.
The volume of the solution was adjusted to approximately
400 mL with de-ionized water. The PH was then adjusted
to 3–4 with concentrated sodium hydroxide and the final
volume was 450 mL. This solution was transferred to the
cell and used for electroplating with a 50 mA cm2 dc
current density at 45 C temperature. The complete elec-
troplating process took 12 h [43].
Conclusions
In this work we employed ALICE/ASH (hybrid and GDH
models) and TALYS-1.2 codes to calculation the excitation
functions of 61Ni(p,n)61Cu, natNi(p,x)61Cu, natNi(d,x)61Cu,
natNi(a,x)61Cu, natZn(p,x)61Cu and 59Co(a,2n)61Cu reac-
tions. The 61Cu physical yield was evaluated with attention
to excitation function and stopping power. Among these
possibilities to produce 61Cu, natNi(a,x)61Cu, 61Ni(p,n)61Cu
and 59Co(a,2n)61Cu reactions have higher cross sections
compared to other reactions but bombardment natNi via
alpha particles doesn’t lead to produce 61Cu in no-carrier
added form. Therefore, 61Ni(p,n)61Cu and 59Co(a,2n)61Cu
reactions are considered as the best reaction to no-carrier
added production of 61Cu at cyclotron.
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1.5.2 67Cu production routes 
67Cu can be produced via different methods using proton, deuteron, and heavy-ion accelerators, 
electron accelerators, and nuclear reactors (see Fig. 1.30). In each method, the probability of a 
nuclear reaction is assessed by the cross-section as a function of the energy. Thus exact 
knowledge of the individual values is of uppermost importance, especially when optimization of 
the product yield and radionuclide purity is considered. 
In recent years the most limiting factor for using 67Cu in clinical trials was its availability. Although 
studies on 67Cu production started about 45 years ago in nuclear reactors since the last decades, 
its production shifted to particle accelerators due to some problems associated with nuclear 
reactors and also the higher quality of the 67Cu product that is required for its medical use in 
targeted therapy [151, 152].  
 
 






68Zn(p,2p)67Cu reaction route 
67Cu can be produced through irradiation of an enriched 68Zn target at a proton accelerator. A 
number of earlier experimental data can be found in the literature about the production of 67Cu 
by proton irradiations on enriched 68Zn or natural Zn targets.  
Regarding TENDL data [153], the maximum cross-section for 67Cu through the 68Zn(p,2p)67Cu 
reaction channel amounts to 22 mb at energy of 70 MeV [154]. According to published data, the 
energy threshold for production of 67Cu using a proton accelerator is at about 30 MeV. A 
cyclotron with energies above 35 MeV is considered a high-energy cyclotron [155], and the 
number of research cyclotrons generating such high-energy protons is limited. Therefore, this 
reaction cannot be regarded as the best reaction route to provide sufficient activities per year 
regarding the low cross-section of the reaction in most available cyclotrons. 
Based on a previously published study (using the 70 MeV proton cyclotron at the ARRONAX 
facility), the yield of 67Cu obtained in the energy range 35-70 MeV is 24.25 MBq/µAh.  
Among other studies, some authors studied 67Cu production using a high energy proton beam 
(660 MeV). Such a high energy range is not reasonable for cost-effectiveness and commercial 
production of 67Cu [155, 156]. 
70Zn(p,α)67Cu reaction route 
One of the other possible routes to the production of 67Cu is proton irradiation of enriched 70Zn 
with a cyclotron. According to previously published data, the maximum cross-section for the 
production of 67Cu from this reaction is 14 mb at an energy of 17 MeV [157]. Regarding previous 
published study, the thick-target yield of 67Cu through the irradiation of 100 % enriched 70Zn 
material was 38 MBq/μAh [158]. 
Although 67Cu production through this reaction channel does not require a high energy cyclotron, 
the very low abundance of 70Zn in natural zinc (below 1 %) does not make this reaction channel 




64Ni(α,p)67Cu reaction route 
Regarding Skakun in 2004 [159], the maximum cross-section for this reaction is 36 mb at an 
energy of 20 MeV. According to the data, the production of 67Cu by irradiation of 64Ni metal 
targets yielded activities of 544 kBq/μAh. Thus this reaction cannot provide high enough activities 
due to the low cross-sections.  
Although the production activity using a 64Ni target is lower than that using a Zn target via the 
68Zn(p, 2p)67Cu or natZn(p,x)67Cu channels, the quality (specific activity and radionuclide purity ) is 
much better [160]. 
67Zn(n,p)67Cu reaction route 
The production of 67Cu is feasible by neutron irradiation of 67Zn targets through the 67Zn(n,p)67Cu 
reaction channel [161, 162]. However, this method requires fast neutrons with energies above 1 
MeV, which requires a fast nuclear reactor. Since the number of fast neutron reactors is limited 
globally and due to the low cross-sections of this reaction channel, this method is not considered 
the best for routine production of 67Cu.  
Based on a previously published study, neutron irradiation of highly enriched 67Zn targets in a 
thermal neutron reactor yielded 29.6 MBq/g 67ZnO of 67Cu and due to the highly enriched target, 
production of undesired isotopes, particularly 65Zn and 69mZn, was reduced significantly which 
would be detrimental to the recovery of valuable target material [162]. The target material in the 
study was zinc oxide since oxides targets are ideal for reactor-based irradiations, as they dissolve 
readily in mineral acids and are simple to work with.  
Photonuclear reaction through 68Zn(γ,p)67Cu 
Currently, charged-particle reactions with proton, deuteron, or alpha and neutron-induced 
fission are considered the main routes for producing diagnostics and therapeutic radioisotopes. 
But, unfortunately, some disadvantages come along with both production techniques. As 
mentioned above, nuclear reactors are planned to be shut down in a few years due to problems 
concerning safety and, also security concerns [163]. Concerning the production using cyclotrons, 
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although they may not have such risks compared to nuclear reactors, they can only produce a 
limited range of medical radionuclides and very limited activities, especially for therapeutic 
radionuclides. Due to these problems, using a high-intensity and high-energy photon beam for 
radioisotope production through photonuclear reaction is becoming an option. Additionally, the 
photonuclear radioisotope production method allows obtaining high specific activities for 
radioisotopes, which are not produced in adequate quantities to satisfy current demands. In this 
technique, when a photon is incident on a nucleus, the excited nucleus decays to release the 
excitation energy. The most probable decays are single or multi neutron emission and, after that, 
proton emission. 
The cross-section for photonuclear reactions is usually at energies from 8 to 30 MeV which are 
called Giant Dipole Resonances (GDR) (see Fig. 1.31 & Fig. 1.32) [164, 165]. Several de-excitation 
events such as nuclear fission, emission of neutrons or gamma rays, or combinations of these 
usually occur through GDR. The photons for irradiating photo-nuclear reaction’s targets are 
commonly produced as Bremsstrahlung radiation [166] using electron accelerators. 
Bremsstrahlung radiation is electromagnetic radiation given off mainly by an electron due to a 
sudden slowing down or deflection caused by another charged particle’s electric field (see Fig. 
1.33). In the photonuclear reaction process, the high electron beam hits to a converter target, 
and through Bremsstrahlung radiation, photons are produced. Convertor should be a material 
with high atomic density and high melting points such as tantalum or tungsten. After that, 
photons hit the production target for radioisotope production (see Fig. 1.34). 
The theoretical estimated activity of 67Cu through irradiation of enriched 68Zn target, via 
photonuclear production, is 16.25 (GBq/125 kW.d). This calculation has been done via MCNPX 
code for a high energy 40 MeV Rhodotron, with 125 kW power [167]. Regarding the experimental 
published data [168], the yield for the irradiation of natural zinc target via a 41 MeV Linac with a 
beam current of 200 μA, obtained 10.33 mCi/g.day (382.21 MBq/g.day). It should be noted that 
regarding Fig. 1.32, there is a huge discrepancy between TENDL and experimental data, and it 





Fig. 1.31 GDR region for photonuclear reaction. The GDR region is defined as a range in cross-
section in which most photon-absorption reactions for almost all of the nuclei occur at. In this 
region (which is in the photon energy range of 8-30 MeV for most middle and heavy mass nuclei), 
the nucleus acts as a whole, and a collective oscillation of all protons against all neutrons in a 
nucleus happens. The schematic representation for the Bremsstrahlung photon flux variations as 
a function of photon energy reveals a decreasing trend of photon flux with increasing photon 
energy. This implies that not all of the incident photons contribute to photonuclear reactions, 






Fig. 1.32 Cross-section of 67Cu via 68Zn(γ,p)67Cu reaction obtained through TENDL compared 
with experimental data[169] 
 





















1.6 Radiochemical separation 
Radiochemistry is the discipline dedicated to the study of the chemical and physical properties 
of radionuclides. Using nuclear reactions, stable nuclides are transformed to radioactive ones and 
it is needed to separate the nuclide of interest from other radioactive and non-radioactive 
nuclides that are present. This can be achieved by performing radiochemical separation 
consisting of conventional separation techniques adapted to radiochemistry's special needs.  
There are different methods to separate copper from the zinc target after irradiation. Each 
technique has its radiochemical yield, and can be considered depending on the application of the 
radioisotope. 
1.6.1 Solvent extraction 
Solvent extraction, also called liquid-liquid extraction, is when the compounds are first mixed and 
then separated based on their relative solubilities in two different immiscible liquids. Mixing has 
an effect on the extraction, which produces little droplets with a large surface for transfer. 
Immiscible liquids are usually aqueous solution and an organic solvent and separate into layers 
after being intensively mixed (see Fig. 1.35) [171]. Immiscible liquids that do not dissolve in one 
another form layers when put together. This is due to the fact that each liquid differs in polarity. 
In this case, one particular liquid is on top and another is on the bottom depending on their 
density. The method of extraction usually is performed by a separatory funnel. First, the liquid 
mixture is added to the separatory funnel. Then the extraction solvents are added to the funnel. 
When extracting solvent is mixed with a solution containing solute, then solute from the original 
solvent gets transferred into an extracting solvent. When stirring is stopped the extracting 
solvent forms a separate layer and now contains the solute of interest. Based on the Nernst law 
[172], when a solute component that is soluble in both solvents is added, it gets distributed 
between them. Then molecules of the solute pass from solvent A to B and from B to A. Finally, at 
dynamic equilibrium, the rate at which molecules of the solute pass from one solvent to the other 
is balanced. Then (see Eq. 1.6), 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑋 𝑖𝑛 𝐴
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑋 𝑖𝑛 𝐵
= 𝐾𝐷                                                                                                               Eq. 1.6 
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where KD is distribution coefficient.  
The solvent extraction method for separation of copper from Zn targets is based on two steps; 
1.) selective extraction of Cu dithizonate (CuDz2, where dithizonate is C13H12N4S) into an organic 
solvent from a dilute acidic solution of the bulk Zn target, 2.) back extraction of Cu into the 
aqueous phase. The separation of Cu and Zn target was previously studied by solvent extraction 
with copper-dithizone [173]. Regarding the previous studies, copper dithizonate has a large 
extraction constant value* in acid solution compared to other metals present in the solution of 
the irradiated Zn target.  
 
 
Fig. 1.35 Schematic of solvent extraction method [174] 
1.6.2 Extraction chromatography 
Extraction chromatography is an extraction process performed in a multi-stage manner on a 
packed column. This technique combines the selectivity and diversity of solvent extraction with 
the high extraction efficiencies of column separation. In this technique, there is a stationary 
phase that consists of one or more ionophores dissolved in an organic solvent and they are 
                                                          
* extraction constant is the concentration ratio of a chemical in one phase to the concentration in a second phase 
when the two concentrations are at equilibrium. 
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immobilized on a porous material (see Fig. 1.36). The porous material is usually composed of 
porous silica with particle sizes ranging between 50 and 150 μm. One of the commercially used 
columns in this process is TEVA resin which was developed by Horwitz et al. [175].  
 
 
Fig. 1.36 Extraction chromatography resin bead [176] 
 
1.6.3 Exchange chromatography 
Ion exchange chromatography refers to a process allowing the separation of ions based on their 
affinity to ion exchangers. The principle of separation is, therefore, by reversible exchange of ions 
between the ions present on the ion exchangers and the target ions in the sample solution. The 
ion-exchange chromatography like other chromatography consists of both mobile and stationary 
phases. The mobile phase is an aqueous buffer into which the sample has been introduced, and 
the stationary phase is usually an inert organic matrix [177]. All ion exchange chromatography 
depends on electrostatic interactions between the resin groups and the element of interest. 
Since buffer pH and ionic strength dramatically affect element binding to the column, it is 
important to ensure that buffer pH is properly selected. It is better to readjust buffer pH after 
adjusting salt concentration and to be sure that buffer counterions are compatible and have the 
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same charge as the resin. In this case, for negatively charged cation exchange resins, phosphate 
buffers are the best choice. There are two types of chromatography to separation of the 
elements; anion-exchange chromatography and cation-exchange chromatography [178, 179]. 
However, it has been shown that anion-exchange chromatography can also be used as the second 
step after cation-exchange chromatography for metal separation such as Cu from Zn, which 
needs some additional steps such as heating to dryness [178, 179].  
1.6.3.1 Cation-exchange chromatography  
Cation-exchange chromatography is a form, which is used to separate ions or ionic complexes 
based on their net surface charge. Cation-exchange chromatography uses a negatively charged 
ion exchange resin with an affinity for ions or ionic complexes having net positive surface charges 
(see Fig. 1.37).  
Regarding Fig. 1.37, in the cation-exchange chromatography process, metal ions (e.g., Cu+2) that 
are initially contained in an aqueous solution are exchanged with ions initially contained in a solid 
resin (see Fig. 1.37). This process can be illustrated by reaction (see Eq. 1.7) [180, 181]. 
𝑅−𝐻+̅̅ ̅̅ ̅̅ ̅̅ + 𝐴+ → 𝑅−𝐴+̅̅ ̅̅ ̅̅ ̅ + 𝐻+                                                                                                        Eq. 1.7 





Fig. 1.37 Schematic diagram of a cation exchange chromatography [182] 
The separation of Cu from the Zn target can be performed mostly by a TK201 resin (Triskem 
International, France). The selectivity of the resin for elements is presented as the weight 
distribution ratio (Dw), which can be obtained by radiotracer measurements. Dw, is obtained by 
measuring the amount of a given metal ion taken up by a measured weight of resin from a given 






where A0 – AS = activity sorbed on a known weight of the resin (g), and AS = the activity in a known 
volume (mL) of solution. 
1.6.3.2 Anion-exchange chromatography 
This technique moves the interaction that exists between charged molecules in a sample and 
oppositely charged moieties in the stationary phase of the chromatography matrix. Anion-
exchange chromatography uses a positively charged ion exchange resin with an affinity for ions 
or ionic complexes having net negative surface charges (see Fig. 1.38). In this technique, the 
charge is easily manipulated by the pH of the buffer used. The crude sample containing ions or 
ionic complexes is used as the liquid phase. When the liquid phase passes through the 
chromatographic column, ions or ionic complexes bind to oppositely charged sites in the 
stationary phase. Then the separated molecules eluted using a solution of varying ionic strength 
(see Fig. 1.38) [178, 179]. The process involving anions is called anion exchange (see Eq. 1.9). 
𝑅+𝑌−̅̅ ̅̅ ̅̅ ̅ + 𝐵− → 𝑅+𝐵−̅̅ ̅̅ ̅̅ ̅̅ + 𝑌−                                                                                                           Eq. 1.9 
where B- and Y- are anions or negatively charged metal ion complexes [182].  
Regarding the IAEA TECDOC-1955 [179], Cu was separated from the irradiated Zn target through 
ion-exchange chromatography in two processes. First, the solution was passed through a cation 
exchange column (AG 50W), and then the column was washed with 9 M HCl to remove Zn and 
Cu ions. Afterward, the solution in 6 M HCl passed through the anion exchange column (AG 1X8). 
Then Cu was eluted by 2 M HCl (see Fig. 1.39). Regarding the study, a radionuclide purity of more 









Fig. 1.39 Schematic steps for the separation of 61Cu from an irradiated Zn target (courtesy of A. 






1.6.4 Evaporation technique or distillation 
The principle in this method is based on different vapor pressures at the same temperature. So, 
regarding the fact that the vapor pressure of Zn is much higher than that of Cu at the same 
temperature (see Fig. 1.40), Zn can be transferred into the gas phase at elevated temperatures 
while Cu with low vapor pressure remains in the solid phase and cannot be evaporated. On this 
basis, it is possible to separate Zn from Cu or other metals at temperatures above 900 0C at 
atmospheric pressure [183]. Ma et al., used the evaporation technique to separate and recover 
Zn form other elements. Regarding their results, Zn was successfully separated by this technique 
under vacuum conditions [183]. 
 
Fig. 1.40 Relationship between saturation vapor pressure and temperature for various 
metals [183] 
1.7 Radiolabeling with Cu isotopes 
An important requirement for the application of radiopharmaceuticals is the formation of a 
thermodynamically stable and kinetically inert complex of the radionuclide with an appropriate 
chelator, which is linked to the targeting agent (peptide). The coordination of Cu(II) has previously 
been investigated with different chelators and peptides, including ATSM, PSMA, DOTATOC, and 
DOTATATE [184, 185, 186, 173, 175]. For example, ATSM (Dithiosemicarbazone) was recently 
68 
 
labeled with 61Cu for head and neck cancer diagnostics [186, 185]. ATSM labeled with Cu isotopes 
is considered a promising hypoxia marker for PET, which has been found to be predictive of the 
outcome of radiotherapy treatment [185]. Furthermore, 64Cu-PSMA-617 also was studied for PET 
imaging of prostate cancer [173]. Prostate-Specific Membrane Antigen (PSMA) is a cell surface 
protein that shows overexpression in PC cells and restricted expression in normal tissue [185]. 
64Cu-DOTATOC was also investigated for PET–CT imaging of neuroendocrine tumors (NETs), 
which need sophisticated imaging modalities due to the fact that tumors originate in different 
parts of the body and have different clinical symptoms [187]. NETs are usually found in the lungs 
and gastrointestinal tract. DOTATOC, also known as edotreotide, is a chelator plus a targeting 
molecule used to treat gastro-entero-pancreatic neuroendocrine tumors and can be labeled with 
Cu radioisotopes (Fig. 1.41). Moreover, 64Cu-DOTATATE was recently studied for patients with 
positive neuroendocrine tumors (NETs). Regarding this study, the radiochemical purity of 64Cu-
DOTATATE was higher than 95% [188].  
 






1.8 Status of research of 61Cu/67Cu 
61Cu with a half-life of 3.3 h is a positron-emitting radionuclide, which emits β+ particles with an 
energy of 1.22 MeV and high BR (60%). 61Cu is considered as one of the most interesting 
radionuclides for nuclear medicine research because of its appropriate nuclear properties and 
ease of production. [115]. Compared to 64Cu with a BR of 17.7%, 61Cu has much higher BR (60%), 
resulting in smaller doses and more than three times the detection sensitivity when PET imaging 
is used. On this basis, 61Cu production via different reaction routes has been investigated in the 
literature [190]. A review in 61Cu production methods showed that cyclotron production of 61Cu 
with protons as a projectile is of upmost interest due to the possibility of 61Cu production in high 
activity required for radiolabeling. As an illustration, in 2005, Szelecsényi et al. produced a high 
activity of about 1.4 GBq/µAh via the bombardment of natZn using 67–60 MeV protons [191]. It is 
Worth pointing out that the use of natZn results in the production of several Ga (63Ga, 64Ga, 65Ga, 
66Ga, 67Ga, 68Ga, 69Ga, 70Ga) and Zn (62Zn, 63Zn, 64Zn, 65Zn, 66Zn, 67Zn, 68Zn, 69Zn, 70Zn) isotopes with 
a mixture of stable, short and long half-lives [192]. So, significantly better results can be obtained 
using enriched 64Zn targets. In addition, this method produces no-carrier added 61Cu, and 
therefore, is appropriate from the chemical separation point of view [193]. Among the other 
possibilities, cyclotron production of 61Ni(p,n)61Cu and 62Ni(p,2n)61Cu require the very low 
isotopic abundance 61Ni (about 1.13%) and 62Ni (3.59%) as an enriched target [194]. Additionally, 
63Cu(p,t)61Cu and 65Cu(p,t2n)61Cu nuclear reaction routes produce 61Cu in carrier added form with 
low specific activity (for more details on the definition of specific activity, refer to Appendix B). 
Some preliminary studies and clinical trials evaluated the potential clinical role of 61Cu for 
diagnostic purposes [195, 196]. For example, ATSM (Dithiosemicarbazone) was recently labeled 
with 61Cu for head and neck cancer diagnosis [197, 198]. Regardless of the researches performed 
in 61Cu, large-scale 61Cu production, and clinical application are limited and still in preclinical 
studies.  
67Cu is one of upmost interest in production and application as a therapeutic radionuclide; 
however, its use is restricted due to its low availability. 67Cu with a half-life of 2.6 d fits in many 
cases with the biological half-lives of many pharmaceutical compounds. Moreover, the mean 
beta-decay energy of 67Cu with 0.141 MeV is appropriate for therapeutic application. The emitted 
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gamma-rays of 67Cu (184.6 keV, 93.1 keV, and 91.3 keV) are comparable in intensities and can be 
used for SPECT. Different production routes of 67Cu via cyclotron [199], nuclear research reactor 
[200], and electron accelerator [201] have been studied in the literature [202]. 67Cu production 
in the (p,2p) nuclear reaction on natural Zn leads to 67Cu production with low specific activity 
because of significant quantities of co-produced stable Cu isotopes [203, 204]. Accordingly, using 
an enriched 68Zn can be useful; however, the (p,2p) reaction for 67Cu production requires a high-
energy proton beam (the threshold is 30 MeV), which is rare [200, 202]. As an illustration for 67Cu 
production through the (p,2p) reaction, reported yields of about 0.503 MBq/µAh and 6.5 
MBq/µAh for the irradiation of respectively, 29 g natural ZnO and 3.7 g of enriched ZnO (99% 
enriched in 68Zn) could be found in the literature [202]. An alternative route for 67Cu production 
is via the 70Zn(p,α)67Cu reaction. This method of 67Cu production is very costly due to the very low 
isotopic abundance of 70Zn in natural Zn (about 0.6 %). Even with the use of a highly enriched 
70Zn (99.7%) target, the production yield is still low (8.14-15.5 kBq/mg mAh) [202, 205]. 67Cu 
production in nuclear research reactors via the (n,p) nuclear reaction on 67Zn requires fast 
neutrons, which can be produced in fast nuclear reactors. These types of nuclear reactors are 
extremely limited in use. As an illustration for 67Cu production via fast neutrons, it was shown 
that about 0.13 MBq/h g ZnO (93.0% enriched in 67Zn) for 1.5 ×1012 n/cm2s fast neutron flux 
could be obtained [200]. An attractive, alternative production route for 67Cu relies on the 
photonuclear reaction on enriched 68Zn through the (γ,p) reaction. It was shown that the 
production of up to 600 GBq/day could be obtained using a 35 MeV e-Linac with 100 kW beam 
power, enough to treat 60 patients/day [206]. Accordingly, among all production routes, the 
production investigation via photonuclear reaction is of upmost interest. 67Cu chemical 
separation, and its use for radioimmunotherapy were reviewed in the literature [201]. 67Cu 
radiolabeling also was investigated in the literature recently [207, 208]. Regarding the study 
performed in 2017, 67Cu was used for labeling cyclam-RAFT-c(-RGDFK-)4 for ovarian cancer 
peritoneal metastases [207]. However, 67Cu is only in the clinical trial phase due to some 
problems associated with large-scale production. Indeed, for large-scale production, one should 
move to high-energy and high-power electron beam accelerators. By providing such facilities, 
67Cu can enter the market for clinical application [209].  
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1.9 Aims of the thesis 
Cancer treatment is of great importance in all countries and particularly attracted considerable 
attention in economically developed as well as developing countries where cancer is the first and 
the second frequent cause of death, respectively. Early detection advancement (known as 
diagnostics), in addition to improvement in new treatment modalities (known as therapeutics), 
are among the leading purposes in nuclear medicine (in which about 95% of the 
radiopharmaceuticals are employed for diagnosis, while the rest are used for therapy). If the 
same pharmaceutical is radiolabeled with radionuclides that are suitable for diagnostic and 
therapeutic applications, this is referred to the theranostics. Theranostic matched isotope pairs 
are those, where the employed radionuclides are from the same chemical element. One of the 
most promising pairs is 61Cu/67Cu due to the appropriate properties, including radioactive decay, 
β-particle energy, γ-radiation energies, and potential radiolabeling with different peptides. 
The investigation of optimized 61Cu/67Cu production routes for radiopharmaceutical applications 
is the first aim of this project. The cyclotron-based 61Cu production through the (p,α) reaction (as 
one of the best 61Cu production routes) and microtron 67Cu production through photonuclear 
(γ,p) reaction is the next aim of the project. Irradiations were performed at the 18 MeV proton 
cyclotron of SWAN Isotopen AG and at METAS (Federal Institute of Morphology), respectively.   
The next aim of this thesis was to introduce a novel and innovative two-step semi-automated 
radiochemical separation method for the efficient radiochemical separation of a micro amounts 
of Cu from the irradiated bulk Zn target. For this purpose, two different connected successive 
processes were designed and applied to efficiently perform the radiochemical separation. The 
first step relied on the difference in evaporation temperature. While the second step is based on 
a semi-automated extraction chromatography to separate Cu from the remaining traces of Zn 
inside the sample. As the final aim of the thesis, radiolabeling of 61Cu with an appropriate peptide 
is performed and the radiolabeling purity is investigated using Thin-Layer Chromatography (TLC) 
































In this study, the production of 61Cu from a 64Zn target via proton-induced nuclear reactions is 
regarded as an attractive option due to low impurity production and high obtainable yield. In this 
project, a solid Zn target was used for the irradiation at the cyclotron. It is worth pointing out 
that a PET medical cyclotron solid target consists of the target material deposited onto a backing 
plate cooled by water and possibly by helium gas flow. Solid targets can be prepared through 
different methods such as rolling, pressing and mechanical reshaping, and electrodeposition 
[210]. The choice of techniques is usually based on a compromise between the cost of 
implementation and the approach to fulfilling the requirements. One of the most common 
techniques for solid target preparation is pressing in which thicknesses of hundreds of μm to 
some mm [210] can be achieved, but this technique is not suitable for hard materials.  
Additionally, as a part of the study, 67Cu production through photonuclear (γ,p) reaction was 
performed. Currently, charged-particle reactions with proton, deuteron, or alpha and neutron-
induced fission are considered the main routes for producing diagnostics and therapeutic 
radioisotopes. But, unfortunately, some disadvantages come along with both production 
techniques (for more details, refer to introduction chapter). 
2.2 Materials and Methods 
2.2.1 Chemicals 
Enriched 64Zn metal pieces were purchased from Trace Sciences International company, Canada, 
with 99.4% purity (see Table 2.1 & Table 2.2 for isotopic and chemical impurities) and were used 
as the target for 61Cu production. Natural Zn foil (purchased from Goodfellow, USA) was used as 
the target for 67Cu production. The main chemical impurities of the Zn foil are given in table 2.3. 
Moreover, enriched 68Zn (for 67Cu production with higher activity compared to natural Zn target) 
was purchased from Trace Sciences International, Canada, with 97.8% purity (see Table 2.4 & 





Table 2.1 Isotopic composition of 64Zn, given from certificate (Trace Sciences International, 
Canada) 
Isotope 64 66 67 68 70 
Enrichment 
(%) 
99.4 0.39 0.04 0.17 <0.01 
 
 


































Table 2.4 Isotopic composition of 68Zn, given from certificate (Trace Sciences International 
company, Canada) 
Isotope 64 66 67 68 70 
Enrichment 
(%) 





























2.2.2 Instruments used for measurements 
The activity of the produced 67Cu (before and after chemical separation) was identified and 
quantified by γ-ray spectrometry using an N-type high-purity germanium (HPGe) coaxial detector 
(Ortec, USA) and the InterSpec software (see Fig. 2.1). A dose calibrator (ISOMED 2010, Nuclear–
Medizintechnik Dresden GmbH, Germany) (see Fig. 2.1) was employed for the quantitative 







Fig. 2.1 HPGe detector setup for gamma spectroscopy and dose calibrator  
 
2.2.3 Irradiations of targets for 61Cu production 
Regarding the investigations of the 61Cu production routes performed before, 61Cu production 
using enriched 64Zn targets through the 64Zn(p,α)61Cu was considered the best route due to high-
yield production and optimal proton energies (which makes production on available low energy 
cyclotrons possible) [211].  
Accordingly, 500 mg enriched 64Zn metal pieces were used for target preparation. Since Zn 
evaporates at atmospheric pressure at above 900 0C (close to the boiling point of Zn), the metallic 
64Zn piece was evaporated inside an oven at a temperature of about 950 0C, and then the 
produced Zn powder was obtained and gathered. This technique helped us to purify the Zn target 
and to convert it to powder form. Then, the next step was to press enriched 64Zn powder in the 
form of a pellet. To make the targets, 85 mg enriched 64Zn powder was pressed with 2 tons of 
pressure (see Fig. 2.2). The thickness and diameter of the target were measured to be 0.5 mm 





After solid target preparation using a press, the pellet was placed inside a magnetically closing 
coin as the target holder (Fig. 2.3). The target coin is cooled during the irradiation using water 
cooling from the back and direct helium gas cooling the target coin from the front part. The 
material employed for the coin has to provide high thermal conductivity and the lowest chemical 
reactivity. Usually, two materials are chosen: aluminum EN AW-6082 or pure niobium (In our 
work, we used aluminum EN AW-6082). The back part of the coin should be able to completely 
stop the protons to avoid contamination of the cooling water, especially when dealing with high-
energy cyclotrons [212].  
 
 
Fig. 2.2 Hydraulic press for making pellets. A pressure of 2 tons was used to press the 64Zn 
target 
 
Fig. 2.3 Front cover (left) and back part (right) of the coin for inserting the 64Zn target inside, 





Later the prepared solid 64Zn target was irradiated with a proton beam of 25 µA at an energy of 
15 MeV for 2 hours at the Bern medical cyclotron at SWAN Isotopen AG. Then, the irradiated 
target was inserted automatically in a shuttle (Fig. 2.4) which was then transferred outside the 
cyclotron bunker by the TEMA Sinergie transfer system (Fig. 2.5). This system transfers the shuttle 




Fig. 2.4 Coin and shuttle for target irradiation and delivery  
 
Fig. 2.5 Target irradiation station and delivery system (TEMA) for the irradiated targets at Bern 





2.2.4 Irradiations for 67Cu production  
In this study, 67Cu was produced through the photonuclear interaction based on the 68Zn(γ,p)67Cu 
nuclear reaction route. The reaction 68Zn(γ,p)67Cu is considered promising and applicable for 
obtaining 67Cu in non-carrier added form and also large production yield. In the photonuclear 
reaction method, radionuclides are produced through irradiation of targets with high-energy 
photons. So, producing considerable photon flux is of great importance for large-scale 
production.   
Accordingly, the 68Zn target was irradiated at the Microtron at METAS (Federal Office of 
Metrology). METAS has a Scanditronics M22 Microtron electron accelerator that produces 
electron beam energies from 5.3 MeV to 22.4 MeV and is equipped with two beamlines [213]. 
One beamline is used for producing therapeutic photons, mainly for dosimetric studies. The 
second beamline is mainly used for research purposes.  
In this case, the Microtron at METAS with an electron beam energy of 22 MeV and an electron 
beam current of 20 µA (see Fig. 2.6) was used to irradiate 450 mg natural Zn foil. Irradiation of 
natural zinc resulted in 65Zn production through the 66Zn(γ,n)65Zn reaction. The produced 65Zn 
can conveniently be used as a tracer during the radiochemistry process.  
Later, a 413 mg enriched 68Zn, was irradiated to prevent the co-production of radionuclidic 
impurities. The irradiation time was 8 hours. 
 





2.3 Results  
2.3.1 61Cu production  
61Cu production was achieved by irradiation of an enriched 64Zn target at the Bern medical 
cyclotron at SWAN Isotopen AG (See Table 2.6). After 1 hour of cooling time, the shuttle 
containing the coin was transferred via a lead container (Fig. 2.7) to the department of chemistry, 
biochemistry, and pharmacy (DCBP) of the University of Bern. Due to the irradiated target's high 
activity, two pieces of equipment were designed by Adrian Bigler and Ronald Zingg at the 
workshop at DCBP to open the shuttle and the irradiated coin, respectively (see Figs. 2.8 and 2.9). 
The first one is the shuttle opening device, designed to open the shuttle easily without radiation 
dose exposure to the fingers. The second piece of equipment, which is named “Coin-Master”, 
allows to open the coin and remove the irradiated Zn target safely. Using this equipment, the 
irradiated coin is inserted into the coin-master (Fig. 2.9) with long tweezers and then, by pushing 
and pulling the handle, the coin is opened, and after that, by turning back the equipment, the 
irradiated target pellet falls out of the coin. Evidently, the dose exposure is reduced significantly 
due to a reduced manual contact with the coin.  
  
 







Fig. 2.8 Shuttle opening device 
 
 
 Fig. 2.9 Coin-Master for opening the irradiated coin 
 
Finally, due to the high activity of the target, the 64Zn target was inserted into a dose calibrator 



























64Zn 345 2 10.9 11.63 0.684 0.626 
64Zn 320 2.2 11.26 11.63 0.750 0.662 
64Zn 330 4 18.8 11.69 1.35 0.910 
64Zn 500 3.5 18.8 11.69 2.17 2.01 
*The theoretical activity calculations were performed using the IAEA Medical Isotope Browser (see: 
https://www-nds.iaea.org/relnsd/isotopia/isotopia.html) 
 
After a few days and a reduction of the activity, one sample of the irradiated 64Zn target was 
measured with both the HPGe detector (Fig. 2.10 shows the peaks of 61Cu including 66.7, 281.9, 
371.9, 509.8, 587.3, 654.68, 815.1, 839.6, 907.1 and 1183.6 keV) and the dose calibrator. Since 
the measurement via HPGe detector was taken after chemical separation, no impurities were 
observed in the peak. The reason for measurement after the chemical separation is due to the 
high activity of the target at the initial time of the process, which could not be measured via HPGe 
detector due to saturation of the detector even at a large distance.  
Regarding the data (Table. 2.7), the correlation factor for the dose calibrator is about 1.5. Fig. 






Fig. 2.10 Peaks of 61Cu measured with a HPGe detector  
 
Table 2.7 Correlation factor between HPGe detector and dose calibrator for measuring the 
activities  




Activity measured by 
dose calibrator 
Correlation factor 
0.113 MBq 283 keV/12.7 % 0.17 MBq 1.50 
0.116 MBq 511 keV/123 % 0.17 MBq 1.46 
0.112 MBq 373 keV/2.1 % 0.17 MBq 1.52 
 
 






2.3.2 67Cu irradiation  
In this study, 67Cu was produced through the irradiation of enriched 68Zn and natural Zn targets 
at METAS. The 67Cu activity was quantitatively determined with a HPGe detector (See Table 2.8). 
Figures 2.12 and 2.13 show the peaks of 67Cu produced after irradiation through the 68Zn(γ, p)67Cu 
reaction for natural Zn and enriched 68Zn targets, respectively. Regarding the peaks measured by 
the HPGe detector, 67Cu was recognized through the peaks 93 and 184 keV. 
 
Table 2.8 details of Zn target irradiations at Microtron at METAS for 67Cu production 














369 7 21 8.6 3.9 
Natural Zn 
foil 
474 8 17.7 12.3 5.7 
68Zn metal 
basis (97.8%) 
























This section of the thesis focused on the production of 61Cu and 67Cu at a cyclotron and a 
Microtron, respectively. In the case of 61Cu production, the Zn target irradiation has already been 
investigated in previous studies [145, 214, 148]. In our study, an enriched 64Zn (metal pieces) was 
purchased as the target material. Using the evaporation technique (see more details in chapter 
3), the material was purified and converted to powder form. Using this technique, pellet targets 
of different thicknesses and diameters were made. In looking at the literature, Asad et al., in 2015 
[145] used an enriched 64Zn target for 61Cu production through the 64Zn(p,α)61Cu reaction. 
However, using a foil target, which has limitations concerning the preparation of targets in 
different thicknesses, could be considered as a disadvantage of their study. In our work, 
irradiations were performed at the Bern medical cyclotron at SWAN Isotopen AG. As can be seen 
in Fig. 2.10, many gamma-ray energy peaks from 61Cu were recognized in the HPGe gamma-ray 
spectrum confirming 61Cu production in the irradiated Zn target. As discussed above, it is worth 
mentioning that no other impurities (short-or longer-lived side products) were observed after 
the chemical separation (see section 2.3.1).  Moreover, several Zn target irradiations were 
performed with different beam currents, target thicknesses, and irradiation times (see Table 2.6). 
The results of the theoretical activity calculations using the IAEA Medical Isotope Browser were 
also presented in Table 2.6. As can be seen, the theoretical calculations slightly underestimate 
the experimental measurements probably due to the lack of accurate available cross-sections 
values for different proton beam energies or using the dose calibrator to estimate 61Cu 
production activity. As Table 2.6 reveals, by increasing the thickness of the target from 330 μm 
to 500 μm, the beam current from 11 μA-h to 18.8 μA-h and the irradiation time from 2 to 3.5 h, 
the 61Cu activity was increased by a factor of three up to 2.17 GBq at EOB. For facilitating 
comparison, Asad et al. in 2015 produced 61Cu through the irradiation of enriched 64Zn foil targets 
via 11.7 MeV proton beam energy and 20-40 μA beam current [145]. Regarding their results, the 
yield at EOB of enriched foil targets was obtained as 48.5-98.5 MBq/µA-h, which is relatively close 
to our results (115.4 MBq/µA-h). In another study, Thieme et al. in 2013 [148] used the 
electroplating technique to prepare enriched 64Zn target. The irradiations of the targets were 





differ in proton beam energy and maximal beam current. In their study, the targets were 
irradiated with various beam currents and different irradiation times. Regarding their results, the 
maximum yield they obtained was 44.8 MBq/µA-h through the irradiation of 164 mg of enriched 
64Zn targets via Cyclone 18/9 [148]. On this basis, compared to our results (115.4 MBq/µA-h), 
they obtained around 2.6 times less activity at EOB. Finally, according to the discussion presented 
in the introduction section of this chapter and results presented in our study and similar works, 
61Cu production through the 64Zn(p,α)61Cu reaction can be considered one of the best production 
routes for large-scale production.  
In the case of 67Cu production, 67Cu was produced through the photonuclear interaction based 
on the 68Zn(γ,p)67Cu nuclear reaction route. Accordingly, natural and enriched 68Zn targets were 
irradiated at the Microtron at METAS. The gamma-ray energy peaks of 67Cu were detected with 
the HPGe detector for both natural and enriched Zn targets in Fig. 2.12 and Fig. 2.13, respectively. 
As can be seen in Fig. 2.12, 65Zn and 69mZn were co-produced through the 66Zn(γ,n)65Zn and 
70Zn(γ,n)69mZn reaction, respectively, for the natural Zn target. However, in the case of using 
enriched 68Zn target (see Fig. 2.13), 65Zn was not detected, and 69mZn was observed in a relatively 
low quantity compared to the natural Zn target (less than 1.4%  of the total activity). The results 
of the performed irradiation for 67Cu production are presented in Table. 2.8. As can be seen, using 
the enriched 68Zn target (in the last experiment) led to a significant increase (about 21 times 
more) in the activity of 67Cu at EOB compared to the use of a natural Zn target (from 12.3 kBq to 
260.9 kBq). However, this significant increase is not only due to using an enriched target but also 
due to reducing the distance between the target holder and the converter at the Microtron 
facility at METAS to increase the number of photons reaching the target. It is worth pointing out 
that 67Cu production through the photonuclear interaction was also studied in the literature [215, 
216]. As an illustration, Hovhannisyan et al., in 2021 [216], investigated 67Cu production through 
photonuclear interaction. Regarding their results, 67Cu was produced by irradiating natural Zn 
targets via bremsstrahlung photons with energies of 30 and 40 MeV. The specific activities of 67Cu 
were obtained as 75.48 and 175.75 kBq/µA-h-g at EOB for bremsstrahlung maximum energies of 
30 and 40 MeV, respectively. This significant increase in their production yield compared to our 





natural Zn target) is due to using high energy photons generated from the Linac accelerator LUE-
75 [216]. In another study, Aliev et al. [215] also investigated 67Cu production via photonuclear 
interaction using the 55 MeV electron accelerator RTM55 of the Skobeltsyn. Regarding their 
results, 67Cu was produced by the irradiation of natural Zn in higher activities than our study 
(about 133 times more) due to target irradiation with high energy photons. Finally, one can 
reasonably conclude that among all of the 67Cu production routes (see introduction section in 
this chapter), production with photonuclear interaction could be considered as a very promising 
route if high energy and high power electron beam accelerators are provided.  
2.5 Conclusion 
In this section of the study, production of 61Cu and 67Cu via cyclotron and photonuclear 
interaction were investigated, respectively. 61Cu was produced by irradiation of an enriched 64Zn 
target at the Bern medical cyclotron with an activity of 2.17 GBq in the final experiment which is 
relatively close to the theoretical value calculated using the IAEA Medical Isotope Browser. 
Regarding such high activities, which are required for the successful radiolabeling, this production 
route can be efficient for large-scale production. In the case of 67Cu production, 67Cu was 
produced through the irradiation of enriched 68Zn target at METAS and the activity obtained was 
260.9 kBq. However, this low activity is due to the non-availability of a high electron energy and 
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In this section of the study, radiochemical separation of Cu from Zn target was performed. On 
this basis, the evaporation technique and extraction chromatography (see introduction chapter) 
were used for the implementation of the project. Accordingly, some new designs were 
developed. After the radiochemical separation, radiolabeling of the DOTA peptide with obtained 
61Cu was performed, and the radiolabeling yield was measured.  
3.2 Materials and methods 
3.2.1 Chemicals 
TK201 columns (particle size 50-100 μm, purchased from Triskem, France) were used to separate 
Zn from produced Cu through extraction chromatography. Chemical isolation was performed 
with ultra-pure (TraceSelect VWR international GMbH, Switzerland), hydrochloric acid (HCl, 37% 
Suprapur, Sigma-Aldrich, Switzerland), and H2O2 (ultratrace 30%). The radiolabeling section was 
performed with DOTATOC (GMP grade from ABX Advanced biochemical compounds, Germany), 
sodium acetate buffer (from Sigma-Aldrich, Switzerland), Ammonium acetate (Sigma-Aldrich, 
99.5%, Switzerland). 
 
3.2.2 Instruments used for measurements 
The activity of produced 67Cu (before and after chemical separation) was identified and 
quantified by γ-ray spectrometry using an N-type high-purity germanium (HPGe) coaxial detector 
(Ortec, USA) and the InterSpec software. A dose calibrator (ISOMED 2010, Nuclear–
Medizintechnik Dresden GmbH, Germany) was employed for the quantitative determination of 
the 61Cu activity. The radiolabeling purity of the samples was measured using Thin Layer 
Chromatography (TLC, Eckert & Ziegler Eurotope GMBH). A Modular-Lab PharmTracer synthesis 







3.3 Automated radiochemical separation of Cu from irradiated Zn targets 
The radiochemical separation for separating Cu from Zn targets was implemented in two steps. 
The first step is performed for the separation of Cu from bulk Zn through a novel evaporation 
technique and the second step is an automated extraction chromatography that is performed to 
separate Cu from the remaining traces of Zn and other impurities inside the sample (see Fig. 3.1). 
 
Fig. 3.1 Radiochemistry steps used in this study to separate Cu from Zn target 
 
3.3.1 Evaporation technique or distillation 
In this study, we used the evaporation technique to separate Cu from the irradiated Zn target. 
For this purpose, a design based on the evaporation technique was introduced (Figs. 3.2, 3.3 & 
3.4). The concept of our design is to separate Cu from the irradiated Zn target based on the 
difference in vapor pressure temperature (see Fig. 1.40) and boiling points (which are 907 0C and 
2562 0C for Zn and Cu, respectively). Accordingly, in contrast to Cu, Zn is evaporated at a 
temperature above 900 0C (at atmospheric pressure) and is deposited and collected in a cold 
section. This entire process was implemented in a quartz tube that consisted of two parts (see 
Fig. 3.2). The first part is exposed to heat (to evaporate the Zn target), and the second part is 






Regarding Fig. 3.2, (1) is for the inlet of argon gas inside the vessel. This step was performed to 
let argon gas blow inside the quartz tube (that is shown in Fig. 3.3) for about 5 minutes through 
an inlet connection (1) (see Fig. 3.2). This step is for removing oxygen inside the quartz tube and 
prohibiting oxidation of the Zn target. Then, the quartz tube containing the irradiated target at 
the conical bottom was put inside a heater, and the heater was warmed up to above 900 0C, (for 
efficient evaporation, we selected the temperature above the boiling point of Zn, which is 9070C. 
The sample was left at this temperature for about 1 hour, and throughout this process, argon gas 
was blown inside the quartz tube as a carrier gas, which prohibits oxidation of the Zn target and 
transports the evaporated Zn towards the cool part. After a cooling time of about 5 min, the acid 
was injected inside the glass through the connection (2) (see Fig. 3.2), and the dissolved Cu at the 
bottom of the quartz tube withdrawn. (3) and (4) are inlet and outlet for water flow in the spiral 
cooler, (5) is an outlet of argon gas passing through the charcoal (activated carbon) to absorb 
volatile radioactive components (e.g., traces of Ga). However, this design was not further used 
for extraction of Cu and next chemical separation step (extraction chromatography). The reason 
is that Zn was collected not only in the cooler section but also on the wall of the quartz vessel, 
which was due to the low temperature gradient in the first design. Additionally, as can be seen 
in Fig. 3.4, recycling of the evaporated Zn was not possible due to the fact that the spiral water 
cooling tube was inside another glass tube, which resulted in the deposited Zn being not 







Fig. 3.2 Evaporation technique to separate Cu from bulk Zn (first design) 
 
 






Fig. 3.4 First setup for the separation of Cu from Zn target based on the evaporation technique 
 
Another design was also implemented for the separation of Cu from the Zn target using the 
evaporation technique (see Figs 3.5, 3.6 & 3.7). Regarding the new design in Figure 3.5, 1) is the 
inlet for entering argon gas inside the vessel, 2) is for acid injection and withdrawing the dissolved 
Cu at the bottom of the quartz tube using a T-shape connection (3-way valve), 3) is an inlet at the 
top for the cooling finger (see Figs. 3.5 & 3.7), which is employed to accumulate Zn 4) is an outlet 
of argon gas and 5) and 6) are inlet and outlet for water flow in the cooling finger and 7) is a 
photograph of the second design of the quartz glass tube. The quartz tube with the irradiated 
target at the conical bottom was put inside a heater, and the heater was warmed-up to 900 0C. 


















Fig. 3.7 Designed set up for the evaporation technique (second design) 
 
After evaporation of Zn, the quartz tube was lifted out of the oven with a lifting table called labor-
boy (see Fig. 3.7) and cooled to room temperature using a fan. Then, most of the radioactive Cu 
was dissolved in 6 mL 8M HCl and transferred to the subsequent clean-up using extraction 
chromatography with TK201 resin (more details are presented in the next chemical separation 
step).  
3.3.2 Automated extraction chromatography 
In the first step of the chemical separation using the evaporation technique, most of the Zn was 
separated; however, for removing the remaining Zn (i.e., in the form of ZnO) and other impurities 
in the sample, a second step of separation (extraction chromatography via TK201 resin) was used. 
TK201 resin is based on a tertiary amine and contains a small amount of long-chained alcohol as 
a radical scavenger to increase its radiolysis stability [176]. For the implementation of extraction 
chromatography, the residue of the evaporation process containing the Cu inside the vessel (in 
the first step of chemical separation) was dissolved and taken out using 8 M HCl acid. Using highly 
concentrated HCl was due to the fact that Cu metal can be dissolved in such a high concentration 





All Dw values (see chapter 1, section 1.6.3.1) in these graphs were obtained through radiotracer 
measurements [176]. According to the available data presented in Fig. 3.8 for TK201 resin in HCl, 
at all HCl concentrations, Zn has higher retention on the column than Cu. In other words, at 8M 
HCl, Cu and Zn are well retained on the TK201 resin with Dw values of about 30 for Cu and about 
140 for Zn.  
 
Fig. 3.8 Dw values of selected elements on TK201 Resin in HCl [176] 
 
For the implementation of the automated extraction chromatography step, an Eckert & Ziegler 
Modular-Lab PharmTracer synthesis module was used. The Modular-Lab PharmTracer is usually 
used for routine production of radiopharmaceuticals and research. This equipment contains 
cassettes containing all the components for a particular synthesis. There are some commercially 
available cassettes and software. E.g. 68Ga DOTATOC, 177Lu DOTATOC and 90Y DOTA-peptides 
synthesis. Its setup consists of a 4-fold module (SLM-4), a Heater Reaction Module (HRM), and a 






Fig. 3.9 Modular-Lab PharmTracer set up 
For using Eckert & Ziegler Modular-Lab PharmTracer, first, the procedure must be programmed 
using modular software. With this software, programming of projects to develop own synthesis 
processes is possible. The software contains an intuitive graphical interface to create projects by 
dragging and dropping symbols. In the following, the process of implementation is described. The 
details of the process of the implementation is as follows: 
In the first step of automated extraction chromatography, a 2 mL TK201 column automatically 
was conditioned with 7 mL H2O and then with 6 mL 8 M HCL [217]. Then after conditioning the 
column, the T-shape connection was turned and put in the other direction to inject the solution 
into the vessel and 3 mL 8 M HCl acid with 1.5 mL H2O2 (ultratrace 30%) was injected into the 
vessel to dissolve the residue of the evaporation process containing the Cu. Then the solution 
inside the vessel was taken out and gain injected inside the vessel and this process repeated four 
times.  Afterward, the next 3 mL 8 M HCl were added, and then after a waiting time of 10 min, 
the solution at the bottom of the glass was automatically transferred from the oven to the TK201 







Fig. 3.10 Joined two-steps chemical separation mechanisms 
 
 





In the next step, the solution containing the dissolved Cu and traces of Zn was passed through 
the TK-201 column and Cu and Zn were retained. 
The column was then washed with 4 mL of NaCl (5 M) in 0.05 M HCl to decrease residual acidity 
on the resin [217]. The total chloride concentration was obtained 5.05 M. Finally, the TK-201 
column was again washed with 8 mL 0.05 M HCl acid to elute [61Cu]CuCl2 while Zn was still 
retained with Dw values of about 6. The vial containing the copper was measured using an HPGe 
detector and a dose calibrator to measure the activity. 
 
3.4 Radiolabeling of DOTATOC with 61Cu 
In this section, radiolabeling of 61Cu is being discussed. In the case of 67Cu, the obtained activities 
were too low to perform labeling studies. Therefore, the radiolabeling with 61Cu was investigated. 
For the radiolabeling of DOTATOC with 61Cu, the activity of 61Cu in the eluate was first determined 
with a dose calibrator and was about 800 MBq at the time of starting the radiolabeling. The 
radiolabeling of DOTATOC was performed with a hydrochloric solution of Cu2+. The CuCl2, which 
was prepared after cassette separation, was incubated with the 50 µg DOTATOC at a pH of 5.5 
sodium acetate buffer (10 M) at 80 0C for about 20 min. The purity of the labeled compound was 
measured by TLC. The TLC plates (Silica-gel 60, Merck) were prepared using 1 M ammonium 
acetate (Sigma-Aldrich, 99.5%) as a mobile phase. 
3.5 Results and discussion 
3.5.1 Automated radiochemical separation of Cu from the irradiated Zn target 
There is some literature for the separation of Cu from Zn target through different methods [179, 
173]. Regarding the IAEA TECDOC [179], The Cu was separated from the irradiated Zn target in 
two steps through cation exchange column (AG 50W) and anion exchange column (AG 1X8) and 
obtained more than 99% radionuclide purity [179]. However, Gopalakrishna et al., in 2018, used 





In this work, separation of Cu from Zn target was performed in two steps, involving the 
evaporation technique and extraction chromatography. In the first setup Zn was collected not 
only in the cooler, but also on the wall of the quartz vessel, which was due to the low temperature 
gradient in the first design. Additionally, as can be seen in Fig. 3.4, recycling of the evaporated Zn 
was not possible due to the fact that the spiral water cooling tube was inside another glass tube 
which resulted in the deposited Zn being not accessible for recycling purposes. On this basis, a 
new design was employed (see Fig.s 3.5 & 3.6) and the evaporated Zn deposited only on the 
surface of the cooling finger (see Fig. 3.12). Due to maximizing the temperature gradient in the 
new design the evaporated Zn could easily be removed after finishing the evaporation process. 
Therefore, the Zn can be recycled for further use (see Fig. 3.12). A lifting table (labor-boy) was 
used to lift the quartz vessel out of the oven, which had a strong effect on the cooling time of the 
vessel. This cooling time was about 5 minutes and is necessary since injection of the HCl in the 
vessel with a temperature above 100 0C would result in the evaporation of the solution. 
 
Fig. 3.12 Deposited Zn on the cooling finger (second design) 
In the next step, an automated extraction chromatography using a TK201 column was performed 
to purify the Cu and to remove remaining Zn and other impurities in the sample. Accordingly, 
some experiments were performed to improve the results. On this basis, experiments were 





HCl acid was injected into the vessel (without mixing with H2O2) for extracting the Cu from the 
vessel. The results obtained from the experiments showed that we were not able to extract most 
of the Cu from the vessel, and it remained at the bottom of the quartz glass. Moreover, as can 
be seen in Table 3.1, for the first two experiments, most of the extracted Cu from the vessel went 
to the waste instead of the vials. This is due to the fact that, the quartz glass was washed several 
times with a total of 30 mL HCl and this caused Cu to start breaking through the column. In 
experiment No. 3, a little amount of H2O2 was added to the quartz glass (100 µL), to investigate 
whether that influenced the dissolution of Cu. As can be seen in Table 3.1, this significantly 
affected the dissolution of the residue of the evaporation process containing the Cu, and 
therefore, much more of the Cu (compared to the experiments No. 1 and 2) was extracted from 
the quartz glass. Additionally, the total volume of HCl for washing the glass decreased from 30 
mL to 22 ml. This resulted in a reduced amount of Cu breaking through the column. Finally, in the 
last experiment, a higher amount of H2O2 (1.5 mL) was added to the quartz glass vessel and it 
was observed that the amount of Cu remaining in the quartz glass was significantly reduced 
(Table 3.1). Importantly, by decreasing the total volume of HCl for washing the glass (from 23 mL 
in the experiment 3 to 6 mL in the experiment No. 4), almost all of the Cu was collected in the 
vials instead of going to the waste (see Table. 3.1). 
Table 3.1 Relative measured activity in each part of the process compared to the total activity 
Experiment No. Vials Glass Column Waste 
Lost 
(e.g., in tubes 
and cassette) 
1. Without H2O2 21% 33% 3.2% 42.1% 0.7% 
2. Without H2O2 30% 23% 3.5% 42.4% 1.1% 
3. With H2O2 70% 17% 0.9% 11.1% 1% 
4. With H2O2 88% 11% 0.6% 0.3% 0.1% 
 
In the case of 67Cu production, 65Zn which was produced through the 66Zn(γ,n)65Zn reaction could 
be used as a tracer (see Fig. 2.12). Afterwards, the vial containing most of the activity was 






Fig. 3.13 Peaks of 67Cu measured by HPGe detector after chemical separation (with background 
subtraction) 
 
3.5.2 Radiolabeling of DOTATOC with 61Cu  
In the radiolabeling section, in the first experiment, the CuCl2, which was prepared after cassette 
separation, was incubated with the DOTATOC and a different buffer solution (ascorbic acid 
solution 0.1 g/mL C6H8O6; see Table 3.2). Then the pH of the solution was measured, and it was 
too acidic (around pH 1) due to using 8M HCl in the separation process for removing the Cu from 
the glass tube. Regarding the TLC after radiolabeling, no peaks corresponding to radiolabeled 
DOTATOC could be observed (see Fig. 3.14). However, in the second experiment, regarding the 
TLC result, DOTATOC was labeled with 61Cu with a 73% labeling yield (see Fig. 3.15 and Table 3.2), 
but the solution was still too acidic. To solve the problem, two steps were performed. First, in the 
chemistry section (extraction chromatography), after loading the TK201 column with the 
irradiated target solution in 8M HCl, the column was then washed with 4 mL of NaCl in 0.05 M 
HCl to decrease residual acidity on the resin. Secondly, for the radiolabeling section, sodium 






 Fig. 3.14 TLC result for the first experiment 
 








Table 3.2 Different parameters for radiolabelling of DOTATOC for different experiments. 
Experiment No. pH Buffer Solution Activity (MBq) 
Radiolabeling 
Purity (%) 





















Afterward, based on the TLC results in the third experiment, the 61Cu-DOTATOC was obtained 
with more than 97% labeling yield (see Fig. 3.16). Regarding the results, 22.7 (radiolabeled 61Cu 







Fig. 3.16 61Cu-DOTATOC labeling yield measured with TLC 
3.6 Conclusion 
In this section of the study, separation of Cu from Zn target was implemented through a novel 
automated system in two steps, involving an evaporation technique and extraction 
chromatography. In the evaporation technique, a new and novel setup was developed, which 
included a quartz tube containing a cooling finger that allows the evaporated Zn to collect around 
it and which can be easily removed. Afterward, the solution was automatically transferred to the 
next step (extraction chromatography with TK201 resin), which was performed to remove 
remaining Zn in the solution. Regarding the results, through the automated system, Cu was 
separated completely from the Zn target. In the radiolabeling section, DOTATOC was labeled with 













ADDITIONAL STUDIES TOWARDS SOME 



















4.1 Targetry and specification of 167Tm production parameters by different 
reactions 
Authors: Mahdi Sadeghi, Nadia Zandi, Hossein Afarideh 
Journal of Radioanalytical and Nuclear Chemistry, 291:731–738 (2012) 
Highlights: 167Tm with a half-life of 9.25 d and γ-ray of 208 keV can be used as a complex with 
hydroxy ethylene diamine tetra-acetic acid (HEDTA) for tumor and bone studies in nuclear 
medicine. This study first describes excitation functions of some major reaction channels 
calculated by ALICE/ ASH and TALYS-1.0 codes, and then calculated data were compared to the 
earlier published experimental data and TENDL-2010 database. Additionally, physical yield and 
optimal thickness of the targets were obtained by SRIM (stopping and range of ions in matter) 
code [218] for each reaction channel. At the next step, the targetry of Er2O3 on a Cu substrate 
through sedimentation technique was performed, and the prepared target was irradiated with 
the proton beam energy of 15 MeV and beam current of 20 µA [219]. The yield of about 3.2 MBq/ 
µA h was experimentally obtained. 
Contributions: I performed the theoretical calculations using TALYS and ALICE code. I also 
performed the targetry of Er2O3 on a Cu substrate through sedimentation technique and 
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Abstract In recent years, there has been a rapid expansion
in the use of radio nuclides for therapeutic purposes. Thulium–
167 is an important radionuclide (T1/2 = 9.25 d) due to it
could be used for tumor and bone studies in nuclear medicine.
167Tm complexed with hydroxy ethylene diamine tetra-acetic
acid (HEDTA) could be used with the aim of bone imaging.
167Tm emits a prominent c ray of 208 keV energy and low
energy electrons. This study describes calculations on the
excitation functions of 165Ho(a,2n)167Tm, 167Er(p,n)167Tm,
natEr(d,xn)167Tm and natEr(p,xn)167Tm reactions by ALICE/
ASH (hybrid and GDH models) and TALYS-1.0 codes. In
addition, calculated data by codes were compared to experi-
mental data that earlier were published and TENDL-2010
database. Moreover, optimal thickness of the targets and
physical yield were obtained by SRIM (stopping and range of
ions in matter) code for each reaction. According to the results,
the 167Er(p,n)167Tm and 165Ho(a,2n)167Tm reactions are
suggested as the best method to produce 167Tm owing to
minimum impurities. The TALYS-1.0 code, predict the
maximum cross-section of about 382 mb at 11 MeV
and 849 mb at 26 MeV for 167Er(p,n)167Tm and
165Ho(a,2n)167Tm reactions, respectively. Finally, deposition
of natEr2O3 on Cu substrate was carried out via the sedimen-
tation method. The 516 mg of erbium(III)oxide with
103.2 mg of ethyl cellulose and 8 mL of acetone were used to
prepare a natEr2O3 layer of 11.69 cm
2. 167Tm was produced
via the natEr(p,n)167Tm nuclear process at 20 lA current
and 15 ? 7 MeV protons beam (1 h). Yield of about
3.2 MBq 167Tm per lA h were experimentally obtained.
Keywords Excitation function  Thulium-167 
Nuclear medicine  Physical yield  TALYS-1.0 
ALICE/ASH  Target thickness
Introduction
In recent years, there has been a fast growth in the make use of
radio nuclides for therapeutic functions [1, 2]. Thulium–167
has been proposed as a useful agent for tumor and bone
studies having a half-life of 9.25 days. 167Tm emits a prom-
inent c-ray of 208 keV energy and low energy electrons. The
Auger-electron emitters 167Tm had high TND (the ratio of the
absorbed dose rate to the tumors and the normal tissue) values
for tumors weighing less than 1 mg and can be produced with
high specific activities [1–6]. There is direct and indirect
reactions to production of 167Tm as follow [7–15]:
165Hoða; 2nÞ167Tm
167Er p; nð Þ167Tm
natEr p; xnð Þ167Tm
natEr d; xnð Þ167Tm
167Er d; 2nð Þ167Tm
169Tm p; 3nð Þ167Yb ! 167Tm
natYb p; xð Þ167Lu ! 167Yb ! 167Tm
168Yb p; xð Þ167cumTm
natErða; xnÞ167Yb! 167Tm
natHf p; xð Þ167Lu! 167Yb! 167Tm
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This study describes calculations on the excitation
functions of 165Ho(a,2n)167Tm, 167Er(p,n)167Tm, natEr
(d,xn)167Tm and natEr(p,xn)167Tm reactions by ALICE/
ASH (hybrid and GDH models) and TALYS-1.0 codes. In
this study, the excitation functions of 167Tm for the various
reactions with incident particle energy up to 50 MeV were
calculated and compared with experimental previous
published data. ALICE/ASH (hybrid and GDH models)
and TALYS-1.0 codes have been used to perform these
calculations. Theoretical calculation of physical yield and
target thickness was done using SRIM code (stopping and
range of ions in matter). To find the aberration amount of the
acquired data and experimental data, and TENDL-2010, they
were compared with each other. Finally, according to the
results, the best reaction to prevent formation radioactive and
non radioactive impurities as far as possible to production
167Tm was chosen. Targets’ essential thickness and suitable
method for preparing target was investigated.
Materials and methods
Calculation of excitation function
Excitation function of 167Er(p,n)167Tm, natEr(p,xn)167Tm,
165Ho(a,2n)167Tm and natEr(d,xn)167Tm reactions was cal-
culated using ALICE/ASH and TALYS-1.0 codes [16, 17].
Further, an optimum energy range was determined so that
formation of radionuclide impurities is avoided as far as
possible.
The ALICE/ASH code
The ALICE/ASH code can be applied for the calculation of
excitation functions, energy and angular distribution of
secondary particles in nuclear reactions induced by nuclei
with the energy up to 300 MeV [16]. The hybrid model and
the geometry dependent hybrid model (GDH) can be used
for the calculation of particle spectra. In the GDH model


















g D nð Þ
TL is the transmission coefficient for 1th partial wave; Rx
(n) is the number of nucleons of x-type in the n-excitation
state, g is the single particle level density equal to A/14 ; kex
is the emission rate of nucleon. This code uses the
Weisskopf–Ewing evaporation model, the Bohr–Wheeler
model for fission, and the geometry-dependent hybrid
model for pre compound decay. This hybrid model is
relevant to the pre-compound decay but not to the
compound decay. The geometry-dependent hybrid model
is a further revision of the hybrid model.
TALYS code
TALYS is a computer code system for the analysis and
prediction of nuclear reactions. The basic objective behind
its construction is the simulation of nuclear reactions that
involve neutrons, photons, protons, deuterons, tritons, 3He-
and alpha-particles, in the 1 keV-200 MeV energy range
and for target nuclides of mass 12 and heavier. It covers an
energy range from 1 keV to 200 MeV [17].
The pre-equilibrium particle emission is described using
the two component excitation model. This model imple-
ments new expression for the internal transition rates and
new parameterization of the average squared matrix ele-
ment for the residual interaction, which is obtained using
the optical model potential [17]. The phenomenological
model is used for the description of the pre-equilibrium
complex particle emission. The equilibrium particle emis-
sion is described using the Hauser–Feshbach model.
TENDL-2010
TENDL is a nuclear data library which provides the output
of the TALYS nuclear model code system for direct use in
both basic physics and applications. The third version is
TENDL-2010, which is based on both default and adjusted
TALYS calculations and data from other sources [18].
Calculation of the physical yield and the
target thickness











r Eð Þ dE
where Y is the activity of the product (in Bq), NL is the
Avogadro number, H is the isotope abundance of the target
nuclide (%), M is the mass number of the target element
(g), r(E) is the cross-section at energy E (mb), I is the
projectile current (lA), dE/d(qx) is the stopping power
(MeV/mg/cm2), k is the decay constant of the product and
t is the time of irradiation (h).
SRIM (stopping and range of ions in matter) code [19]
was used to calculation the required thickness of the target.
The physical thickness of the target layer that was calcu-
lated by SRIM code is for 90 geometry beam toward the
target. To better heat transfer on the surface of the target
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and the beam cover all surface of the target (11.69 cm2), 6
geometry beam toward the target during the bombardment




To produce 167Tm from 167Er, sedimentation technique
were used by Tarkanyi et al. in 2010 [8], they determined
the excitation functions of proton induced reaction on the
targets containing erbium oxide. Consequently, it has been
obtained the maximum cross-section of 455 mb at
10.8 MeV. The target samples were prepared of highly
enriched erbium oxide, 167Er2O3 powder, via sedimentation
technique. Subsequently, small amount of erbium-oxide
powder was suspended in EtOH/H2O and let to settle
slowly onto an Al backing of 13.0 mm diameter and
0.1 mm thickness [8].
The experimental data and the results of the nuclear
model calculations of the 167Er(p,n)167Tm reaction are
given in Fig. 2. According to TALYS-1.0 code, data for
167Er(p,n)167Tm reaction, beneficial range of proton energy
to produce 167Tm from 167Er target is 6–15 MeV that
maximum cross-section is 382 mb at 11 MeV (Fig. 1). The
cross-section data from TALYS-1.0 and ALICE/ASH
(hybrid and GDH models) codes showed that bombarding
167Tm with proton particles leads to produce 166Tm (7.7 h)
in 6–15 MeV. 166Tm (7.7 h) has short half life compared to
167Tm and can be reduced by choosing proper energy
range. As can be seen on Fig. 2, The TALYS-1.0 and
ALICE (hybrid and GDH models) calculated results codes
are in good agreement with the cross section values
reported by Tarkanyi et al. in 2010 [8]. Considering the
excitation function and SRIM data we conclude that
6–15 MeV is the optimal energy range for production of
167Tm which leads to physical yield of 5.8 MBq/lA h and
required thickness of target is 51.3 lm for 6 geometry of
the beam toward the target (Table 1).
natEr(p,xn) 167Tm reaction
In 2008 Tarkanyi et al. [9], investigated production of
167Tm on erbium up to 70 MeV and found the maximum
value of cross section is about 358 mb at 18.8 MeV. In this
part of study we calculated the excitation functions of natEr
(p,xn) 167Tm reaction by ALICE/ASH (hybrid and GDH
models) and TALYS-1.0 codes and compared with cross
section values reported by Tarkanyi et al. [9] in Fig. 4.
Regarding to TALYS-1.0 code data for natEr(p,xn) 167Tm
reaction, 167Tm has a maximum cross-section of about
323 mb at 19 MeV; its beneficial excitation functions
occur between 7 and 23 MeV. As the natural erbium is
composed of six stable isotopes (Table 2), 169Tm (stable),
168Tm (93.1 d), 166Tm (7.7 h), 165Tm (30.06 h) and 164Tm
(2 min) are simultaneously produced in this energy range
(Fig. 3). Actually 169Tm is an stable isotope; therefore, this
reaction doesn’t lead to production of 167Tm in no carrier-
added form [20, 21].
In fact, separation of isotopic contamination 169Tm is
not possible by chemical methods. Although, 168Tm
Fig. 1 Excitation function of 167Er(p,n)167Tm reactions calculated by
TALYS-1.0 code
Fig. 2 Excitation function of 167Er(p,n) 167Tm reaction calculated by
ALICE/ASH (hybrid and GDH models) and TALYS-1.0 codes and
experimental data
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(93.1 d) half life is more than 167Tm (9.25 d), but other
produced radioisotope can be reduced by choosing proper
energy range. The physical yield of 167Tm was obtained
4.2 MBq/lA h. According to the SRIM code the required
thickness of target is 51 lm for 6 geometry of the beam
toward the target (Table 1).
165Ho(a,2n) 167Tm reaction
Holmium can be used to produce 167Tm via alpha-particles
bombardment. Furthermore, 165Ho(a,2n)167Tm reaction
was determined one of the considerable reactions due to its
mono-isotopic (165Ho, 100% natural abundance). The
acquired data from TALYS-1.0 code showed that 167Tm
has full benefit excitation function of 17–34 MeV (Fig. 5).
Bombarding 165Ho with alpha-particles leads to production
of 166Tm, 168Tm and 164Ho impurities at the energy range
of 17–34 MeV. To limit the produce isotope and non-iso-
tope impurities and to attain its benefit energy range, the
17–26 MeV energy range was considered. As can be seen
Fig. 3 Excitation function of natEr(p,xn)167Tm reaction calculated by
TALYS-1.0 code











167Er(p,n)167Tm 15 ? 6 51.3 5.8
natEr(p,xn)167Tm 15 ? 7 51.0 4.2
165Ho(a,2n)167Tm 34 ? 17 18.0 4.9
natEr(d,xn)167Tm 70 ? 10 505.5 16.7
Fig. 4 Excitation function of natEr(p,xn)167Tm reaction calculated by
ALICE/ASH (hybrid and GDH models) and TALYS-1.0 codes and
experimental data








Fig. 5 Excitation function of 165Ho(a,2n)167Tm reaction calculated
by TALYS-1.0 code
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on Fig. 6, the ALICE and TALYS results are in acceptable
agreement with the cross-section values reported by
Gadkari [22], Singh [23], Singh [24], Mukherjee [25] and
Tarkanyi et al. [7]. The calculated physical yield is
4.9 MBq/lA h. The recommended target thickness was
calculated using the SRIM code (Table 1).
natEr(d,xn)167Tm reaction
Excitation function of the deuteron induced reaction on
natEr was calculated and evaluation of the acquired data
showed that the range of energy to produce 167Tm is 10 to
70 MeV. TALYS-1.0 code predicted the maximum cross
section to be about 247 mb at 22 MeV (Fig. 7). In this
energy range there is lots of impurities and 169Tm isotope
(stable) will be produced. Accordingly, this reaction
doesn’t lead to 167Tm production in no carrier-added state
[20, 21]. According to SRIM code the thickness has to be
505.5 lm for 6 geometry beam toward the target and the
physical yield is 16.7 MBq/lA h (Table 1). The calculated
data are compared with the cross section values reported by
Tarkanyi et al. [11] (Fig. 8). It should be noted that TA-
LYS-1.0 code predicted cross sections for natEr(d,xn)167Tm
reaction is lower than ALICE/ASH, TENDL-2010 and
experimental data.
Target preparation
Among the possibilities to produce 167Tm, with respect to
existing facilities, we employed natEr(p,x)167Tm reaction to
test the target preparation, the target quality, the irradiation
and the thick target yield. The medical application require
highly enriched 167Er target.
A suspension of 103.2 mg ethyl cellulose (C20H38O11,
Aldrich), 516 mg natEr2O3 (Aldrich, 99.99%) and 8 mL
acetone was employed to prepare a natEr2O3 layer depos-
ited on copper substrate. According to SRIM code the
thickness has to be 510 lm for 90 geometry beam toward
the target. To minimize the thickness of the
Fig. 6 Excitation function of 165Ho(a,2n)167Tm reaction calculated
by ALICE/ASH (hybrid and GDH models) and TALYS-1.0 codes and
experimental data
Fig. 7 Excitation function of natEr(d,xn)167Tm reactions calculated
by TALYS-1.0 code
Fig. 8 Excitation function of natEr(d,xn)167Tm reaction calculated by
ALICE/ASH (hybrid and GDH models) and TALYS-1.0 codes and
experimental data
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erbium(III)oxide layer and to increase heat transfer, a 6
geometry beam toward the target is preferred, in which this
case a 51 lm natEr2O3 layer is recommended. Physical
thickness of erbium oxide layer is chosen as for a given
beam/target angle geometry to provide bombarding beam
exit energy of about 7 MeV. The natEr2O3 suspension
solution was stirred for several minutes and loaded into
cylinder of the upper disk immediately. A particular device
made of Teflon (PTFE) was constructed. It consists of two
plates of 19 9 10 cm2 surface and 3 cm height. The upper
plate contains an elliptical window of 11.69 cm2 (same as
the copper substrate). The copper substrate was placed
between these two plates, the upper part is fitted on it with
six supporting pins and it is sealed by an O-ring fitted-
window [26–30]. The solution evaporated slowly through
the hole at the room temperature after about 24 h.
Adhesion agent amount and target quality control
Adhesion is an important factor for adhering and coating
among physical properties of the samples. Insufficient
amount of ethyl cellulose causes poor adhesiveness of
deposited erbium(III)oxide layer. On the other hand, their
over abundance reduces thermal conductivity of the target.
To optimize the quantity for maximum adhesion and
thermo-stability of natEr2O3 layer, the samples were
examined with different quantities of EC with respect to
natEr2O3 (Table 3). Homogeneity of the
natEr2O3 layer,
which may affect the production rate of 167Tm, was
determined by standard deviation of the layer thickness
measured at several spots by micrometer, while the mor-
phology by SEM (see Fig. 9). Results of the thermal shock
tests and adhesion agent amount are given in Table 3.
Irradiation
The natEr2O3 target was bombarded in this study.
167Tm was
produced via proton induced reactions on erbium(III)oxide
at the AMIRS (Cyclone-30, IBA, Belgium) cyclotron with
15 MeV protons at 20 lA current beam for 1 h.
Conclusions
In this study we employed ALICE/ASH (hybrid and GDH
models) and TALYS-1.0 codes to calculation the excitation
Table 3 Influence of ethyl cellulose (EC) amount and thermal shock test with 8 mL acetone for 516 mg natEr2O3
W(EC) (mg) W(EC)/W(Er2O3) (%) td (mg cm
-2) Adhesiona Comments 200 C 300 C
77.4 15 43.4 Tolerable Porous Stable Unstable
103.2 20 43.9 Excellent Reflective, smooth Stable Stable
129 25 42.8 Excellent Reflective, smooth Stable Unstable, peeling off
154.8 30 41.7 Unfavourable Porous Unstable Unstable, peeling off
The heating of the target for 60 min followed by submersion of the hot target in cold water (8 C)
td = calculated thickness of the deposit on Cu backing
a Adhesion at room temperature
Fig. 9 SEM of erbium oxide deposit on the Cu backing: a for 516 mg of natEr2O3, 103.2 mg of EC, and 8 mL of acetone suspensions (no crack
was observed), b respectively for 516 mg, 77.4 mg and 8 mL
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functions of 165Ho(a,2n)167Tm, 167Er(p,n)167Tm,
natEr(d,xn)167Tm and natEr(p,xn)167Tm reactions. Accord-
ingly, 167Er(p,n)167Tm and 165Ho(a,2n) 167Tm reactions are
suggested as the best method to produce 167Tm because of
minimum impurities; Additionally, lower thickness of the
target is another advantage of those reactions.
A suspension of 103.2 mg ethyl cellulose, 516 mg
natEr2O3 and 8 mL acetone was employed to prepare a
natEr2O3 layer deposited on copper substrate. According to
SEM scans, observation of neither crack formation nor pit
on the surface indicated a good adhesion for the target
preparation of 167Tm. Sedimented natEr2O3 target was
irradiated by 15 MeV protons. Through the irradiation of
516 mg natEr2O3 at 20 lA beam current for 1 h, yield of
about 3.2 MBq/lA h was found (using c-ray spectros-
copy), which is 24% less compared to the yield calculated
from the excitation function. Production of 167Tm from
natEr(p,xn)167Tm reaction is not suitable because of lots of
impurities and simultaneously isotope stable (169Tm) pro-
duction. Therefore, in order to the cyclotron production of
no-carrier-added 167Tm from Er, highly enriched 167Er
target, is suggested.
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Ignatyuk AV (2011) High yield production of the medical
radioisotope 167Tm by the 167Er(d, 2n) reaction. Appl Radiat
Isot 69:475–481
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Summary. Thulium-167, having a half-life of 9.25 d, is an
important therapeutic radionuclide. It was produced via the
natEr(p, xn)167Tm nuclear reaction by irradiation of a sedi-
mented target with 15 MeV protons at a beam current of
20 μA. Radiochemical separation of 167Tm from a solution
of the irradiated erbium target in hydrochloric acid was per-
formed using di-(2-ethylhexyl) phosphoric acid (HDEHP) in
n-hexane and in chloroform separately. The effect of different
molarities of HDEHP on extraction efficiency was investi-
gated. The radiochemical yield of 167Tm amounted to about
80±5% while using n-hexane/HDEHP (1 M). The experi-
mentally obtained production yield was about 3.2 MBq/μA h.
It was comparable with the theoretical value of 4.1 MBq/μA h
obtained from nuclear model calculations using the TALYS
and EMPIRE codes.
1. Introduction
167Tm (T1/2 = 9.25 d) emits a prominent γ -ray of 208 keV
energy, low energy electrons (< 200 keV) and X-rays. Hence
it can be used in nuclear medicine, especially for ther-
apy [1–3]. Tumor imaging was done with 167Tm-citrate be-
cause of strong tumor affinity and suitable physical char-
acteristics [4]. 167Tm accumulated in viable tumor tissue
and tissue containing viable and necrotic tumor tissue [5].
Many researchers measured experimentally excitation func-
tions for the formation of 167Tm by different projectiles on
various targets. There are three direct principal routes to pro-
duce 167Tm at a cyclotron:
(i) the bombardment of natEr with proton and deuteron,
i.e. the natEr(p, xn)167Tm and natEr(d, xn)167Tm reac-
tions [6–8];
(ii) the bombardment of 167Er with proton and deuteron, i.e.
the 167Er(p, n)167Tm and 167Er(d, 2n)167Tm reactions [9,
10] and
(iii) alpha induced reaction on 165Ho, i.e. the 165Ho(α, 2n)
167Tm reaction [11].
*Author for correspondence (E-mail: nadia_zandi@yahoo.com).
Also 167Tm can be produced through the indirect reac-
tions [12–14]: 169Tm(p, 3n)167Yb →167Tm, natYb(p, x)167Lu
→167Yb →167Tm, natEr(α, xn)167Yb →167Tm and natHf(p, x)
167Lu →167Yb →167Tm.
The separation of lanthanides is notoriously difficult and
many processes have been used over the years with varied
levels of success. In 1950, Fitch and Russel reported on the
ion-exchange separation of lanthanides using complexing
agents, and careful control of pH and ion concentration [15].
Over the last forty years, solvent extraction technique was
extensively used. The selectivity in solvent extraction for the
neighbors of lanthanides is generally low because they are
chemically very similar.
In recent years separation of thulium and erbium were
reported with resin containing 1-hexyl-4-ethyloctyl iso-
propylphosphonic acid (HEOPPA) by Wang et al. [16],
α-hydroxyisobutyric acid (α-HIB) by Schwantes et al. [17],
a mixture of acidic phosphorus based reagents by Xi-
anglan et al. [18] and ion imprinted polymer particles via
solid phase extraction by Kala et al. [19].
The aim of this work was to produce 167Tm by develop-
ing a target that has sufficient stability at high power beam
bombardment, and separating 167Tm from the irradiated tar-
get by solvent extraction [18, 20] using di-(2-ethylhexyl)
phosphoric acid (HDEHP) into n-hexane and into chloro-
form separately. Attention was also devoted to the excitation
functions and stopping power of protons in erbium oxide
(using SRIM code) [21]. We calculated theoretical physical




A suspension of ethyl cellulose (C20H38O11, Aldrich),
natEr2O3 (Aldrich, 99.99%) and acetone was used to prepare
a natEr2O3 layer deposited on copper substrate (8.7 g/cm3)
[7, 23].
For production of 167Tm, the target was bombarded with
15 MeV protons for 1 h at 20 μA beam current. The energy
range and power density at the target were 15–6 MeV and
15.4 W cm−2, respectively.
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2.2 Ethyl cellulose removal
The irradiated target was dissolved with 50 mL acetone.
The obtained solution was evaporated to near dryness, the
residue was dissolved in 12 M HCl (50 mL) and the obtained
solution was filtered with Whatman-41 filter paper for re-
moving the residual ethyl cellulose. Washing the filter with
12 M HCl following the filtration ensures ethyl cellulose re-
moval and radiothulium elution.
2.3 Tm/Er separation technique
The first extraction was performed into n-hexane/HDEHP.
A 10 mL portion of aqueous feed solution (ErCl3 and
TmCl3) was equilibrated with 2.5 mL of the organic solvent
(1 M HDEHP) in a separatory funnel by shaking the two
phases vigorously for 5 min and then allowing the phases to
separate for at least 10 min. The organic phase was washed
four times. Thulium and erbium were extracted into the
organic phase (HDEHP in n-hexane) which was then trans-
ferred into a separatory funnel and was washed with 8 M
HC1 (80 mL). In this condition, ErCl3 was back extracted
into aqueous phase and TmCl3 remained in the organic
phase [20].
2.4 Chemical and radionuclidic purity control
To determine percentage of Er impurity in the final solution,
separation was repeated in cold. Weighed amounts of Er2O3
and Tm2O3were dissolved in 12 M HCl and mixed. After-
wards the separation procedure was carried out using the
same process as explained for 1 M n-hexane/HDEHP. The
obtained solution was examined by ICP-AES. Identification
and assay of gamma-ray emitting radionuclide was carried
out using γ -ray spectrometry with a high purity (HPGe) de-
tector (Canberra™ model GC1020-7500SL).
3. Results and discussion
3.1 Tm/Er separation
Solvent extraction of 167Tm from irradiated erbium(III)oxide
target hydrochloric solution, was carried out using n-hexane/
Fig. 1. Separation of Tm from Er using di-
(2-ethylhexyl) phosphoric acid (HDEHP) in
n-hexane and chloroform with different mo-
larities of HDEHP.
HDEHP (1 M) and the radiochemical yield was 80± 5%.
Thulium was effectively separated from ethyl cellulose (EC)
and erbium.
3.2 Effect of HDEHP molarities on extraction of
thulium
The extraction was performed into n-hexane/HDEHP and
also into chloroform/HDEHP with different molarities of
HDEHP (0.5, 0.75, 1, 1.5 and 2 M) to find the condition
under which the Tm and Er separate more efficiently. The
results showed that by extraction into n-hexane/HDEHP
(1 M), the thulium and erbium were extracted more into or-
ganic phase and in the latest stage (back extraction) Tm
was separated from Er more efficiently. Indeed, n-hexane/
HDEHP (1 M), is the best condition to separate Tm from Er
compared to other conditions (Fig. 1).
3.3 Chemical and radionuclidic purity control
The solution obtained after separation of Tm from Er in
nonradioactive test was analyzed by ICP-AES. The amount
of Er impurity detected for the prepared solution (1 M
n-hexane/HDEHP) was 4.7 ppm. Through the irradiation of
natEr2O3 (the entire natEr2O3 target was dissolved in acetone),
yield of about 3.2 MBq 167Tm per μA h was experimen-
tally obtained (Table 1). Using the (HPGe) detector (Can-
berra™ model GC1020-7500SL) thulium-167 was mainly
identified by the following γ peaks: 208 keV (41%), 57 keV
(4.6%) [24].
3.4 Experimental production yield
As the natural erbium is composed of six stable isotopes
(162Er = 0.14%; 164Er = 1.61%; 166Er = 33.6%; 167Er =
22.9%; 168Er = 26.8%; 170Er = 14.9%), 167Tm is produced
mainly via two channels, i.e. 167Er(p, n)167Tm and
168Er(p, 2n)167Tm reactions. Indeed the yield obtained from
this study is contribution of two reactions. 168Er(p, 2n)167Tm
reaction has a high cross section to produce 167Tm in this
energy range (about 930 mb at 15 MeV) [25] and as can be
seen in Table 1, by considering TALYS-1.0 code [26], the
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Table 1. Yields of 167Tm in proton irradiation of erbium.
Reaction Energy range Yield Reference
(MeV) (MBq/μA h)
natEr(p, xn)167Tm 15–6 3.2 This work
15–6 4.1 Theoretical calculation a
15–6 4.2 Theoretical calculation b
167Er(p, n)167Tm 15–6 5.8 Theoretical calculation a
15–6 6.2 Theoretical calculation b
168Er(p, 2n)167Tm 15–6 10.3 Theoretical calculation a
15–6 10.5 Theoretical calculation b
a: Theoretical calculation by TALYS-1.0 code (this work);
b: Theoretical calculation by EMPIRE (3.1 Rivoli) code (this work).
theoretical yield obtained from 168Er and 167Er is 10.3 and
5.8 MBq/μAh respectively. Somewhat similar values were
obtained using the EMPIRE (3.1 Rivoli) code [27]. There-
fore with respect to isotopic abundance, the theoretical yield
from natural erbium is calculated as 4.1 MBq/μA h. This
theoretical yield is comparable to our experimental yield of
3.2 MBq/μA h.
The experimental yield is slightly lower because of the
use of natEr2O3 target as compared to natEr target assumed
in calculations. The proton induced reaction considered here
leads to 167Tm in no-carrier-added form.
4. Conclusion
The sedimentation technique was successfully applied to
prepare a target for cyclotron production of 167Tm. The ra-
diothulium produced via proton bombardment of natural
Er2O3 was separated from hydrochloric acid solution suffi-
ciently using n-hexane/HDEHP (1 M).
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Abstract Erbium-165 with 10.3 h physical half-life decays
completely by electron capture to the ground state of stable
isotope 165Ho and it is an ideal radio lanthanide for Auger elec-
tron therapy. Excitation function of 165Er via natEr(p,x)165Tm ?
165Er, 166Er(p,2n)165Tm ? 165Er, 165Ho(p,n)165Er and 165Ho
(d,2n)165Er reactions were calculated using ALICE/ASH
(Hybrid and GDH models) and EMPIRE 3.1 codes and then
were compared with the reported measurement by experimental
data and TENDL-2011. Physical yield and target thickness were
evaluated with attention to excitation function, stopping power
and SRIM code. 165Er was produced using the sedimentation
technique through the natEr (p,x)165Tm ? 165Er reaction. The
deposited target was irradiated with 15 MeV proton beams at
20 lA current for 1 h. The 165Tm production yield was 26 MBq/
lA h at the end of bombardment.
Keywords 165Er  Auger electron  Excitation
function  EMPIRE-3.1  ALICE/ASH  Physical yield 
Production yield
Introduction
165Er (10.3 h), decaying by electron capture to stable
165Ho, offers an excellent promise for use in diagnostic
nuclear medicine especially in conjunction with multi-wire
proportional-counter cameras [1], and also is a potent
nuclide for targeted radionuclide therapy [2]. New cancer
targeted therapies that make use therapeutic antibodies or
small molecules have made treatment more tumors specific
and less toxic. Auger-emitting radio-nuclides have poten-
tial for the therapy of cancer due to their high level of
cytotoxicity and short-range biological effectiveness [3].
Certain Auger electron emitters are particularly prom-
ising for targeted therapies because they deposit most of
their decay radiation energy very locally (few micrometer
to tens of micrometer range in soft tissue). Hence the
therapeutic effect can be concentrated onto single cells or
even onto the cell’s nucleus (DNA) if selectively inter-
nalizing carriers are found [4].
In the previous works we evaluated cyclotron production of
167Tm, 142Pr, 85Sr, 119Sb and 61Cu by ALICE/ASH, TALYS-
1.0 and TALYS-1.2 codes and compared to existing data and
TENDL-2010 [5–11]. The aim of this work was investigation
of excitation functions of natEr(p,x)165Tm ? 165Er,
166Er(p,2n)165Tm ? 165Er,165Ho(p,n)165Er and 165Ho(d,2-
n)165Er reactions and comparison of them with EXFOR
database and TENDL-2011 [12, 13]. Also with attention to the
excitation functions and stopping powers of projectiles in
erbium oxide (using SRIM code) [14], we calculated theo-
retical physical yield and target thickness. Eventually 165Er
was produced using natEr(p,x)165Tm ? 165Er reaction and
production yield at the end of bombardment was compared
with theoretical physical yield and the previous published
results.
Excitation functions
In this part of work we employed new calculation code
(EMPIRE 3.1 Rivoli) [15, 16] and excitation functions of
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some reactions to produce 165Er using ALICE/ASH and
EMPIRE 3.1codes have been studied. According to results an
optimum energy range was determined and employed to avoid
the formation of radionuclide impurities and decrease the
excitation functions of inactive impurities as far as possible.
EMPIRE 3.1 code
The EM PIRE (version 3.1 Rivoli), the latest version of the
EM PIRE code, is a modular system of nuclear reaction
codes comprised of various nuclear models and designed
to perform nuclear reaction calculations over a wide range
of energies and incident particles. The covered energy
range is from resonance region (*keV) to several hun-
dreds of MeV, and the projectile could be any nucleon, ion
(including heavy ion) or a photon. EMPIRE is equipped
with a complex system of codes to describe all the impor-
tant nuclear reaction mechanisms It consists of a number of
linked FORTRAN codes, input parameter libraries, and the
experimental data library [15–17]. The code accounts for
the major nuclear reaction mechanisms, including direct,
pre-equilibrium and compound nucleus ones. The optical
model and the direct reaction calculations were performed
by the ECIS-03 code [18]. The optical model, discrete
levels and deformation parameters were retrieved from
the RIPL-2 library [19]. The direct channel calculations
were performed by using the coupled channels model or
the distorted wave Born approximation (DWBA) method.
EMPIRE contains both the quantum mechanical (MSD/
MSC) and classical models (DEGAS, PCROSS, HMS)
to describe pre-equilibrium reactions. The option of
EMPIRE-specific level densities was selected for all the
calculations. An improved version of the Hauser–Feshbach
theory was used for compound nucleus reactions. The 3.1
version of the EMPIRE code is equipped with the module
that makes use the information contained in the Atlas of
neutron resonances to produce resonance files and related
covariances for the ENDF-6 formatted files.
The ALICE/ASH code
The ALICE/ASH code is a modified and advanced version of
the ALICE/91 code. This code has been written to study the
interaction of intermediate energy nucleons and nuclei with
target nuclei. The code calculates energy and angular dis-
tributions of particles emitted in nuclear reactions, residual
nuclear yields, and total nonelastic cross-sections for nuclear
reactions induced by particles and nuclei with energies up to
300 MeV [4]. The parameters used in the ALICE/ASH code
are as follow: (i) the Weisskopf–Ewing model for equilib-
rium calculations [20] (ii) The hybrid model and geometry
dependent hybrid model (GDH) for pre-equilibrium emis-
sions [21] (iii) the Fermi gas level density with the level
density parameter ‘‘a = A/y’’ (the default value of y was 9).
The hybrid model and the geometry dependent hybrid model
(GDH) can be used for the calculation of particle spectra.
Calculation of the physical yield and the target
thickness












where Y is the product activity (in Bq) of the product, NL is
the Avogadro number, H is the isotope abundance of the
target nuclide, M is the mass number of the target element,
r(E) is the cross-section at energy E, I is the projectile
current, dE/d(qx) is the stopping power, k is the decay
constant of the product and t is the time of irradiation.
To obtain the optimum physical dimensions of the target
such as the thickness, some estimation from the SRIM code
(the stopping and range of ions in matter); were performed.
SRIM is a group of programs which calculate the stopping
and range of ions (up to 2 GeV/amu) into matter using a
quantum mechanical treatment of ion-atom collisions. This
calculation is made very efficient by the use of statistical
algorithms which allow the ion to make jumps between
calculated collisions and then averaging the collision
results over the intervening gap.
The physical thickness of the target layer is chosen in
such a way for a 90 geometry beam/target to ensure that
the incident beam exits the target layer with a predicted
energy; so the required thickness of the layer will be
smaller with a coefficient 0.1.
TENDL-2011
TENDL is a nuclear data library which provides the output
of the TALYS nuclear model code system for direct use in
both basic physics and applications. The last version is
TENDL-2011, which is based on both default and adjusted
TALYS calculations and data from other sources [13].
Results and discussion
natEr(p,x) 165Tm ? 165Er reaction
Regarding to ALICE/ASH code data for natEr(p,x) 165Tm ?
165Er reaction, 165Tm has a maximum cross-section of about
924 N. Zandi et al.
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586 mb at 22 MeV; its beneficial excitation functions occur
between 8 and 40 MeV (Fig. 1). As the natural erbium is
composed of six stable isotopes (162Er = 0.14 %; 164Er =
1.61 %;166Er = 33.6 %; 167Er = 22.9 %; 168Er = 26.8 %;
170Er = 14.9 %), some isotopic impurities will be produced
from different channels in this energy range. 168Tm is a long
lived radioisotope (93.1 days) and will be produced at the
threshold energy of 16 MeV and also existence of it in pre-
pared radio-medicine could be result in excessive dose to the
patient, therefore 8-15 MeV energy range was considered.
For this reaction, the cross section measurements have been
published by Tarkanyi et al. [22]. As can be seen in Fig. 2, The
ALICE/ASH (Hybrid and GDH models) and EMPIRE-3.1
calculated results codes are in good agreement with the cross
section values reported by Tarkanyi et al. [22].
166Er(p,2n) 165Tm ? 165Er reaction
Excitation function of the proton induced reaction on 166Er
was calculated and evaluation of the acquired data showed
that the range of energy to produce 165Tm is 12–27 MeV.
ALICE/ASH code predicted the maximum cross section to
be about 1,234 mb at 21 MeV (Fig. 3). In this energy
range there are two isotopic impurities (164Tm and 166Tm).
Production of radionuclidic impurities can be avoided by
choosing 16–23 MeV energy range, therefore 166Er(p,2n)
165Tm ? 165Er reaction can be represented as the best
reaction to produce 165Er due to very high cross section to
produce 165Tm in no-carrier added form [23]. The results
obtained from ALICE/ASH (Hybrid and GDH models) and
EMPIRE-3.1 codes agree well with the measured data from
Tarkanyi et.al [24] (Fig. 4). The physical yield and recom-
mended target thickness was calculated using the SRIM code
(Table 1).
165Ho(p,n)165Er reaction
Excitation functions based on ALICE/ASH code calculation
are shown in Fig. 5 at different decay channels after proton
bombardment of holmium-165. Using this reaction, the best
range of incident energy to produce 165Er was assumed
7–11 MeV whose maximum cross section by ALICE/ASH
code is 112 mb at 9 MeV. In this energy range a stable iso-
tope 164Er is simultaneously produced and could not be
separated by chemical methods; therefore 7–9 MeV energy
range should be considered to production of 165Er in no-
carrier-added state. Figure 6 shows the comparison between
cross section values reported by Tarkanyi and Beyer [25, 26]
and the results of nuclear model calculations employing the
different theoretical calculations. It should be noted that the
cross section values obtained by nuclear model calculation
ALICE/ASH (Hybrid and GDH models) and TENDL-2011
Fig. 1 Excitation function of natEr(p,x)165Tm ? 165Er reaction cal-
culated by ALICE/ASH (Hybrid model) code
Fig. 2 Excitation function of natEr(p,x)165Tm ? 165Er reaction cal-
culated by ALICE/ASH (Hybrid and GDH models) and EMPIRE-3.1
codes and experimental data
Fig. 3 Excitation function of 166Er(p,2n)165Tm ? 165Er reaction
calculated by ALICE/ASH (Hybrid model) code
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are lower than experimental data reported by Tarkanyi and
Beyer [25, 26] and also EMPIRE-3.1 code is more close to
the experimental data and gives gradually higher maximum
cross section value at 9 MeV compared to other calculational
codes. As mentioned above, these discrepancies between the
codes are due to the different models for description of the
mechanisms and cross section depends on the type of model
that describes these mechanisms, therefore results can vary.
Also the hybrid model and geometry dependent hybrid
model (GDH) are designed for pre-equilibrium emissions
and the probability of pre-equilibrium mechanism reduces in
this energy range. The physical yield of 165Er was obtained
29.4 MBq/lA. h and the required thickness of target is
21.1 lm for 6̊ geometry beam toward the target (Table 1).
165Ho(d,2n)165Er reaction
Through this reaction to produce 165Er, the best range of inci-
dent energy was assumed 8–18 MeV that maximum cross-
section is 645 mb at 12 MeV. In this energy range 164/166Er
impurities are simultaneously produced (Fig. 7). These impu-
rities are stable isotopes and could not be separated by chemical
methods, therefore to limit production of stable isotopes and to
production of 165Er in no-carrier added form as far as possible,
8–11 MeV energy range are considered. As can be seen on
Fig. 8, ALICE (Hybrid and GDH models) and EMPIRE-3.1
calculated results codes are in acceptable agreement with the
cross section values reported by Tarkanyi et al. [27] and
TENDL-2011. Theoretical physical yield in view of the chosen
energy range is 37.4 MBq/lA h and by considering SRIM data,
recommended thickness of the target is 10.6 lm for 6 geom-
etry beams toward the target (Table 1).
Fig. 4 Excitation function of 166Er(p,2n)165Tm ? 165Er reaction
calculated by ALICE/ASH (Hybrid and GDH models) and EMPIRE-
3.1 codes and experimental data
Table 1 165Er physical yield









natEr(p,x)165Tm ? 165Er 15–8 50.0 26.0 This work
15–8 – 27.7 Theoretical calculation
15–10 – 25.0 Tarkanyi [19]
166Er(p,2n)165Tm ? 165Er 23–16 60.7 315.2 Theoretical calculation
165Ho(p,n)165Er 11–7 21.1 29.4 Theoretical calculation
165Ho(d,2n)165Er 11–8 10.6 37.4 Theoretical calculation
Fig. 5 Excitation function of 165Ho(p,n)165Er reaction calculated by
ALICE/ASH (Hybrid model) code
Fig. 6 Excitation function of 165Ho(p,n)165Er reaction calculated by
ALICE/ASH (Hybrid and GDH models) and EMPIRE-3.1 codes and
experimental data
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Target preparation and production yield
With respect to existing facilities, the natEr(p,x) 165Tm ?
165Er reaction was employed to produce 165Tm radionu-
clide that leads to 165Er production. It should be noted that
medical application require highly enriched 166Er target.
The natEr2O3 target was prepared by the stack foil tech-
nique first reported by Chandra et al. [28] and improved by
Tarkanyi et al. [29] and Hermanne et al. [30]. High purity
natEr foils were stacked with Al backing.
In this study we employed sedimentation technique to
prepare natural erbium oxide target.
A suspension of ethyl cellulose (C20H38O11, Aldrich),
natEr2O3 (Aldrich, 99.99 %) and acetone was employed to
prepare a natEr2O3 layer deposited on copper substrate [7, 31].
The coated natural natEr2O3 target was introduced into a
target holder and bombarded with 15 MeV protons at
current of 20 lA for 1 h to reduce the proton beam energy
from 15 to 8 MeV. Through the irradiation of natural tar-
get, the yield of 165Tm was obtained about 26 MBq/lA h.
This experimental yield is slightly lower because of the use
of natEr2O3 target as compared to
natEr target assumed in
calculations (Table 1).
Conclusion
In order to study practicality of the cyclotron production 165Er,
excitation function of natEr(p,x)165Tm ? 165Er, 166Er(p,2n)
165Tm ? 165Er, 165Ho(p,n)165Er and 165Ho(d,2n)165Er reac-
tions were calculated by ALICE/ASH and EMPIRE-3.1
codes, and compared with the data taken from the TENDL-
2011 and EXFOR database. By virtue of excitation function
and SRIM code, physical yield and target thickness were
calculated for each reaction.
By investigation the results, high yield production of 165Er in
no carrier added form can be obtained through the
166Er(p,2n)165Tm ? 165Er reaction; therefore it can be consid-
ered as the best reaction to produce 165Er among the possibilities.
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Possible reactions leading to the production of 135La are discussed in
this study and corresponding theoretical yields calculated using Monte-
Carlo (MCNPX) code are presented. The pilot 135La production was per-
formed employing the 16 MeV protons provided by a PETtrace cyclotron
and a natBaCO3 target.
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1. Introduction
The Auger electron therapy is one of the most promising and important
cancer therapies due to delivery of radiation dose only to individual cells [1].
Its effectiveness has been recently summarized in Refs. [2–4]. The Auger
electron emitters cause much less off-target effects than β emitters [4]. 135La
with the half-life of 19.5 h and almost 100% decay to the stable 135Ba [1] by
electron capture is one of the important candidates for this kind of therapy.
It also emits only low-intensity gamma rays (predominantly 480.5 keV, 1.5%)
which contribute to the patient dose at a negligible level.
135La can be produced using proton or deuteron bombardment of barium
via 135Ba(p, n)135La, 136Ba(p, 2n)135La, 134Ba(d, n)135La, 135Ba(d, 2n)135La
reactions and alpha bombardment of cesium 133Cs(α, 2n)135La.
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In 2015 and 2018, respectively, Mansel [5] and Fonslet [1] reported pro-
duction of 135La using protons bombarding a barium target. Nevertheless,
to date, only few research works have been performed to study 135La produc-
tion routes. The cross sections are reported only for: natBa(d, x), natBa(p, x),
natLa(p, x) and 133Cs(α, 2n) [2–10]. In this work, some possible routes of
135La radionuclide production have been analysed in terms of production
yield regarding the small medical cyclotron facilities and cost of targets
needed for the discussed reaction. The production yield was calculated us-
ing the Monte Carlo N-Particle eXtended (MCNPX) code [11, 12].
2. Materials and methods
2.1. Theoretical calculations of TTY
The assessment of the applicability of a 135La production route was
mainly based on evaluation of Thick Target Yield (TTY) describing num-
ber of the produced radionuclides (activity) per unit of time and current of
the applied beam. Theoretical TTY for production of the radionuclide of









where TTY is thick target production yield [Bq/Ah], NA is the Avogadro
number [1/mol], H is the isotope abundance of the target nuclide [%], M is
the molar mass of the target element [g/mol], σ(E) is the cross section at
energy E [cm2], dE/d(xρ) is the stopping power [MeV/(mg/cm2)], λ is the
decay constant of the product [1/h], E1 −E2 is the energy deposited in the
target material [MeV], Z is the atomic number of the projectile, and e is the
elementary charge [As].
In our calculations, we used the cross sections from the TENDL-2017
nuclear data library based on the TALYS code [15]. The stopping powers
used in the calculation were derived from the SRIM 2013 code (Stopping and
Range of Ions in Matter) [16].
The activity produced at the given irradiation time or the irradiation
time needed to produce the required activity can be calculated from the
following relation (considering decays of the produced radionuclide):







where AEOB — activity at the End Of Bombardment, I — beam current, λ
— decay constant, tirr — irradiation time.
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2.2. TTY predictions for 135La production
135Ba(p, n)135La and 136Ba(p, 2n)135La reactions
The optimal proton energy range for the 135Ba(p, n)135La reaction is of
16 to 5 MeV [15]. Since the natural abundance of 135Ba is relatively low
(6.5%) (Table I), a highly enriched barium target would be necessary for
efficient production of 135La in this reaction. The best energy range for the
136Ba(p, 2n)135La reaction is between 35 to 12 MeV, however, it is worth
mentioning that for the energy corresponding to the best range of the first
reaction, the 135La production yield is of comparable level. In other words,
using natural barium both 135La production channels have to be considered.
The theoretical calculation shows the production yield at 16 to 5 MeV of
proton energy range for the 100% enriched isotopes, 135Ba and 136Ba equals
to 165.48 MBq/µAh and 151 MBq/µAh, respectively and 16 MBq/µAh for
a natural Ba target (Table II).
TABLE I
Natural abundance of barium isotopes.
Isotope 132Ba 134Ba 135Ba 136Ba 137Ba 138Ba
Abundance [%] 0.1 2.4 6.5 7.8 11.2 71.7
TABLE II
135La theoretical production yield in various reactions.




136Ba(p, 2n)135La 151.20 16→ 12
135Ba(d, 2n)135La 570.45 35→ 8
134Ba(d, n)135La 33.27 14→ 8
133Cs(α, 2n)135La 38.28 40→ 16
∗This TTY value was calculated for 16 → 5 MeV proton energy range, taking
into account the contribution of the 135Ba(p, n)135La and 136Ba(p, 2n)135La
reactions.
Taking into account composition of the natural barium, it makes the
135La production efficiency relatively high and considering the energy of
protons delivered by cyclotrons such as PETtrace, C18/9 or EclipseTMRD,
this production route seems to be the most effective for the 135La production
in PET centres.
133
864 J. Jastrzębski et al.
135Ba(d, 2n)135La reaction
The efficient energy range for the 135La production in 135Ba(d, 2n)135La
reaction is between 35 to 8 MeV. The theoretical calculation shows that
the production yield in this energy range is 570.45 MBq/µAh (Table II).
However, it requires high-energy deuterons that are not provided by the
medical cyclotrons most commonly installed in the PET centres.
134Ba(d, n)135La reaction
The production energy range for the 134Ba(d, n)135La reaction is of 14
to 8 MeV [15]. The theoretical calculation shows that the production yield
in the mentioned energy range equals 33.27 MBq/µAh (Table II). Due to
the limited production efficiency and the very low abundance of 134Ba in
natural barium (2.4%), which would require the use of expensive enriched
target material, the reaction cannot be considered as a good candidate for
the efficient production of 135La.
133Cs(α, 2n)135La reaction
Regarding the best energy range of 133Cs(α, 2n)135La production route
(40–16 MeV), the calculation shows that the production yield equals
38.28 MBq/µAh (Table II). Taking into account that the yield is very low
compared to other possible production routes, this reaction cannot be con-
sidered as a reasonable candidate.
2.3. Pilot production of 135La using PETtrace cyclotron
2.3.1. Proton beam energy and beam current measurements
The verification of the experimental results requires measurements of the
proton energy and the current of extracted beam. This is needed as well to
optimize a target thickness and to reduce the radiation dose originating from
the isotopes produced inside reactions [17].
Using the method proposed by Gagnon et al. [17], we verified the pro-
ton energy to be 15.98 ± 0.03 MeV. The beam current was measured by
irradiating the copper and titanium foils of the same thickness (11 µm) and
evaluating the activity of each radionuclide (62Zn, 65Zn and 48V) produced
respectively in Cu and Ti [18]. The obtained average beam current was
9.41± 1.85 µA which we found consistent with Faraday Cup measurements
(10.2± 0.1 µA).
2.3.2. Target and irradiation condition
Considering the above TTY calculations and energy of protons deliv-
ered by PETtrace installed at HIL UW, the production of the 135La via
the natBa(p, x)135La reaction was tested. Natural barium carbonate tar-
get (BaCO3) with thickness of 427 mg/cm2 prepared as a pellet [19] was
134
Investigation of the Production of the Auger Electron Emitter 135La . . . 865
bombarded for 10 minutes at the PETtrace cyclotron solid state target sta-
tion [20] with a proton beam of 15.7 MeV energy and 9.4 µA intensity.
The foils of Cu (11 µm) and Ti (11 µm) were placed in front of the bar-
ium carbonate pellet for off-line beam current verification. Target activity
after irradiation was measured with a HPGe detector. Moreover, due to
the fact that natural barium is composed of 6 stable isotopes (Table I), the
co-produced impurities were also investigated.
3. Results and discussion
The activity of 135La produced in our pilot irradiation was equal to
9.57 MBq at EOB what corresponds to about 6 MBq/µAh of TTY (Fig. 1,
left panel). The activities of coproduced impurities (Fig. 1, right panel)
namely 132La and 132Cs were measured as 0.43 MBq and 0.83 MBq, respec-
tively (Table III).
Fig. 1. Thick target yield for natBa(p, x)135La reaction and measured evolution of
135La activity relative to the activity of coproduced impurities.
TABLE III
Activity of 135La and impurities produced in natural Ba target.
Isotope Half-life Activity at EOB
135La 19.5 h 9.57± 0.20 MBq
132La 4.72 h 0.43± 0.18 MBq
132Cs 6.48 d 0.83± 0.31 MBq
4. Conclusion
The most important 135La production routes were considered based on
the production yield and natural isotope abundance. The theoretical pro-
duction yield for each reaction was obtained using the MCNPX code and
135
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the results showed that natBa(p, x)135La reaction represents a reasonable
production route considering common facilities of the PET centres. The
activity of 135La produced by bombarding a natural barium target with
protons of 15.7 MeV (attenuated by Cu and Ti foils) for 10 minutes with
the beam current of 9.4 µA was equal to 9.57 MBq with impurities on the
level below 1% at EOB.
Work completed with ENSAR2 (grant agreement No. 654002) support.
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H I G H L I G H T S
• Medical isotope production using fast neutron flux is investigated.
• Tehran Research Reactor is considered for radionuclide production.
• New flux trap designs are proposed to enhance the fast neutron flux.
• MCNPX code is employed to investigate the results.
• The results all indicate a significant enhancement in production yield.






A B S T R A C T
The aim of this work is to increase the magnitude of the fast neutron flux inside the flux trap where radionuclides
are produced. For this purpose, three new designs of the flux trap are proposed and the obtained fast and thermal
neutron fluxes compared with each other.
The first and second proposed designs were a sealed cube contained air and D2O, respectively. The results of
calculated production yield all indicated the superiority of the latter by a factor of 55% in comparison to the first
proposed design.
The third proposed design was based on changing the surrounding of the sealed cube by locating two fuel
plates near that. In this case, the production yield increased up to 70%.
1. Introduction
Most radionuclides are produced by exposing suitable target mate-
rials to the neutron flux in a nuclear reactor for an appropriate time.
Thermal neutron capture nuclear reactions are currently used for major
radionuclide production. Thermal neutrons are those which are in
thermal equilibrium with molecules/atoms of the surrounding medium
(Manual for reactor produced radioisotopes, 2003). One of the most
important factors for radionuclide production is a neutron flux intensity
which should be optimized by considering special places within the
reactor core or its surrounding (Mele, 1990).
Tehran research reactor (TRR) is commonly used to produce
radionuclides via thermal neutrons (Aboudzadeh et al., 2015; Khalafi
and Gharib, 2005; Deilami-nezhad et al., 2016). But it is noteworthy to
mention that, production of some radionuclides such as 64Cu and 67Cu
requires as large fast neutron flux as possible owing to their energy
thresholds (Johnsen et al., 2015). In the case of being thermal reactor, it
is not easily accessible to produce medical radionuclide via fast neu-
trons by considering the traditional design of the flux trap which con-
tains only water that normally increases thermal to fast neutron flux
ratio. So, some considerations should be taken and some new design
should be introduced to produce efficiently.
In this study, some new design was taken to improve fast neutron
flux in the central flux trap to produce medical radionuclides as high as
possible in the TRR. Accordingly, MCNPX code (MCNPX User'’s manual,
2002) was employed for both benchmarking and simulating the reactor
core and then was used to design the proposed different flux trap for
reaching to the best results. For this purpose, this paper is organized in
5 sections: In the second section, descriptions of TRR are presented
briefly. In the third section, simulation of the reactor core and bench-
marking of the obtained results against experimental measurements are
carried out. The new proposed designing of the flux trap along with the
calculated results, including thermal and fast neutron fluxes have been
presented in the section four. Eventually, the fifth section gives the
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2. Description of Tehran Research Reactor
Tehran Research Reactor is the only facility for reactor-based pro-
duction of radionuclides which is needed for the extensive usage in all
hospitals and medical centers in the country. This reactor is a 5 MW
pool-type light-water moderated, heterogeneous solid fuel reactor in
which the water is also used for cooling and shielding (AEOI, 1989,
2001). Its core configuration consists of MTR-type fuel elements which
are inserted in the specific grid plate assemblies (Khalafi and Gharib,
2005; Lashkari et al., 2012).
There are two types of low enriched uranium (LEU) fuel elements:
Standard Fuel Element (SFE) and Control Fuel Element (CFE). In terms
of fuel elements, they both consist of enriched 235U (approximately
20%) which are 19 plates for SFE and 14 for CFE, but in terms of
configuration, CFEs also house fork-type control rods which are illu-
strated as white lines (Fig. 1). Also, it is worth to point out that the fuel
is made of U3O8 powder dispersed in a pure aluminum matrix (Lashkari
et al., 2012).
The arrangement of fuel assemblies including both SFEs and CFEs in
the reactor core always is considered 9 × 6 array. Moreover, it is ap-
parent and obvious in the figure that, some graphite boxes are located
in the core surrounding as efficient reflectors for reaching to the much
more neutron economy (Lashkari et al., 2012).
3. Methodology and results
3.1. Validation and benchmarking
In this section of the study, validation of simulation has been pre-
sented. On this basis, the first operating core of TRR was modelled and
the results were compared with experimental measurements (Zaker,
2004). Table 1 reflects the comparison between the obtained results
and the experimental measurements.
Regarding Table 1, the calculated Relative Percent Errors (RPE)
which can be defined as Eq. (1), are below 9% and consequently the











4. Procedure of new design
In order to design the flux trap and perform the corresponding
calculations and simulations, first it is necessary to consider an opera-
tional core. On this basis, the core which is shown in Fig. 1 has been
considered (Khalafi and Gharib, 1999).
As shown in the Fig. 1, the core configuration includes 22 SFEs and
4 CFEs and one Regulating Rod (RR). The core simulation was also
carried out using MCNPX code regarding Table 2 as the required input
data.
Prior to applying the new design of the flux trap, the variation of
thermal and fast neutron flux in central flux trap (FT) while filling with
ordinary water, should be considered (Fig. 2). Accordingly, the MESH
Tally card at MCNPX code was employed to draw the fast and thermal
neutron fluxes along the D-line direction (see Fig. 2). Considering the
figure, it is obvious that the thermal flux in central flux trap is higher
than the fast flux due to the existing water inside the trap which
moderates the fast neutrons (Fig. 2).
While this situation is appropriate for the production of radio-
nuclide with thermal flux, it is not acceptable for those that need fast
neutrons. Consequently, using the Monte Carlo code, we proposed 3
Fig. 1. The TRR core configuration used for designing.
Table 1
Comparison of the calculated neutronic parameters and their RPEs with the experimental
data for the first operating core.
Parameters (pcm) MCNPX Reference (Zaker, 2004) RPE(%)
Excess reactivity 6844 7461 8.27
Worth of Safety Rod 1 6052 5670 6.74
Worth of Safety Rod 2 5883 5471 7.53
Worth of Safety Rod 3 4778 4633 3.13
Worth of Safety Rod 4 4840 4711 2.74
Worth of Regulating Rod 504 476 5.88
Table 2
Data of CFE and SFE (AEOI, 1989, 2001).
CFE SFE
Enrichment 20% 20%
Number of fuel plates 14 19
Total fuel plate thickness 0.15 cm 0.15 cm
Meat thickness 0.07 cm 0.07 cm
Cladding thickness 0.04 cm 0.04 cm
Water channel thickness 0.27 cm 0.27 cm
Meat width 6 cm 6 cm
Meat length 61.5 cm 61.5 cm
Side wall thickness 0.45 cm 0.45 cm
Inner distance between side wall 6.7 cm 6.7 cm
Meat material U3O8-Al U3O8-Al
FP cladding and side wall material Al 6061 Al 6061
Absorber material for Shim Safety Rods Ag-In-Cd –
Absorber material for Fine Regulating Rods AlSl 316L –
Material in the gap between Cladding and Absorber He at 1 atm –
Guide Plates Material Al 6061 –
Cladding material for absorber plate AlSl 316L –
Fig. 2. Distribution of thermal and fast flux along D direction in the core when FT con-
tained H2O.
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new designs which have the potential to change the above situation.
Firstly, we designed a sealed cube of aluminum alloy (AL 6061) with
a thickness of 1 mm to prevent the water penetration. These features
were based on the wall of the Empty Boxes (EBs) inside the reactor core
which already were designed for the same purposes (see Fig. 3).
Moreover, the entire space of the sealed cube was filled with air that
has lower moderation of neutrons owing to its much less density and
scattering probability (owing to a higher atomic number of composing
materials) compared with H2O. So, it could reasonably be argued that
due to the lack of water inside the sealed cube, it could be a suitable
reservoir to place target materials to be bombarded with fast neutron
(Fig. 7). Regarding the fact that the moderation of fast neutron in air is
remarkably less than H2O, the fast neutron flux of the latter case is
higher than the former case. To be more precise, regarding Fig. 2 and
Fig. 4, the ratio of the maximum fast neutron flux in the flux trap while
filling with air is approximately 1.3 to the situation when the flux trap
is filled with water and consequently by considering Eq. (2) (Lamarsh,
1965; Duderstadt and Hamilton, 1976) which shows the yield of a
radionuclide produced in a reactor, we could reach 30% higher pro-
duction yield.
= −
−Y N σ ϕ e(1 )i j j g g λ t, i (2)
Where Yi and λi indicate the production yield and decay constant of the
produced isotope i, respectively. Moreover, in Eq. (2), ϕg is neutron flux
in neutron energy group g and σj g, is the microscopic neutron cross
section of the target in the corresponding neutron energy group g. Also,
Nj in the equation represents the atomic density of the bombardment
target material.
Secondly, the entire space of the flux trap was filled with heavy
water. This choice was partly due to the higher collision probability of
D2O than Air (because of the density) and lower moderation of D2O
than H2O for the incident neutrons (Fig. 5) (Lamarsh, 1965; Duderstadt
and Hamilton, 1976; Bell and Glasstone, 1970). In other words, when
the collision probability increases by increasing the density, the number
of neutrons pass through one cm2 in one second will rise. Additionally,
owing to the fact that, the moderation of deuterium nucleus is fewer
than H2O, the fast neutrons moderate less.
These features could somewhat help to increase the neutron flux
compare with the situation when the sealed cube was filled with H2O
and Air. Fig. 6 shows the variation of the obtained fast and thermal
neutron fluxes along the D-line direction of the reactor core when the
flux trap contained D2O.
Regarding Eq. (2) and performing simple mathematical calcula-
tions, it could be shown that the ratio of the production yield will be
increased about 16% when the sealed cube contained D2O instead of
air. Moreover, it could easily be shown that the production yield could
be increased about 75% when the sealed cube filled with D2O rather
than H2O. Moreover, the calculated fast neutron fluxes have been il-
lustrated in Fig. 7 in order to clarify the difference between the ob-
tained results for the aforementioned proposed designs.
As can be argued, the last proposed design shows its highest cap-
ability to use for medical radionuclide production via fast neutrons. The
explanation of the reasons for this behavior of the three materials has
been presented previously and individually.
In order to increase the fast neutron flux as much as possible, we
proposed the third new design. In this section of simulation, we ex-
tracted 17 fuel plates of one SFE and put the remained two fuel plates in
the first and last empty positions in the guide plate. Then, we located
the D2O contained sealed cube in the middle of the guide plate based on
the above obtained results which had the highest fast neutron flux
Fig. 3. The first proposed design of flux trap.
Fig. 4. Distribution of thermal and fast flux along D direction in the core when FT con-
tained Air.
Fig. 5. The second proposed design of flux trap.
Fig. 6. Distribution of thermal and fast flux along D direction in the core when FT con-
tained D2O.
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inside the flux trap (Fig. 8). This proposed design was a little more
different from the previous ones where only the prevention of fast
neutron moderation was the purpose. In fact, by locating the fuel plates
near the sealed cube, the fast neutrons which be produced in the fuel
plates could reach to the sealed cube with lower collisions and conse-
quently lower moderation (Lamarsh, 1965; Duderstadt and Hamilton,
1976; Bell and Glasstone, 1970). The mentioned distance between fuel
plates and sealed cube was equal to the half of the pitch (distance be-
tween two fuel plates) due to the required fuel plates cooling (Fig. 8)
(Wakil, 1971). By considering the above points, the fast and thermal
neutron fluxes have been calculated and illustrated in Fig. 9.
For facilitating comparison between the previous last proposed de-
signs (sealed cube contained D2O) and the current obtained results
based on fuel plate's insertion, the variation of the fast neutron fluxes
along the D-line direction in the flux trap have been shown in Fig. 10.
Regarding the Fig. 10, the latest new design has higher fast neutron
flux in the entire flux trap and accordingly this proposed design based
on insertion of fuel plates near the sealed cube which contained D2O
could be reasonably considered the best proposed design.
5. Conclusion
This paper deals with the development and enhancement of the
Tehran Research Reactor for production of radionuclides based on the
fast neutron flux using MCNPX code. For this purpose, some new de-
signs were proposed both in terms of reducing the fast neutron
moderation and increasing the fast neutron production. The first and
second designs were comprised of a sealed cube contained air and D2O
instead of ordinary water (H2O) to reduce the moderation of fast neu-
trons. Consequently, the production yield increased about 30% and
55%, respectively. Finally, the last design was proposed based on the
insertion of 2 fuel plates near the flux trap contained D2O. Although the
production yield has been increased about 70% than the second pro-
posed design, the difference was not considerable due to the limitation
of distance between the inserted fuel plates and the sealed cube.
Fig. 7. Comparison between the obtained fast neutron flux while the sealed cube con-
tained H2O, Air and D2O.
Fig. 8. Detailed scheme of the third new flux trap design.
Fig. 9. Distribution of thermal and fast flux along D-line direction in the core based on the
third proposed design.
Fig. 10. Comparison of the fast neutron flux for all proposed designs.




This project was performed based on the IAEA coordinated research
project (contract 21021) and the authors would like to express their
gratitude to Nuclear Science and Technology Research Institute which
sponsored the project under the scholarship program. The authors also
would like to thank the IAEA for suggesting and supporting this re-
search.
References
Aboudzadeh, M.R., Moassesi, M.E., Amiri, M., Shams, H., Alirezapour, B., Sadeghi, M.,
Fakhraei Sari, M., Keyvani, M., 2015. Preparation and Characterization of Chitosan-
capped Radioactive Gold Nanoparticles: Neutron Irradiation Impact on Structural
Properties…. Safety Analysis Report for the Tehran Research Reactor (HEU), Tehran-
Iran (13, 339-345.AEOI, 1966).
AEOI, 1989. Tehran Research Reactor Amendment to the safety Report. Tehran-Iran.
AEOI, 2001. Safety Analysis Report for the Tehran Research Reactor (LEU). Tehran-Iran.
Bell, G.I., Glasstone, S., 1970. Nuclear Reactor Theory. Van Nostrand Reinhold Company,
New York.
Deilami-nezhad, L., Moghaddam-Banaem, L., Sadeghi, M., Asgari, M., 2016. Production
and purification of scandium-47: a potential radioisotope for cancer theranostics.
Appl. Radiat. Isot. 118, 124–130.
Duderstadt, J.J., Hamilton, L.J., 1976. Nuclear Reactor Analysis, second ed. John. Wiley
& Sons Inc, New York.
Johnsen, A.M., Heidrich, B.J., Durrant, C.B., Bascom, A.J., U¨nlu, K., 2015. Reactor
production of 64Cu and 67Cu using enriched zinc target material. J. Radioanal. Nucl.
Chem. 305, 61–71.
Khalafi, H., Gharib, M., 1999. Calculational tools to conduct experimental optimization in
Tehran research reactor. Ann. Nucl. Energy 26, 1601–1610.
Khalafi, H., Gharib, M., 2005. Optimization of 60Co production using neutron flux trap in
the Tehran research reactor. Ann. Nucl. Energy 32, 331–341.
Lamarsh, J.R., 1965. Introduction to Nuclear Reactor Theory. Addison-Wesley Publishing
Company.
Lashkari, A., Khalafi, H., Mirvakili, S.M., Forughi, S., 2012. Neutronic analysis for Tehran
Research Reactor mixed-core. Prog. Nucl. Energy 60, 31–37.
Lashkari, A.H., Khalafi, H., Kazeminejad, Keyvani, M., Ezzati, A., Hosnirokh, A., 2015.
Experimental study of neutronic parameters in Tehran research reactor mixed-core.
Prog. Nucl. Energy 83, 398–405.
Manual for reactor produced radioisotopes, 2003. International Atomic Energy Agency
IAEA, IAEA-TECDOC-1340.
MCNPX User’s manual, 2002. version 2.4.0, Los Alamos National Laboratory, New
Mexico.
Mele, I., 1990. Optimization of TRIGA Reactor Operation Using Reactor Calculations. J.
Stefan Report.
Wakil, M.M. El, 1971. Nuclear Heat Transport. The Haddon Craftsmen, Inc., Scranton,
Pennsylvania, The United States.
Zaker, M., 2004. Conversion and Start up of Tehran Research Reactor with LEU Fuel.
International Atomic Energy Agency, Vienna.































This Ph.D. thesis focused on the production and separation of the theranostic pair 61Cu/67Cu from 
Zn targets and radiolabeling of a peptide (DOTATOC). On this basis, we investigated the 
production of 61Cu and 67Cu and presented them in three steps, including: production, 
radiochemical separation, and radiolabeling.  
In the first step, in chapter two, some possible reaction routes to the production of 61Cu and 67Cu 
were investigated. Regarding the results, 64Zn(p,α)61Cu and 68Zn(γ,p)67Cu reactions were 
concluded as the best reaction routes among all possible pathways to the production of 61Cu and 
67Cu, respectively. Accordingly, for the 61Cu production through the (p,α) nuclear reaction, an 
enriched 64Zn target was irradiated by a proton cyclotron at SWAN Isotopen AG at Inselspital 
Bern. After that, the radionuclides contained in the irradiated target were quantified by gamma-
ray spectroscopy. A dose calibrator (ISOMED 2010, Nuclear–Medizintechnik Dresden GmbH, 
Germany) was employed for quantitative measurement of 61Cu due to the high level of activity, 
which could not be measured and quantified with the HPGe detector. Regarding the results, as 
was expected, 61Cu could be obtained in sufficient quantity (about 2 GBq) required for the 
radiolabeling purpose. The advantage of this method is the feasibility of production in such high 
activity in medical cyclotrons, which are available mostly in nuclear medicine clinics. In the case 
of 67Cu production, although some literature studied 67Cu production using different methods 
such as cyclotron production and production with a nuclear reactor, both mentioned production 
routes are associated with some problems and cannot be used as cost-effective and routine 
production routes in hospitals and nuclear medicine clinics. On this basis, the most possible 
production pathways of 67Cu were investigated in this project, and regarding that, the feasibility 
of producing 67Cu using photonuclear reactions was considered. Afterward, the production of 
67Cu was performed via irradiations of 68Zn with Bremsstrahlung generated by a 22 MeV 
Microtron at METAS (Federal Office of Metrology), and then the irradiated target was delivered 
to the radiochemistry laboratory at the University of Bern for measuring the gamma-ray spectra 





energy and high power electron accelerator facilities in Switzerland, 67Cu could not be obtained 
in sufficient activities (obtained only in kBq) which is not enough for labeling purposes.  
In the second step (i.e., radiochemistry section), the obtained Cu was separated from the 
irradiated Zn target through a novel evaporation method based on the difference in vapor 
pressure temperatures of Cu and Zn. On this basis, a novel setup was designed for the 
implementation of the technique, and most of the radioactive Cu was separated from the Zn 
target. In the following, the residue of the evaporation process containing the Cu was dissolved 
with 8M HCl and H2O2 (30%), and transferred then to an automated extraction chromatography 
(with TK201 resin) using a Modular-Lab PharmTracer system (see Fig. 3.9) for removing remaining 
Zn and other impurities in the eluent. From the conjugated two chemical separation steps, the 
process was performed automatically, and all safety issues were considered for efficient chemical 
separation. According to the results, the obtained Cu (88% of the total radioactive Cu) was 
completely separated from the irradiated Zn target (no observation of Zn in the product).  
In the third step of the project (i.e., radiolabeling section), it was demonstrated that the obtained 
activity of 61Cu is adequate (compared with the obtained 67Cu) for the labeling of biomolecules 
with a DOTA chelator. Based on the results, we could conclude that the DOTA-TOC coordinated 
and labeled well with the obtained Cu with more than 97% labeling yield.  
In parallel to this study, the production of further potential radionuclides such as 167Tm, 165Er, 
and 135La were investigated as potential candidates for applications in nuclear medicine. In the 
case of 167Tm, cyclotron production of 167Tm and radiochemical studies of the obtained Tm from 
the irradiated Er target through the solvent extraction technique were investigated. Regarding 
the results, the radiochemical yield of 167Tm was obtained with about 80±5% yield using n-
hexane/HDEHP (1 M). In the case of 165Er, the excitation function of some major reaction 
channels leading to 165Er production was investigated using ALICE/ASH (Hybrid and GDH models) 
and EMPIRE 3.1 codes. Moreover, targetry through the sedimentation technique and then 
cyclotron production was performed. However, due to using a natural Er target, the activity was 
not obtained in a sufficient amount. In the case of 135La, cyclotron production and theoretical 





However, due to limited activities (not reachable in GBq quantity), 135La cannot satisfy the 
demand and replace prominent auger electrons emitting radionuclides such as 111In and 67Ga for 
further use in clinical applications. In the case of 67Cu production, some new designs in the flux 
trap of research reactors to increase the magnitude of the fast neutron flux inside the flux trap 
where radionuclides are produced were investigated. These new designs can be employed for 
the production of some radionuclides, such as 67Cu, which cannot be produced in the thermal 
flux in nuclear reactors.  
 
5.2 OUTLOOK 
This study's realm focused on the theranostic pair 61Cu/67Cu production and purification for use 
in clinical applications. The diagnostic, 61Cu was obtained in adequate quantities for clinical 
applications, while 67Cu could not be obtained in sufficient quantities using the Microtron facility 
at METAS due to irradiation with a low energy and low power electron beam. So, for follow-up 
experiments, in the near future, we intend to reduce the distance between the sample target 
and converter at the Microtron facility at METAS to increase the number of photons reaching the 
target. On these terms, higher activity of 67Cu can be obtained.  However, another possibility can 
be purchasing a high electron beam power and energy accelerator (such as Rhodotron, model 
TT300-HE) in Switzerland to suffice 67Cu production demand, which can significantly increase the 
67Cu production activity. It is worth to point out that a Rhodotron is commercially available by 
the company IBA; however, the required photonuclear irradiation setup has not been yet 
developed and is under design and development in our group. Additionally, as a shared project 
in collaboration with SWAN Isotopen AG (as part of the University of Bern), we decided to start 
an investigation of the experimental cross-section measurements of 61Cu during the irradiation 
with the cyclotron. This demand arises from the incompatibility between theoretical yield and 
experimentally obtained activity at EOB in addition to the lack of sufficient experimental 





In the radiochemistry section, we reached the desired goal in the research area, furthermore, 
this automated setup can be used for the first time in a GMP (Good Manufacturing Practice) 
environment. Moreover, due to the fast and promising implementation of the entire automated 
developed setup, which is more crucial, particularly for 61Cu (with half-life of 3.3 h), a large-scale 
production could be easily accessible. In foreseen plan in the future, we desire to complete the 
automated systems in other parts such as using an automated lift table instead of a labor-boy, 
which decreases dose exposure during the experiment. It is worth pointing out that the 
developed setup based on the evaporation technique is potentially able to be applied for the 
separation of other elements that have a difference in their vapor pressure temperatures. 
Moreover, by the use of the developed setup, one can prepare highly pure solid targets in 
different shapes and dimensions. More precisely, the collected powder around the cooling finger 
(which is purer than the original purchased material) can be recovered easily and be used for 
solid target preparation in different shapes and dimensions.  
Within the radiolabeling section, the immediate plan stands on setting-up a High-performance 
liquid chromatography (HPLC) equipment to confirm the obtained results in the case of 
radiolabeling yield. Higher quantities of available 67Cu radioactivity would facilitate investigations 
towards radiolabeling a DOTA chelator with 67Cu. Additionally, we plan to start research on other 
possible chelators and peptides such as DOTA-TATE, which could increase the application of 
61Cu/67Cu theranostic pairs in different preclinical studies. Based on the promising radiolabeling 
results obtained within this thesis, the 61Cu/67Cu theranostic pair has the potential to be used for 
the first time in human studies in the future.   
Finally, as the other proposed plan in the near future, we decided to start an investigation on 
64Cu production using the SWAN cyclotron. On this topic, first, we plan to look into different 
possible production pathways, and regarding the results, we would move towards the best 
possible reaction route. Also, we plan to work on the theranostic pair 64Cu/67Cu and make a 
comparison with the 61Cu/67Cu pair for a better understanding of their function as theranostics 
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2021-02-09 15:48:07 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 15:48:23 GQW-SY GQW-SY Syringe starts, volume: 7000 ul, speed: 450 ul/s
2021-02-09 15:48:28 timer_1 Timer 1 Wait 5.00 s
2021-02-09 15:48:28 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 15:48:28 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 15:48:28 FOF-SM3 FOF-SM3 Valve switched to direction 2-3
2021-02-09 15:48:28 FOG-SM1 FOG-SM1 Valve switched to direction 1-2
2021-02-09 15:48:29 FOG-SM2 FOG-SM2 Valve switched to direction 2-3
2021-02-09 15:48:29 FOG-SM3 FOG-SM3 Valve switched to direction 1-3
2021-02-09 15:48:29 FOH-SM1 FOH-SM1 Valve switched to direction 1-3
2021-02-09 15:48:29 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 15:48:29 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 15:48:29 FOI-SM1 FOI-SM1 Valve switched to direction 1-3
2021-02-09 15:48:29 FOI-SM2 FOI-SM2 Valve switched to direction 1-3
2021-02-09 15:48:29 FOI-SM3 FOI-SM3 Valve switched to direction 1-2
2021-02-09 15:48:29 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 15:52:09 GQW-SY GQW-SY Syringe starts, volume: -7000 ul, speed: 32 ul/s
2021-02-09 15:52:14 timer_1 Timer 1 Wait 5.00 s
2021-02-09 15:52:14 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 15:52:14 FOF-SM2 FOF-SM2 Valve switched to direction 2-3
2021-02-09 15:52:14 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 15:52:45 GQW-SY GQW-SY Syringe starts, volume: 6000 ul, speed: 200 ul/s
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2021-02-09 15:52:50 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 15:52:50 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 15:52:50 FOF-SM3 FOF-SM3 Valve switched to direction 2-3
2021-02-09 15:52:50 FOG-SM1 FOG-SM1 Valve switched to direction 1-2
2021-02-09 15:52:50 FOG-SM2 FOG-SM2 Valve switched to direction 2-3
2021-02-09 15:52:50 FOG-SM3 FOG-SM3 Valve switched to direction 1-3
2021-02-09 15:52:50 FOH-SM1 FOH-SM1 Valve switched to direction 1-3
2021-02-09 15:52:50 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 15:52:50 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 15:52:50 FOI-SM1 FOI-SM1 Valve switched to direction 1-3
2021-02-09 15:52:50 FOI-SM2 FOI-SM2 Valve switched to direction 1-3
2021-02-09 15:52:50 FOI-SM3 FOI-SM3 Valve switched to direction 1-2
2021-02-09 15:52:50 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 15:55:59 GQW-SY GQW-SY Syringe starts, volume: -6000 ul, speed: 32 ul/s
2021-02-09 15:56:04 timer_1 Timer 1 Wait 5.00 s
2021-02-09 15:56:04 PCtrl Flow Control Msg: change column 2?
2021-02-09 15:56:05 Stop Stop Button switched from off to on
2021-02-09 15:57:21 PCtrl Flow Control Msg was confirmed
2021-02-09 15:57:21 Stop Stop Button switched from on to off
2021-02-09 15:57:21 FOF-SM1 FOF-SM1 Valve switched to direction 2-3
2021-02-09 15:57:21 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 15:57:21 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 15:57:21 FOH-SM1 FOH-SM1 Valve switched to direction 1-3
2021-02-09 15:57:21 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 15:57:21 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 15:57:21 FOI-SM1 FOI-SM1 Valve switched to direction 1-3
2021-02-09 15:57:21 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 15:57:38 GQW-SY GQW-SY Syringe starts, volume: 7000 ul, speed: 450 ul/s
2021-02-09 15:57:43 timer_1 Timer 1 Wait 5.00 s
2021-02-09 15:57:43 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 15:57:43 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 15:57:43 FOF-SM3 FOF-SM3 Valve switched to direction 2-3
2021-02-09 15:57:43 FOG-SM1 FOG-SM1 Valve switched to direction 1-2
2021-02-09 15:57:43 FOG-SM2 FOG-SM2 Valve switched to direction 2-3
2021-02-09 15:57:43 FOG-SM3 FOG-SM3 Valve switched to direction 1-3
2021-02-09 15:57:43 FOH-SM1 FOH-SM1 Valve switched to direction 1-3
2021-02-09 15:57:43 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 15:57:43 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 15:57:43 FOI-SM1 FOI-SM1 Valve switched to direction 1-3
2021-02-09 15:57:43 FOI-SM2 FOI-SM2 Valve switched to direction 1-3
2021-02-09 15:57:43 FOI-SM3 FOI-SM3 Valve switched to direction 1-2
2021-02-09 15:57:44 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:01:23 GQW-SY GQW-SY Syringe starts, volume: -7000 ul, speed: 32 ul/s
2021-02-09 16:01:28 timer_1 Timer 1 Wait 5.00 s
2021-02-09 16:01:28 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:01:28 FOF-SM2 FOF-SM2 Valve switched to direction 2-3
2021-02-09 16:01:28 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:02:00 GQW-SY GQW-SY Syringe starts, volume: 6000 ul, speed: 200 ul/s
2021-02-09 16:02:05 timer_1 Timer 1 Wait 5.00 s
2021-02-09 16:02:05 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:02:05 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:02:05 FOF-SM3 FOF-SM3 Valve switched to direction 2-3
2021-02-09 16:02:05 FOG-SM1 FOG-SM1 Valve switched to direction 1-2
2021-02-09 16:02:05 FOG-SM2 FOG-SM2 Valve switched to direction 2-3
2021-02-09 16:02:05 FOG-SM3 FOG-SM3 Valve switched to direction 1-3
2021-02-09 16:02:05 FOH-SM1 FOH-SM1 Valve switched to direction 1-3
2021-02-09 16:02:05 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:02:05 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:02:05 FOI-SM1 FOI-SM1 Valve switched to direction 1-3
2021-02-09 16:02:05 FOI-SM2 FOI-SM2 Valve switched to direction 1-3
2021-02-09 16:02:05 FOI-SM3 FOI-SM3 Valve switched to direction 1-2
2021-02-09 16:02:06 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:05:14 GQW-SY GQW-SY Syringe starts, volume: -6000 ul, speed: 32 ul/s
2021-02-09 16:05:19 timer_1 Timer 1 Wait 5.00 s
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2021-02-09 16:05:20 Stop Stop Button switched from off to on
2021-02-09 16:43:40 PCtrl Flow Control Msg was confirmed
2021-02-09 16:43:40 PCtrl Flow Control Msg: Chemical separation start?
2021-02-09 16:43:40 Stop Stop Button switched from on to off
2021-02-09 16:43:41 Stop Stop Button switched from off to on
2021-02-09 16:44:05 PCtrl Flow Control Msg was confirmed
2021-02-09 16:44:06 PCtrl Flow Control Msg: Put column 1 and 2?
2021-02-09 16:44:06 Stop Stop Button switched from on to off
2021-02-09 16:44:06 Stop Stop Button switched from off to on
2021-02-09 16:45:36 PCtrl Flow Control Msg was confirmed
2021-02-09 16:45:36 Stop Stop Button switched from on to off
2021-02-09 16:45:37 PCtrl Flow Control Msg: Change valve argon to syringe?
2021-02-09 16:45:37 Stop Stop Button switched from off to on
2021-02-09 16:45:46 PCtrl Flow Control Msg was confirmed
2021-02-09 16:45:46 Stop Stop Button switched from on to off
2021-02-09 16:45:47 Set string Set string String: Comment1 = Load Oven 1th (const.)
2021-02-09 16:45:47 PCtrl Flow Control Msg: put HCl with H2O2?
2021-02-09 16:45:47 Stop Stop Button switched from off to on
2021-02-09 16:45:57 PCtrl Flow Control Msg was confirmed
2021-02-09 16:45:57 Stop Stop Button switched from on to off
2021-02-09 16:45:58 FOF-SM1 FOF-SM1 Valve switched to direction 2-3
2021-02-09 16:45:58 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:45:58 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:45:58 FOH-SM1 FOH-SM1 Valve switched to direction 1-3
2021-02-09 16:45:58 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:45:58 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:45:58 FOI-SM1 FOI-SM1 Valve switched to direction 1-3
2021-02-09 16:45:58 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:46:05 GQW-SY GQW-SY Syringe starts, volume: 3000 ul, speed: 450 ul/s
2021-02-09 16:46:08 timer_1 Timer 1 Wait 2.00 s
2021-02-09 16:46:08 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:46:08 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:46:08 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:46:08 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 16:46:08 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:46:08 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:46:08 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:46:15 GQW-SY GQW-SY Syringe starts, volume: -3000 ul, speed: 450 ul/s
2021-02-09 16:56:15 timer_1 Timer 1 Wait 600.00 s
2021-02-09 16:56:15 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:56:15 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:56:15 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:56:15 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 16:56:15 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:56:15 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:56:16 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:56:38 GQW-SY GQW-SY Syringe starts, volume: 10000 ul, speed: 450 ul/s
2021-02-09 16:56:43 timer_1 Timer 1 Wait 5.00 s
2021-02-09 16:56:43 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:56:43 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:56:43 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:56:43 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 16:56:43 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:56:43 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:56:44 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:57:06 GQW-SY GQW-SY Syringe starts, volume: -10000 ul, speed: 450 ul/s
2021-02-09 16:57:11 timer_1 Timer 1 Wait 5.00 s
2021-02-09 16:57:11 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:57:12 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:57:12 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:57:12 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 16:57:12 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:57:12 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:57:12 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
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2021-02-09 16:57:39 timer_1 Timer 1 Wait 5.00 s
2021-02-09 16:57:40 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:57:40 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:57:40 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:57:40 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 16:57:40 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:57:40 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:57:40 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:58:03 GQW-SY GQW-SY Syringe starts, volume: -10000 ul, speed: 450 ul/s
2021-02-09 16:58:03 timer_1 Timer 1 Wait 0.00 s
2021-02-09 16:58:03 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:58:03 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:58:03 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:58:03 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 16:58:03 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:58:03 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:58:03 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:58:26 GQW-SY GQW-SY Syringe starts, volume: 10000 ul, speed: 450 ul/s
2021-02-09 16:58:31 timer_1 Timer 1 Wait 5.00 s
2021-02-09 16:58:31 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:58:31 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:58:31 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:58:31 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 16:58:31 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:58:31 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:58:31 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:58:54 GQW-SY GQW-SY Syringe starts, volume: -10000 ul, speed: 450 ul/s
2021-02-09 16:58:54 timer_1 Timer 1 Wait 0.00 s
2021-02-09 16:58:54 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:58:54 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:58:54 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:58:54 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 16:58:54 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:58:54 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:58:54 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:59:17 GQW-SY GQW-SY Syringe starts, volume: 10000 ul, speed: 450 ul/s
2021-02-09 16:59:22 timer_1 Timer 1 Wait 5.00 s
2021-02-09 16:59:22 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 16:59:22 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 16:59:22 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 16:59:22 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 16:59:22 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 16:59:22 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 16:59:23 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 16:59:45 GQW-SY GQW-SY Syringe starts, volume: -10000 ul, speed: 450 ul/s
2021-02-09 16:59:45 timer_1 Timer 1 Wait 0.00 s
2021-02-09 16:59:45 PCtrl Flow Control Msg: put 8M HCl left?
2021-02-09 16:59:46 Stop Stop Button switched from off to on
2021-02-09 17:00:23 PCtrl Flow Control Msg was confirmed
2021-02-09 17:00:23 Stop Stop Button switched from on to off
2021-02-09 17:00:23 Set string Set string String: Comment1 = Load Oven 2nd (const.)
2021-02-09 17:00:23 FOF-SM1 FOF-SM1 Valve switched to direction 2-3
2021-02-09 17:00:24 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:00:24 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:00:24 FOH-SM1 FOH-SM1 Valve switched to direction 1-3
2021-02-09 17:00:24 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:00:24 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:00:24 FOI-SM1 FOI-SM1 Valve switched to direction 1-3
2021-02-09 17:00:24 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:00:32 GQW-SY GQW-SY Syringe starts, volume: 3000 ul, speed: 450 ul/s
2021-02-09 17:00:34 timer_1 Timer 1 Wait 2.00 s
2021-02-09 17:00:34 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:00:34 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:00:34 FOF-SM3 FOF-SM3 Valve switched to direction 1-2



















printed 2021-07-29 11:16 at: PDF, Page 5 of 8Batch: B20210209001, Procedure: chemical seperation, Device: HJZM0G2
Timestamp Object ID Object Name Process Step Comment
2021-02-09 17:00:34 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:00:34 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:00:34 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:00:41 GQW-SY GQW-SY Syringe starts, volume: -3000 ul, speed: 450 ul/s
2021-02-09 17:10:41 timer_1 Timer 1 Wait 600.00 s
2021-02-09 17:10:41 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:10:42 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:10:42 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:10:42 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 17:10:42 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:10:42 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:10:42 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:11:04 GQW-SY GQW-SY Syringe starts, volume: 10000 ul, speed: 450 ul/s
2021-02-09 17:11:09 timer_1 Timer 1 Wait 5.00 s
2021-02-09 17:11:09 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:11:09 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:11:10 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:11:10 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 17:11:10 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:11:10 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:11:10 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:11:33 GQW-SY GQW-SY Syringe starts, volume: -10000 ul, speed: 450 ul/s
2021-02-09 17:11:38 timer_1 Timer 1 Wait 5.00 s
2021-02-09 17:11:38 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:11:38 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:11:38 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:11:38 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 17:11:38 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:11:38 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:11:38 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:12:01 GQW-SY GQW-SY Syringe starts, volume: 10000 ul, speed: 450 ul/s
2021-02-09 17:12:06 timer_1 Timer 1 Wait 5.00 s
2021-02-09 17:12:06 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:12:06 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:12:06 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:12:06 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 17:12:06 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:12:06 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:12:07 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:12:29 GQW-SY GQW-SY Syringe starts, volume: -10000 ul, speed: 450 ul/s
2021-02-09 17:12:29 timer_1 Timer 1 Wait 0.00 s
2021-02-09 17:12:29 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:12:29 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:12:29 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:12:29 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 17:12:29 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:12:29 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:12:30 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:12:53 GQW-SY GQW-SY Syringe starts, volume: 10000 ul, speed: 450 ul/s
2021-02-09 17:12:58 timer_1 Timer 1 Wait 5.00 s
2021-02-09 17:12:58 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:12:58 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:12:58 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:12:58 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 17:12:58 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:12:58 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:12:58 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:13:21 GQW-SY GQW-SY Syringe starts, volume: -10000 ul, speed: 450 ul/s
2021-02-09 17:13:21 timer_1 Timer 1 Wait 0.00 s
2021-02-09 17:13:21 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:13:21 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:13:21 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:13:21 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 17:13:21 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
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Timestamp Object ID Object Name Process Step Comment
2021-02-09 17:13:21 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:13:44 GQW-SY GQW-SY Syringe starts, volume: 10000 ul, speed: 450 ul/s
2021-02-09 17:13:49 timer_1 Timer 1 Wait 5.00 s
2021-02-09 17:13:49 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:13:49 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:13:49 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:13:49 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 17:13:49 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:13:49 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:13:50 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:14:12 GQW-SY GQW-SY Syringe starts, volume: -10000 ul, speed: 450 ul/s
2021-02-09 17:14:12 timer_1 Timer 1 Wait 0.00 s
2021-02-09 17:14:12 Set string Set string String: Comment1 = Load Column (const.)
2021-02-09 17:14:12 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:14:12 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:14:12 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:14:12 FOH-SM1 FOH-SM1 Valve switched to direction 2-3
2021-02-09 17:14:12 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:14:12 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:14:13 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:14:47 GQW-SY GQW-SY Syringe starts, volume: 10000 ul, speed: 300 ul/s
2021-02-09 17:14:57 timer_1 Timer 1 Wait 10.00 s
2021-02-09 17:14:57 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:14:57 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:14:57 FOF-SM3 FOF-SM3 Valve switched to direction 2-3
2021-02-09 17:14:57 FOG-SM1 FOG-SM1 Valve switched to direction 1-2
2021-02-09 17:14:57 FOG-SM2 FOG-SM2 Valve switched to direction 2-3
2021-02-09 17:14:57 FOG-SM3 FOG-SM3 Valve switched to direction 1-3
2021-02-09 17:14:57 FOH-SM1 FOH-SM1 Valve switched to direction 1-3
2021-02-09 17:14:57 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:14:57 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:14:57 FOI-SM1 FOI-SM1 Valve switched to direction 1-3
2021-02-09 17:14:57 FOI-SM2 FOI-SM2 Valve switched to direction 1-3
2021-02-09 17:14:57 FOI-SM3 FOI-SM3 Valve switched to direction 1-2
2021-02-09 17:14:57 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:20:11 GQW-SY GQW-SY Syringe starts, volume: -10000 ul, speed: 32 ul/s
2021-02-09 17:20:16 timer_1 Timer 1 Wait 5.00 s
2021-02-09 17:20:36 timer_1 Timer 1 Wait 20.00 s
2021-02-09 17:20:36 PCtrl Flow Control Msg: put NaCl solution right?
2021-02-09 17:20:36 Stop Stop Button switched from off to on
2021-02-09 17:20:46 PCtrl Flow Control Msg was confirmed
2021-02-09 17:20:46 Stop Stop Button switched from on to off
2021-02-09 17:20:46 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:20:46 FOF-SM2 FOF-SM2 Valve switched to direction 2-3
2021-02-09 17:20:46 FOF-SM3 FOF-SM3 Valve switched to direction 1-2
2021-02-09 17:21:07 GQW-SY GQW-SY Syringe starts, volume: 4000 ul, speed: 200 ul/s
2021-02-09 17:21:11 Stop Stop Button switched from off to on
2021-02-09 17:23:48 timer_1 Timer 1 Wait 5.00 s
2021-02-09 17:23:48 FOF-SM1 FOF-SM1 Valve switched to direction 1-3
2021-02-09 17:23:48 FOF-SM2 FOF-SM2 Valve switched to direction 1-3
2021-02-09 17:23:48 FOF-SM3 FOF-SM3 Valve switched to direction 2-3
2021-02-09 17:23:48 Stop Stop Button switched from on to off
2021-02-09 17:23:48 FOG-SM1 FOG-SM1 Valve switched to direction 1-2
2021-02-09 17:23:49 FOG-SM2 FOG-SM2 Valve switched to direction 2-3
2021-02-09 17:23:49 FOG-SM3 FOG-SM3 Valve switched to direction 1-3
2021-02-09 17:23:49 FOH-SM1 FOH-SM1 Valve switched to direction 1-3
2021-02-09 17:23:49 FOH-SM2 FOH-SM2 Valve switched to direction 1-3
2021-02-09 17:23:49 FOH-SM3 FOH-SM3 Valve switched to direction 1-3
2021-02-09 17:23:49 FOI-SM1 FOI-SM1 Valve switched to direction 1-3
2021-02-09 17:23:49 FOI-SM2 FOI-SM2 Valve switched to direction 1-3
2021-02-09 17:23:49 FOI-SM3 FOI-SM3 Valve switched to direction 1-2
2021-02-09 17:23:49 GQY-HR GQY-HR normal mode, Wait 200 ms Tsp: 0 C
2021-02-09 17:25:56 PCTRLHMI PCTRLHMI The running process breaks, because of an error Error
2021-02-09 17:25:57 Stop Stop Button switched from off to on
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Radioactivity is a process that occurs when an unstable atomic nucleus loses energy by emitting 
energy in the form of emitted particles of ionizing radiation or electromagnetic waves, called 
radiation. With the passage of time, the number of parent nuclei remaining decreases (due to 
nuclear disintegrations). Radioactivity, or simply activity (A), can be defined as the number of 
disintegrations per second (dps) of a given sample of a radionuclide [164]. The unit of 
radioactivity is the Becquerel (1 Bq=1 dps) or Curie (Ci) (1 mCi=37 MBq, 1 Ci is the activity of 1g 
226Ra) . 
The number of decay events (−dN), that is expected to occur in a small interval of time (dt), is 










The solution to this first-order differential equation is the function: 
𝑁 = 𝑁0  𝑒
−𝜆𝑡, 
 
 where 𝑁0 is the number of atoms at time t = 0.  
 
Specific activity 
 Specific activity is the activity per quantity of a radionuclide and the units are Bq/mg or Ci/mg. 
